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Abstract 
Detailers are one of the most powerful components of pharmaceutical marketing. Drug 
manufactures spend a lion's share of their marketing budgets on their detailers, and with 
direct-to-consumer (DTC) marketing coming under closer scrutiny, it is likely that 
detailing will receive even more funding in the coming years. 
This thesis analyzes how differences in detailing regulations in the United States, United 
Kingdom, Sweden, Italy, and France lead to differences in the promotion and sales of 
antinausea, antihypertensive, and antipsychotic medications during the time period of 
1992 to 2003. In order to determine if promotional efforts vary across generations of 
medications in the same therapeutic class, antinausea and antipsychotic medications are 
classified as new and old generations and antihypertensives are classified as new, middle, 
and old generations in this study. Qualitative and quantitative methods are used to 
examine population, economic, price, promotional, regulatory, and cultural factors that 
contribute to the sales of phanunaceutical products. 
The qualitative discussion includes an overview of all five sample countries' health care 
systems, health care policies, and the prevalence of hypertension, cancer incidence, and 
psychosis. Econometric tools are used to conduct the quantitative analysis. The effect on 
pharmaceutical sales and the diffusion of new generation pharmaceutical products is 
examined. Chow tests are conducted for cross-country differences. 
This study fnds that there are significant cross-country differences in the diffusion of the 
three therapeutic classes in the five sample countries examined in this thesis. The 
different factors examined contribute to diffusion in varying extents in the five sample 
countries. Culture is found to play an important role in the sale and use of all three 
therapeutic classes, but an especially crucial role in the case of antipsychotics. The 
promotional factors appear to play a significant role in the diffusion of new generation 
products relative to older generation products, but are not found to have a statistically 
significant effect on the larger therapeutic level. 
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Chapter 1 - Introduction 
1.1 - Motivation and Objective 
Prescription drugs are among the most regulated products in all developed countries. Not 
only is the sale of these products closely monitored, a great deal of regulation also deals 
with their promotion. While every country regulates the promotion of pharmaceutical 
products, the regulations themselves vary greatly across countries and therapeutic 
categories. 
In all countries, the lion's share of promotional dollars is spent on a group of semi- 
professionals called "detailers", who directly interact with physicians on behalf of 
pharmaceutical companies. Detailers have two main objectives: to educate physicians on 
the newest medicines and promote their companies' products. Though the one-on-one 
time detailers spend with physicians is very limited, it has proven to be one of the most, if 
not the most, effective ways to alter a physician's prescribing behavior. While its 
effectiveness alone makes detailing worth examining, the fact that detailing is difficult to 
regulate because it is hard to dictate what a detailer can and cannot say to a doctor behind 
closed doors, makes it an especially interesting area to examine for a policy study. 
In this thesis, I examine modern day detailing and highlight changes that have occurred 
over the years. I focus on how detailing differs across countries, looking closely at 
differences in regulation, culture, and incentives of different stakeholders. I will try to 
assess how variances in these categories alter how risks and benefits of new drugs are 
conveyed in different countries around the world. In order to narrow the scope of the 
study, five countries and three therapeutic categories were chosen. 
The three therapeutic categories I have chosen are antihypertensives, antinausea, and 
antipsychotics. The reason for choosing antihypertensives is that they are a "standard" 
class of drugs, and there is little discrepancy in how they are prescribed. Furthermore, 
antihypertensives are traditionally under used, making them an interesting category to 
examine in a study about the promotion of pharmaceutical products. Antinausea drugs are 
primarily used in the treatment of cancer patients and pregnant women, but what makes 
these products interesting for this study is that they are predominantly promoted to nurses 
rather than physicians. Finally, antipsychotics were chosen because they offer a glimpse 
into the mental health sector. Also, antipsychotics are prescribed more uniformly across 
countries than other mental health drugs, due to the fact that it is easier to diagnose 
psychosis than depression. This reduces the noise that is traditionally added when 
researching mental health products. 
The countries in the analysis are the United States, Sweden, France, Italy, and the United 
Kingdom. The US was chosen because it is the country that spends the most on health 
care in the world. Sweden serves as a quasi-control because the Swedish government 
owns all the pharmacies in the country through a national chain, the Apoteket AB. Thus, 
the government sells all prescription pharmaceutical products in the country. No other 
country exerts this level of control on pharmaceutical products. France is interesting 
because the French use more drugs than do residents of any other country; however, the 
national health care system negotiates drug prices, and is able to keep the cost of this high 
prescription drug usage low. Italy is experimenting with an interesting set of regulations 
with respect to detailers, and is therefore included in this study. Finally, the United 
Kingdom is included because the national health service of the country pays for most 
common medical services, but not for pharmaceuticals. Also, health care expenditures on 
the whole have been lower in the UK than in other Western European countries. 
There has been a significant amount of research on the effect of pharmaceutical 
promotion of pharmaceutical prescribing and use. Bernard McCormick et al. examined 
the effect on prescribing habits of restricting contact between internal medicine residents 
and pharmaceutical detailers [I], and Frederick Huang et al. studied the effect of 
attending pharmaceutical company sponsored conferences on the prescribing behavior of 
physicians [2]. In addition, Chren and Landefeld studied how the frequency and degree of 
contact with pharmaceutical companies affects prescribing behavior by examining 
interactions ranging fi-oin detailer's visits to conference attendance and research 
collaboration [3]. There is also literature on the effect of promotion and regulation on the 
sale of pharmaceutical products. For example, Ernst Berndt et al. studied the role of 
marketing, price competition, and product quality in the antiulcer drug industry of the 
United States [4], and the study by Ernst Berndt et al. on the price indexes for 
antidepressant medications [5]. Ling Cui examined cross-country and cross-therapeutic- 
class differences for antidepressants and antihypertensives in Germany and Japan [6] .  
This thesis is unique in that it is a broader cross-country and cross-therapeutic-class study 
on the detailing of pharmaceutical products than most previous research in this area, 
which have focused on a single country, and usually on a specific therapeutic class within 
that country. Furthermore, this thesis takes into account many different factors in 
examining the relationship between detailing and drug sales, such as regulations, culture, 
and economic factors. It also looks at antinausea medications, which is a therapeutic class 
that has not been studied extensively in the past. Therefore, this thesis provides a more 
holistic view of detailing than most of the work done in the past in this area. 
1.2 - Background on Health Care Systems in the Five Sample 
Countries 
This section describes the health care systems in the five sample countries. It looks at the 
role government plays in providing healthcare, payment structures, and the cost and use 
of health care services in each country. 
A. United States of America 
The United States spends more on health care than any other nation in the world. There is 
no single national health care system that provides health insurance to all residents. 
Instead, the US health care system is a complex matrix of private and publicly funded 
programs. 
Financing the US Health Care System 
The US health care system is the most expensive system in the world, accounting for 
around 15% of the nation's GDP [7]. The default legal system for health care is "fee-for- 
service", where patients pay for medical services when they receive them. However, very 
few Americans actually pay the full cost of health care services themselves. 
The majority of Americans rely on private insurance to cover medical expenses. The 
private insurance market in America is massive, with more than 1,300 separate private 
health insurance providers [8]. In 2005,70.9% of all Americans had some form of private 
insurance [9]. In addition, the national and state governments provide health care 
insurance to the elderly, the poor, and the disabled. The breakdown of health care 
expenditure is given in Fig. 1.1 below. 
Figure 1.1: Makeup of Health Care Funding in the United States in 2003 
Source: 2005 OECD Health Database 
While there is no universal health care system in the US, the portion of health care 
covered by public funding has been rising steadily over the years. The large number of 
people served by the different government funded health insurance programs makes the 
US government the single largest purchaser of health care services in the country. The 
Center for Medicare and Medicaid Services projects that, including nursing home 
expenditures, 33 cents of every dollar spent on health care services in the U.S. is paid by 
Medicare and Medicaid [lo]. The portion of health care provided by private insurance is 
also increasing, though at a slower rate than public funding. Out-of-pocket health care 
expenditure has steadily declined over this same period. The graph in Fig.l.2 shows the 
trend in health care expenditure in the US over four decades. 
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Figure 1.2: Health Care Spending by Funding Sources 
Source: 2005 OECD Health Database. 
Private Health Insurance 
There are two main models for private health insurance in the US: the preferred provider 
organization (PPO) and the health maintenance organization (HMO). Private insurance 
companies negotiate the price of medical services directly with providers, such as 
hospitals, physicians, and pharmaceutical companies. Usually, larger insurance 
companies can use their size to get larger discounts fiom medical service providers. 
Under a PPO, there is often a pre-selected group of health care providers that have 
contracts with the health insurance company to provide services to patients covered under 
the PPO for a discounted rate. If patients visit health care providers within this 
"network", then they normally only pay a small co-payment (10-20% of the total fee) for 
the medical treatment they receive. If patients chose to visit providers outside of the pre- 
selected group, then the percentage of the cost of services they must cover out-of-pocket 
typically increases by some percentage. 
On the other hand, HMOs are prepaid health insurance plans that "manage" the health of 
their client. Like PPOs, HMOs have a network of health service providers; however, the 
difference is that in an HMO, patients are required to use providers in the network. If 
patients visit a provider not associated with the HMO, the HMO will usually not cover 
the cost of the visit, unless the HMO authorized the visit in advance. In exchange for the 
additional restrictions on providers patients can use, HMOs charge lower rates than other 
forms of private health insurance. 
Most Americans receive health insurance through benefits programs fiom their 
employers. Employers establish a contract with private insurance providers (PPO or 
HMO) and pay a large portion of the employees' health insurance premium on their 
behalf In less fie uent cases, employers will hire medical professionals and provide 4 health care directly . 
Government Funded Health Insurance 
While there are many sources of public fimding for health care in America, the three 
major ones are managed by the Department of Health and Human Services (HHS) and 
are Medicare, Medicaid, and State Children's Health Insurance Program (SCHIP). 
Medicare 
Established in 1965, Medicare is funded by the federal government and provides health 
care insurance to people age 65 and over, and people with certain disabilities. In 2004, 
Medicare covered 42.3 million American citizens, and provided assistance to 96% of 
elderly citizens over the age of 65 [l 11. 
Medicare is financed through payroll taxes and the Self-Employment Contributions Act 
of 1954. The payroll tax is equal to 2.9%, where employers and employees each pay 
1.45% of the employee's earnings associated with employment towards the Medicare 
fund. Self-employed individuals pay 2.9% of net earnings towards financing Medicare. 
Medicaid 
Medicaid was created at the same time as Medicare and is the largest government funded 
health care program in the country. Medicaid is jointly funded by the states and federal 
govemment to provide health insurance for individuals and families with low incomes 
and assets. Though participation in Medicare is voluntary, all states have had a Medicare 
program since 1982. Since Medicaid programs are run at the state-level, policies on 
eligibility, services, and payments vary substantially among the states. As long as the 
state program meets the federal guidelines for Medicaid programs, the federal 
government pays for a portion of a state's Medicaid costs2, and the state covers the rest 
[121* 
There are a few key differences between Medicare and Medicaid. First, Medicaid is 
available to legal residents of all ages, so long as they meet the income eligibility criteria 
set in their state of residence. Secondly, Medicare does not have premiums or 
deductibles, so it is entirely free to those who receive it. Because of the different 
eligibility criteria for the two programs, it is possible for people to be enrolled in both 
Medicare and ~ e d i c a i d ~ .  
In 2004, Medicaid covered 52 million Americans and carried a price tag of $305 billion. 
Medicaid covers a wide range of medical services, ranging from child birth to nursing 
' Google Inc., along with many academic institutes in the US, falls under this category. 
The percentage of Medicaid expenses covered by the federal government varies by state. 
In 2004, there were 7 million individuals who were "dual enrolled" in Medicare and Medicaid. 
homes. In fact, Medicaid funding accounts for approximately 50% of all nursing home 
costs and 20% of all health care spending in the US [12]. Table 1.1 shows the number of 
people covered by Medicare and Medicaid, and the total amount spent on these two 
programs in 2004. 
Table 1.1: Medicare and Medicaid Coverage in 2004 
People 
U.S. Total 
Medicare 
*The 7 million "dual enrolled" individuals were only counted once to calculate the total number of 
people covered by Medicare and Medicaid. 
Source: Kaiser Commission on Medicaid and Uninsured, 2005. 
Money 
Medicaid 
Medicaid & Medicare 
State Children's Health Insurance Program 
294 Million 
42 Million 
Created in 1997, the State Children's Health Insurance Program (SCHIP) is a national 
program to provide health insurance to children in families with an income too high to 
qualify for Medicare, but not high enough to be able to afford private health insurance 
premiums. In 2005, SCHIP provided health care services to over 6 million children. 
$1.54 Trillion 
$297 Billion 
52 Million 
87 Million* 
Like Medicaid, SCHIP is a state run program, and every state has one. The SCHIP 
program grants considerable flexibility to the states to determine how to structure the 
program. States have the fieedom to design SCHIP programs independent fiom 
Medicaid, use SCHIP funding to expand Medicaid funding, or create a system that is a 
combination of the previous two. The federal government gives states funding for SCHIP 
programs at a rate that is higher than the standard Medicaid match. The additional 
funding provided for SCHIP is helping states improve the health care they can provide to 
residents. 
$305 Billion 
$602 Billion 
The Uninsured 
Even with multiple government and private health insurance programs in the United 
States, a significant portion of the population is uninsured. In 2005, 41.1 million 
individuals, or 14.1% of the population, lacked health insurance [13]. The large number 
of uninsured is not only a problem because health care is a necessity for all people, but 
because the cost of providing treatment to these individuals raises the cost of health care 
for the rest of the nation. Uninsured people tend to receive health care at later stages of an 
illness when treatment becomes more expensive, and usually in emergency or intensive 
care units, where the cost is the highest of all settings [14]. The cost of this treatment is 
then distributed to the rest of the population in the form of higher taxes and health 
insurance premiums. The breakdown of health insurance coverage is given in the graph 
in Fig. 1.3. 
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Figure 13: Health Insurance Coverage in the United States from 2000 to 2004 
Source: Center for Disease Control, Nationul Health Survey 2005. 
B. Sweden 
The Swedish National Health Service (NHS) was started in 1970, and provides health 
care services for the entire country. The responsibility of providing health care is located 
at the county level, so the local political leaders of Sweden's 21 geographical areas are in 
charge of almost all health care services in the country. While no uniform basic care 
package exists, the county councils are required to use the nationally-stipulated ranked 
principles of human rights, need or solidarity, and cost-effectiveness in setting health care 
programs [ 1 51. 
Managing and Financing the National Health Care System 
The NHS operates under three political and administrative levels: national government, 
county council and local authority (municipality). At every level, authorities are publicly 
elected and have the right to levy taxes to finance their activities. 
The national government's role is to set the legislation for the health care system and 
ensure that these laws are followed. The government agency in charge of ensuring that 
system runs efficiently and pursues its fhdamental objective is the Ministry of Health 
and Social Affairs. The county councils are responsible for primary and secondary care, 
and the municipalities are in charge of elderly care and nursing homes. 
The Health and Medical Services Act of 1982 sets the basis for the NHS. The Act stated 
the peoples' equal right to accessible quality health care, the need to respect the patient's 
integrity and right to make hislher own decisions, and urged that treatment be performed 
in consultation with the patient to the maximum degree possible. The Health and Medical 
Services Act also transferred the responsibility of providing health care services from the 
national government to the county councils. 
The county councils levy income taxes on their constituency. The county councils use the 
revenue to run hospitals, health centers and other health institutions. Since providing 
health care is the largest responsibility of the county, health care expenditure accounts for 
85% of total county expenditure and 71% of these operations are financed from tax 
revenues [15]. The other major revenue sources are grants and payments for certain 
services received from the central government, which the central government collects 
through the national income tax and indirect taxation. 
The umbrella organization of the Swedish local authorities is the Swedish Association of 
Local Authorities (Svenska Kommunforbundet). In the realm of health care, the 290 
municipalities are responsible for the care of the elderly, disabled, and long-term 
psychiatric patients. Due to their responsibility for the care of the elderly, the 
municipalities operate public nursing homes and home-care services [16]. 
While user fees are an integral part to the Swedish health care system, they are "more 
ideological than financial" [17]. They are used to curb the demand for unnecessary health 
care, but not be a financial burden on the people. In face, user fees represent only about 
2% of the total health care expenditure of the country [15]. The patient fee ceiling is only 
SEK 900 (about $1 1 7 ~ )  for any twelve-month period, after which point all medical 
services become free. All treatment for patients under the age of 20 is free as well. 
One of the major goals of the Swedish national health care system is price controls. In 
2002, the Pharmaceutical Benefits Board (Lakemedelsform~nsnamnden) was established 
for the purpose of determining which pharmaceutical drugs should be subsidized. The 
agency also sets the price of prescription drugs via negotiations with pharmaceutical 
companies. In addition, Sweden bases the allowable price of a medication on the price 
charged for the drug in other countries, and, in particular, on the price in the 
manufacturer's home country [18]. Furthermore, a new directive requires that any drug on 
the Pharmaceutical Benefits Board subsidy list be replaced with the cheapest comparable 
generic product by the pharmacists [16]. 
The state-owned National Corporation of Swedish Pharmacies (Apoteket AB) has the 
sole and exclusive right to retail medicines in Sweden and distributes products through a 
nationwide chain of 900 pharmacies. Under the social insurance scheme, patients pay the 
entire cost of prescribed pharmaceutical preparations up to SEK 900. Above this amount, 
Currency conversions based on exchange rate in April 14,2006 of US$1 = SEK 7.6934. 
a rising scale subsidy operates (See Table 1.2), with a ceiling of SEK 4,300 (US $559) 
for a twelve-month period [IS]. After a patient reaches this ceiling all medications 
become fkee. 
Table 1.2 Patient Out-of-Pocket Expenditure on Prescription PharmaceuticPLP in 
In 2002, public fimds accounted for 85.9% of total Swedish health expenditure. The 
remaining 14.1% was financed through private expenditure, most of which was out-of- 
pocket payments by individuals. A small portion of the private expenditure came fiom 
voluntary insurance5, which is mostly purchased by employers and very rare in Sweden. 
Sweden 
Health Care Services 
Cost of Pharmaceuticals in SEK (US$) 
0-900 ($0- 1 17) 
901-1700 ($1 18-221) 
1701-3300 ($222-428) 
3301-4300 ($429-558) 
4301+ (%559+) 
The Swedish people pay the highest taxes in the world, the majority of which goes to 
funding the health care system [17]. When a recession in the early 1990's caused lines to 
be longer than ever, the public demanded improvements be made to the system. What 
resulted was a set of reforms that fundamentally restructured the health care system of 
Sweden. 
Patient Out-of-Pocket Expense 
100% 
50% 
25% 
10% 
0% 
In 1992, the Patient Choice and Care Guarantee reforms were created. These reforms 
allow patients to choose where and by whom they wish to be treated. Furthermore, the 
reform guarantees that a patient will be offered help by a primary care facility on the 
same day that they ask for help, and a medical consultation must be given within eight 
days. If the primary care physician determines that a specialist is need, the patient is 
guaranteed the right to within three months if the diagnosis is clear, or within one month 
if the diagnosis still needs to be determined. These reforms have reduced the waiting 
times significantly over the last decade [17]. 
Another major change that occurred during the same period was the shift in emphasis 
from in-patient to outpatient care. Increasingly more medical visits are occurring outside 
of hospitals, and the number of day surgeries is rising [19]. These changes are helping 
alleviate the pressure on the hospitals and increase accessibility to care, which is a 
primary tenant of the NHS. 
Finally, during the later part of the 19903, most county councils shifted from a 
purchaser-provider model to a purchaser-provider split. The move was made in an effort 
to increase the efficiency of the health care system and control costs, since under a 
%ue to the fact that less than 1% of Sweden's population has voluntary insmce ,  the exact brdup  of the 
private expenditure is not known. 
purchaser-provider split, public and private institutions competed more intensely for 
patients. Studies done on the Swedish health care system have found that the move to the 
purchaser-provider spilt has in fact increased the efficiency of health care services in the 
country [17]. From 1990 to 2000, the percentage of care provided by private hospitals 
rose from negligible levels to 9% of total county council expenditure, and over 29% of all 
visits to a doctor occur at private medical establishments [19]. This shift to the private 
sector is occumng because private hospitals are run more cost-effectively than public 
ones [17], and the purchaser-provider split rewards this efficiency. 
C. France 
The French national health care insurance system was founded in 1928. In 2000, the 
World Health Organization (WHO) classified it as the "best health system in the world". 
The national health care insurance system in France serves two major functions: 
providing health care to French residents and controlling the cost of medical care in the 
country. 
Providing Health Care Insurance to French Citizens 
The national health care insurance system in France is open to all French citizens and 
currently covers 99.8% of the population. A wide range of medical services is covered 
under the program, including physician visits, prescription medications, hospitalization 
fees, medical tests and surgical procedures. Also, unlike many other countries with 
national health insurance programs, there are no waiting lists for surgeries in France [20]. 
While most medical services require co-payments, the size of the co-payment varies 
depending on the treatment, and ranges from 25-45% of the total cost. In certain 
circumstances no co-payments are required6. Prescription drugs are separated into three 
classes based on the urgency with which they are needed. Drugs in the first category are 
reimbursed 100 %, the second 70 %, and the third, or least essential category of drugs, 
are reimbursed 24 % [2 1 1. 
Health insurance falls under a branch of the Social Security system in France and is 
funded by a collection of regional and local national health care funds called Sickness 
Insurance Funds (SIFs). The Ministry of Social Affairs and the Ministry of Finance 
oversee the administration of these funds, which are the main organizational feature of 
the health care system. The majority of the funds, 60%, come from contributions from 
workers' salaries. The remainder is collected through indirect taxes on alcohol and 
tobacco and direct contribution paid by all revenue proportional to income, including 
retirement pensions and capital revenues [20]. 
The national insurance plan complete covers the cost of prenatal care, treatment of work-related injuries, 
care of the handicapped, care of veterans and military pensioners, or for the treatment of any disease that 
falls on a list of long, costly or otherwise defined sicknesses such as diabetes, cancer, AIDS, heart disease, 
transplantation, end-stage renal disease, and mental illness. 
Inclusion in the General ~ u d ,  which is the major national health insurance fund, requires 
that the employee and employer contribute 6.8 % and 12.8 % of the employee's gross 
salary, respectively, into the fund. This results in a combined contribution of 19.6% of an 
employee's salary to the general fund. The contributions are divided between health care 
for employees and their families (16% of the gross salary) and unemployment insurance 
(3.6% of the gross salary) [21]. Self-employed citizens only contribute 12.8% of their 
gross salary to the general fund, and as a result, do not receive all health care benefits or 
unemployment insurance. Unemployed individuals initially receive the same amount of 
coverage under the general fund as they did when they were employed. The length of 
time benefits remained unchanged is calculated via a complicated formula, which 
includes an individual's age and the amount he or she previously worked [21]. If 
individuals are still unemployed after this length of time passes, they are required make 
the contributions themselves, or request assistance from the local government [2 11. 
While the national health care insurance system in France is comprehensive, gaps still 
exist. Thus, more than 80 % of French citizens have some form of supplemental 
insurance through private mutual insurance companies [7]. While individuals can 
purchase such insurance on their own, most receive it through their employers [21, 221. 
This supplemental insurance works by the same mechanisms as SIFs, employees and 
employers make contributions based on wages. The chart in Fig. 1.4 shows the payment 
distribution of health care expenditures for the average French citizen. 
Unaccounted 
Out-of-Pocket 3% 
Figure 1.4: Payment distribution of health care expenditures in France 
Cost Containment within the French National Health Insurance System 
The second important function served by the national health care insurance system in 
France is that of cost control. The system controls the cost of medical care in France by 
limiting the amounts physicians and companies can charge for medical treatment [21]. 
The primary control mechanism for cost control is the nationally negotiated fee schedule, 
which determines the maximum amounts that can be charged for various medical 
services. This fee schedule is negotiated annually by a committee of representatives from 
the three major SIFs and the three major physicians unions in France. Once the 
committee develops the fee schedule, it must be approved by the General Fund, at least 
one of the other major SIFS, at least one of the physicians unions, the Ministry of Finance 
and the Ministry of Social Security. Once approval is granted, the fee schedule must be 
followed by all hospitals, pharmacies, laboratories, other treatment facilities, and most 
physicians in France 1211. Only tier-two physicians are permitted to charge fees in excess 
of the national fee schedule, and in exchange, these physicians give up some of their own 
national health insurance benefits. No new physicians can gain tier-two status, but 
physicians who were in that tier before it was closed as still allowed to charge fees above 
the national fee schedule [21, 221. Any fees above what is stated in the national fee 
schedule are not covered by the national health insurance, and individuals who decide to 
visit tier-two physicians must cover the additional expense themselves or through 
supplementary insurance [23]. 
Medical cost control in France does not reduce the level of medical treatment available to 
the French. In fact, the lower cost of health care has quite the opposite effect. People in 
France visit physicians more frequently, are admitted to the hospital more often, and 
purchase more medicine than people in America. The only category where Americans 
use medical services to a higher degree than the French is in visiting specialists; however, 
this may be due to the fact that only 40% of French physicians are specialists, compared 
to 80 % in the United States [24]. 
D. Italy 
In 1978, Italy established the national health system, which is called Servizio Sanitario 
Nazionale (SSN). In 2000, the WHO named Italy's health care system the second best in 
the world7. The goals of the SSN were to provide universal access to uniform health care 
for all Italians citizens and to improve the government's control on expenditures. 
Currently, the program provides universal health care; however the level of care available 
varies greatly by region [25]. 
The Organization of the Health Care System 
When the SSN was created, a three-tier system was created to distribute the responsibility 
of providing health care for the country. The system is composed of the State, regional 
governments, and the Local Health Care Enterprises (Aziende Sanitarie Locali or ASL). 
These three tiers work together to provide health care to the entire country. 
After the Italian constitution was reformed in 2001, the State determines the basic 
benefits package, called the "livelli essenziali di assistenza" or LEA. The LEA lists all 
services that must be uniformly available in the entire country. The twenty regions have 
' France was ranked #I for overall health care in the 2000 WHO study. 
responsibility for organizing and administering the health care system 1151. Regions are 
allowed to provide services beyond those in the LEA; however, they must fund such 
services through local revenues. Finally, the ASLs are the local agencies that ultimately 
purchase health care services for the people with government funds. Their h c t i o n  
resembles that of a third party payer. 
The SSN covers a multitude of health care services including physician visits to general 
practitioners and specialists, in addition to in-patient treatment, such as lab tests, 
surgeries and hospitalization costs. The program also subsidizes prescription medications, 
outpatient treatment and dental treatment. 
The SSN works with a wide variety of providers including both public and private 
hospitals, clinics, physicians and nurses. In order for a private health care provider to be 
reimbursed via the SSN it must be accredited by the region. While some regions have 
additional criteria for private providers to qualify for reimbursement through the SSN, 
other regions encourage competition for patients among public and private providers 
1261. 
Italian people have considerable freedom in choosing their physicians and where they 
receive medical services. The only restrictions on patients are that they must use the ASL 
to which they are assigned (which is geographically determined), and most forms of 
treatment require a physician's prescription or referral. Thus, the general practitioner 
serves as the "gate keeper" in the Italian national health care system. If a patient requires 
treatment that cannot be provided within their region, or cannot be provided within a 
"reasonable" time, the patient can go to another region or even to another country in the 
EU for the treatment. Patients use this flexibility often, which is illustrated by the fact 
that more Italians seek treatment outside of their country than any other EU country [27]. 
Once patients receive authorization to leave their region for treatment, patients can 
receive financial aid for not only the cost of the treatment itself, but also travel expenses 
and additional costs, including those of an "authorized accompanying person" [26]. The 
actual level of reimbursement varies from region to region. 
Unfortunately, bureaucracy is rampant in the system, leading to long wait lists for 
surgeries and certain types of treatment. As the cost of health care has risen over the 
years, the flexibility that Italian patients enjoy has been reduced. It is increasingly 
becoming harder to receive SSN fhnding for treatment outside of Italy, as the final 
decision about the necessity of such treatment is being given to the ASL instead of the 
primary care physician 1261. 
Furthermore, during the health care reforms that took place in 1999, the goal of the SSN 
to provide uniform healthcare to all Italians was revisited, what was meant by "uniform" 
was redefined. The legislators decided that due to the rising cost of health care, the SSN 
would only guarantee coverage for services that were "necessary", "effective", 
"appropriate" and "efficient" in terms of delivery [27]. 
Financing the Italian Health Care System 
From its inception, the goal of the Italian national health care system was to be financed 
by general taxation; however this did not become a reality until 1998. For the first few 
decades, compulsory employer contributions accounted for half of the funding and the 
remainder was collected through a variety of sources (See Fig.l.5). In 1998, a regional 
corporation tax replaced the compulsory employer contributions and brought the SSN 
one step closer to being funded only through general taxation. 
The decision of whether or not to have co-payments was left up to the regions. It was not 
until 2002 that all regions added this form of payment to their programs. Even with the 
introduction of co-payments in all regions, public financing covers about 74% of health 
expenditure in Italy. The remaining expenses covered by private finding mainly pay for 
private health care services and over-the-counter (OTC) drugs, which are not covered by 
the SSN. Private insurance providers cover a small portion of the private expenditure on 
health care. Only 15% of Italians have private insurance [27]; however, as the cost of 
health care rises and SSN reduces coverage, it is possible that more Italians will turn to 
private insurance in the fbture. The chart in Fig.l.5 illustrates the general decomposition 
of funding sources for the SSN. 
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Figure 13: Break down a f f i d h g  seurees for the SSN. 
Since 2001, the regional gbvemmts have M i g i v e n  a pre-established share of the 
revenue collected in their regions from value added taxes, individual income taxes, and 
the fuel tax to pay for health care. Because regions do not take in the same amount of tax 
revenue per capita, or have the same spending on heat& care, a National Ekpalization 
Fund was created to make grants based on a variety of variables8. These grants help 
insure that all Italians receive “uniform and essential" levels of health care as detemnined 
by the Italian Ministry of Health. 
These variables are: population size and age composition, fiscal capacity of thc region, size of territory 
and any special features of the region, and historical expenditure on health care. However, the historical 
expenditure allowance will be phased out over a dozen years (France 2001). 
E. United Kingdom 
The United Kingdom (UK) established the National Health Service (NHS) in 1948 to 
provide healthcare for all the residents of the UK. Currently, health policy is the top item 
on the political agenda in the UK, and is focusing on both ''finance and provision of 
health care" [IS]. The following summary will briefly discuss the organizational and 
financial setup of the NHS, as well as what services it provides the people of the UK. 
Organization and Finance of the National Health Service 
The NHS falls under the Department of Health and is headed by the Secretary of State for 
Health. The Department of Health designs the overall health priorities of the nation, but 
the NHS is essentially run at the regional and local level. 
Health services in the UK are divided into "primary" and ''secondary" and are provided 
by local NHS organizations called "trusts". These trusts are the main purchasers of health 
care services [IS]. Since 2003, funding allocations are made directly to trusts from the 
NHS. 
There are about 300 primary care trusts in England and they receive around 75% of the 
NHS budget [28]. Each trust individually decides what health care services will be 
provided in the area and is responsible for thc efficient delivery of these services. 
Services that fall directly under the responsibility of primary care trusts include: general 
practitioners, dentists, pharmacists, opticians, NHS Direct, and NHS walk-in centers. 
Primary care trusts are also able to outsource care to private health care providers. 
Finally, primary care trusts refer patients to the secondary trusts when specialized 
treatment is needed. - - - a; - . 
Secondary care trusts provide funding for specialized patient care and services. There are 
many different types of secondary trusts, each focusing on a different type of medical 
care. The different types of trust includeg: L , ~ p q  p r\%(.pci~:\ . ,. . i 
x : l l  * '  
1 .  r 5 
Acute trusts: Short-term care, such as acci nts-ggd Tvem~rgeeci~s, maternity, 
# . #  surgery, x-ray. ! A  ; . . , . , , . . . . 
Care trusts: Focus on health and social care, carrying out a variety of services, 
such as mental health services. ~ ~ q e k t i k ~  bJ&j 31L, 1 
Mental health trusts: Specialist mental health trusts, providing care, such as 
psychological therapy and specialist medical and training services for people with 
severe mental health problems 
Ambulance trusts: There are over 30 ambulance services for England, each run 
by its own trust. These trusts are responsible for . transporting . patients to hospital. 
-- - - 
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The secdary  trusts summary relies heavily on a report by the BBC Action Network on April 1,2005. 
http://www.bbc.co.uk/dna/~ti~etwork/A24549 - . - . - - - - - , -.-r.- .  - .- - . - . . - - . . 
The NHS is fimded through national taxation. Budgets for the NHS are created every 
three years as part of the "general public expenditure planning process", but these 
budgets can be adjusted as needed during the three years [15]. 
Although general national taxation h d s  the majority (80%) of the NHS, an additional 
significant source of funding (12%) is the National Insurance Fund. The National 
Insurance Fund collects money fiom the UK workforce. Employees contribute 10% of 
income between GBP 87-575 (US$164-1087) per week, and employers contribute 1 1.9% 
on earnings above GBP 87'' (US$164). Self-employed individuals contribute GBP 2 per 
week and a percentage of their profits. The remainder of fbnding for the NHS comes 
from receipts and miscellaneous sources (See Fig. 1.6). 
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Figure 1.6: libding soulres for the NHS. 
Source: European Observatory on Health Care System, 2002. 
The key feature of the NHS is that almost all medical services provided by the NHS are 
fiee of charge. Patients in the UK can visit a general practitioner, a specialist, or stay in a 
hospital for h e .  A recent policy finther entitles people in the UK to h e  residential 
nursing care [15]. User fees are used for prescription drugs, ophthalmic services, and 
dental care. While other user fees may vary, &ere is a flat fee on all prescription 
medications". Currently, the flat fee is GBP 6.65 (USS12.57) per prescription. The 
expenditures of the MIS are illustrated in the chart in Fig. 1.7. 
lo GBP to US$ conversions done using exchange rate on May 10,2006 of lGBP = $1.89. 
" The following groups receive prescription medication for fiee: patients under the age of 19, people on 
welfare, war pensioners on drugs relating to war injuries, pregnant women and new mothers, disabled, 
people with listed medical conditions, and NHS in-patients. 
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Source: European Observatory on Health Care Systems, 2002 
Health Care Services Provided 
There are no minimum medical services that must be provided in the UK. Rather, the 
National Health Service Act of 1977 gives the Secretary of State the responsibility of 
providing services "to such extent as he considers necessary to meet all reasonable 
requirements". Thus, the level of medical care avail&!& to patients varies among regions. 
In all regions, patients have the right to visit a general practitioner (GP) whenever they 
choose. Most GPs in the UK work for the government, with only around 200 completely 
private GPs in all of the UK [IS]. The GPs provide health care services as needed to 
patients. If, however, a GP feels that a patient needs to see a specialist, the GP will give 
the patient a referral. Without a referral, specialist visits are not covered by the NHS. 
While patients in the UK generally are able to visit at GP without any wait time, access to 
secondary care is far more limited. The average wait for a specialist consultation is two 
and a half months, and if surgery is recommended, the wait for hospital in-patient 
treatment is approximately three months [IS]. These long waiting periods have led to an 
increase in private hospitals in the UK. Cunently, there are around 300 private hospitals 
with the majority owned by one of five for-profit chains [28, 151. 
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The long waiting periods have also led to an increase in the demand for private insurance. 
In 2000, 1 1.5% of the population had supplemental private medical i n s m c e  [29]. About 
two-thirds of all private insurance policies are purchased by employers, mostly for white- 
collar employees [15]. Private insurance is used to pay for medical services not covered 
by the NHS or for visiting private health care providers without referrals from primary 
~ m ~ ~ , 4 '  ;TrT  '?Ti ,mi? K-,7- 
care trusts. I .. , 
The long waiting times have been the main factor for the increased political focus on 
health care in the UK. The fact that the UK has historically under-funded health care with 
respect to other Western European countries [7] has probably led to the long waiting 
periods. To help alleviate the situation, the Chancellor of the Exchequer has committed to 
increasing the budget for the NHS by 6% annually in real terms over the next few years 
[15]. This increased funding will help the NHS build new facilities and provide more 
health care services to the people of the UK. 
1.3 - Comparing the Sample Countries 
When health care spending of the five sample countries are compared, interesting 
features of the systems can be seen, especially with respect to pharmaceutical products. 
The data used to create the charts and graphs that follow is all from OECD Health Care 
Data 2 005. 
In all of the countries, the portion of GPD devoted to health care spending has been rising 
(Fig.l.9). Similarly, per capita health care expenditure has been steadily rising (See 
Fig.l.8). While all five countries show a similar trend, health care expenditure is rising 
faster in the US than in the EU countries. 
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Figure 1.9: Total Health Care Spending per Capita 
Focusing on the pharmaceutical market, we find that pharmaceutical sales are rising in all 
the countries, but the rate of increase is much higher in the United States (Fig. 1. lo). Over 
the period fiom 1992 to 2002, the growth rate in pharmaceutical sales in Sweden was 
approximately 148%, 668% in Italy, 598% in the UK, 1097% in France and an 
astonishing 113 13% in the US over the same ten year period. However, it is important to 
keep in mind that the population of the US is much higher than mat of the other countries, 
and this greatly contributes to the higher levelof eg%ndr@re. 
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Figure 1.10: Total Pha~ceutical Sales tn Sample Comtrim 
Per capita spending on pharmaceuticals has also been increasing every year (Fig. 1.1 1). 
The highest spending is once again in the US, with Italy and France next with very 
similar per capita spending, followed by Sweden and UK. It is interesting to note that 
while the US spends over eight times as much on pharmaceuticals as the next closest 
country (France), the per capita pharmaceutical expenditure is only 1.8 times higher in 
the US than in France. The fact that pharmaceutical spending the US may not be as high 
as is often believed becomes even more evident when pharmaceutical spending is 
compared to total health care expenditure (Fig.l.12). When examining the sample 
countries, it can be seen that while pharmaceutical spending as a portion of total health 
care spending has been rising in the US, as in all the other countries, US actually spends 
less of its health care budget on pharmaceutical than the other countries. Pharmaceuticals 
accounted for 12.9% of total health care expenditure in the US in 2003, while it 
represented 20.9% and 22.1% of France and Italy's health care expenditure, respectively. 
-- -- 
Figure 1.11: Per Capita Spending on Phanlceuticals in Sample Countries 
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Figure 1.12: Pharmaceutical Soending as a Percentage of Total Health Care 
Expenditure 
1.4 - T h d  Organization 
This thesis contains eignt major sektions. C- - -^ :r ' is the introduction, and Chapter 2 
gives an overview of detailhi and de t ang  regulations in each of the five sample 
countries. Chapter 3 provides a discussion on the data sources, regression models and 
definitions of the variables used in these models. Chapter 4 through Chapter 6 provide 
detailed discussions about the sales of antinausea, antihypertensive, and antipsychotic 
medications in the United States, United Kingdom, Sweden, Italy, and France, as well as 
factors that contributed to the sales of these medications. Chapter 7 compares the cross- 
country differences in medication sales each of the three therapeutic classes. Finally, 
Chapter 8 provides a conclusion of the findings of the t-q hesis and gives policy 
recommendations.~jf .:d - a r Y. - - - n  
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Chapter 2 - Detailing and Detailing Regulations 
This chapter provides a brief description of detailing and how it has changed over the 
years. Also, a summary of the different detailing regulations in the United States, United 
Kingdom, France, Italy and Sweden is presented. 
2.1 - Introduction to Detailing 
The lion's share of the pharmaceutical industry's promotional budget is spent on a group 
of semi-professionals called "detailers", who directly interact with medical professionals 
on behalf of pharmaceutical companies. The name "detailer" was established because it is 
the job of these professionals to present prescribing information, or the 'details', about 
new medications to physicians [30]. Thus, detailers have two main objectives: to educate 
physicians on the newest medicines and promote their companies' products. Over the 
years, the profile of the detailer has changed, though the crucial role they play in 
promoting pharmaceutical products has not. 
In the 1940s, modern day detailing first began to take shape, as major pharmaceutical 
companies moved away fiom using general salesmen to market their products, to having 
a group of specially trained in-house representatives promote their products [30]. In order 
to establish the legitimacy of detailers, the pharmaceutical set strict standards on who was 
hired as a detailer. All representatives were required to be "clean, chaste, moral, married, 
educated, and pleasant" [30]. Because of the general belief in the 1940s and 1950s that 
traveling sales positions were not suitable for women, detailers were almost exclusively 
men. Women did not join pharmaceutical sales force to any significant until the mid- 
1970s [30], but the number of women in the field has grown rapidly with time, and 
currently the number of men and women detailers is almost equal [3 11. 
As the pharmaceutical industry has grown over the past six decades, so has the number of 
pharmaceutical representatives it employs. In 1944, there was a total 7,000 detailers in 
America, while in 2004 the average large pharmaceutical company has sales force with 
4,97 1 representatives [32]. Between 1995 and 2005, the number of detailers has grown 
300 percent [31], which is a good indication that detailing continues to be an effective 
method of promoting pharmaceutical products. The pharmaceutical industry currently 
spends $12 billion annually on an estimated 90,000 pharmaceutical representatives in 
America alone [32,33]. 
Different countries have different educational requirements for detailers. For instance, 
though there are no government imposed requirements in the US, most pharmaceutical 
companies require representatives to be college graduates with knowledge of science and 
human anatomy. The European Council directives that serve as the basis for promotional 
regulations for most EU countries indicate that pharmaceutical representatives need 
to have a sufficient scientific knowledge to provide information that is precise and as 
complete as possible about the products they promote. Italy decided to place more 
restrictive requirements on detailers in the country, requiring representatives to have a 
degree in medicine, surgery, biology, biochemistry, or pharmacology [34]. France also 
requires sales representatives to have degrees in science or medical disciplines, though 
the degree list is broader in France than in Italy [34]. 
2.2 - Detailing Regulations in the Five Sample Countries 
Though the one-on-one time detailers spend with physicians is very limited, usually not 
exceeding fifteen minutes, it has proven to be one of the most effective methods by which 
to alter a physician's prescribing behavior. In all countries, pharmaceutical promotional 
activities, including detailing, are regulated. Interestingly, each of the five sample 
countries examined in this thesis has taken a different approach, leading to a great array 
of regulations. The following portion of the thesis provides a brief summary of the 
different detailing regulations in effect in the US, UK, France Italy and Sweden. 
A. United States 
In the US, the federal government regulates the promotional activities of pharmaceutical 
companies. The Food and Drug Administration (FDA) is the federal agency responsible 
for ensuring that pharmaceutical products are honestly, accurately and informatively 
represented to the public. The Division of Drug Marketing, Advertising and 
Communications (DDMAC) at the FDA's Center for Drug Evaluation and Research 
(CDER) is primarily responsible for monitoring that prescription drug information 
provided by pharmaceutical companies is "truthfbl, balanced, and accurately 
communicated" [35]. 
DDMAC meets this responsibility through comprehensive surveillance of all forms of 
media advertisements: print, radio, Internet and television. The FDA is also regulates the 
promotional activities of detailers, and monitors that the information provided by these 
sales representatives is honest and balanced like the other forms of promotion. Section 
502(n) of the Food Drug and Cosmetics Act is the main regulatory guideline for 
advertisements for pharmaceuticals in the US, and states that advertisements must 
include: the established name, the brand name (in relevant cases), the formula showing 
quantitatively each ingredient, and information in brief summary which discusses side 
effects, contraindications, and effectiveness [3 51. 
If the FDA feels that promotional activities are misrepresenting a pharmaceutical product, 
the FDA has the authority to remove the advertisement or stop the inappropriate 
detailing. For example, in 2004, the FDA required Pfizer to pull its "wild thing" 
television commercials for Viagra off the air because the agency felt that the commercials 
made claims about Viagra that were not substantiated by clinical data [36]. Similarly, the 
FDA issued a warning letter to AstraZeneca requiring the company to send "Dear 
Healthcare provider" letters to all the health care professions who had been received false 
information &om AstraZeneca's sales representatives that the generic version of 
AstraZeneca's Diprivan, produced by a competitor, was "not therapeutically equivalent to 
Diprivan" [3 71. 
In addition to the FDA, the activities of detailers are regulated by the pharmaceutical 
industry itself. In 2002, the Pharmaceutical Research and Manufacturers of America 
(PhRMA), the trade organization of research-based pharmaceutical and biotechnology 
companies in the US, developed the PhRMA Code on Interactions with Healthcare 
Professionals. The PhRMA code, which went into effect on July 1, 2002, provides 
specific guidelines for all types of interactions between pharmaceutical companies and 
healthcare professions including informational presentations and meetings, consulting 
relationships, scholarships and educational funds, and educational and practice-related 
items. The Code prohibits detailing activities that were previously considered acceptable, 
such as taking physicians to play golf at the pharmaceutical company's expense, or 
providing tickets to concerts and sporting events [38]. 
B. France 
France uses the 'rational use of medicines' Directives established by the European 
Economic Community (EEC) in 1992 to guide its regulations on pharmaceuticals. The 
directive that pertains advertising and detailing is the 92/28/EEC, and this directive 
outlines the interactions between pharmaceutical representatives and healthcare 
professions. 
The directive requires that pharmaceutical companies will train their sales 
representatives, and ensure that these detailers have "sufficient scientific knowledge to be 
able to provide information which is precise and as complete as possible about the 
medicinal products which they promote" [39]. Representatives are required to bring 
summaries of product characteristics and details about the price of every product that the 
detailer plans to present to the healthcare profession. Also, detailers are required to 
provide the French Medicines Agency, the French equivalent of the FDA, with 
information about adverse effects they learn about during their detailing visits. 
Like the PhRMA code, the EEC directives prohibit detailers from providing gifts or 
benefits to healthcare professionals, unless the gifts are "inexpensive and relevant to the 
practice of medicine or pharmacy" [39]. The EEC directives state that any free samples 
given to physicians "must be in response to a written request, signed and dated" by the 
physician. Though the EEC directives do not place a limit the number of free samples 
that can be given, France has chosen to restrict the all detailers to a maximum of ten 
samples per physician per year [40]. While the EEC also allows member countries to 
restrict the number of times a detailer can visit a physician, France has chosen to not 
implement this added restriction. 
C. Italy 
In Italy, promotional and detailing activities are regulated by Legislative Decrees 
541/1992 of 1992, which was Italy's way of implementing the European Directive 
92198lEEC. Interestingly, Italy has chosen to more strictly regulate detailing than what is 
required by the EEC directives. 
The Ministry of Health chose to grant regional autonomy granted on the specific 
activities of detailers, such as the number of visits, frequency of visits, space in hospitals 
that representatives can use, and overseeing complementary public education programs 
[40, 411. However, the Ministry of Health is the overall regulating body, and keeps 
national records on promotional activities. 
Due to the regional autonomy allowed by the Ministry of Health, only 5 out of 2 1 regions 
have placed annual caps on the number of visits a detailer can pay a healthcare 
professional [41]. Regardless of whether or not the number of visits is regulated, all 
regions must report average number of visits received by that region's physicians to the 
Ministry of Health. 
Italy strictly regulates the number of samples detailers can leave doctors. Detailers can 
only leave two samples per visit, and may not exceed ten samples annually for any drug 
that has been on the market for less than 18 months on the market. For medications that 
have been on the market for over 18 months, the cap is increased to five samples per 
visit, with a maximum of 25 samples per year. 
The one area where regulations in Italy are laxer than other sample countries is with 
respect to gifts and "gadgets" given by pharmaceutical representatives to physicians. The 
Italian regulations place no monetary cap on the value of gifts, but states that the 
incentive must have "minimal value" [4 11. 
As in the US, the major pharmaceutical trade organization in Italy, Farmindustria, also 
has a code of professional conduct. The Farmindustria Code of Profession Conduct 
provides all member pharmaceutical companies with a general set of guidelines and rules 
that each member company is required to follow. In the case of detailing, these guidelines 
require detailers to identify themselves as pharmaceutical sales representatives to the 
healthcare professional and be knowledgeable about the products they are promoting 
[42]. In order to have the code of conduct taken seriously, Farmindustria requires each 
member company to hire a third-party auditor on an annual basis to certify the company's 
compliance with laws and the industry code on marketing practices 1431. 
Italy has started to more strictly regulate meetings and congresses held by pharmaceutical 
companies. On June 15, 2002, Law 11212002 came into effect, which put a 50% cut on 
the number and the funding of congress activities carried out outside Italy from that year. 
Then on June 26, 2004 the Ministry of Health adopted stricter rules on conferences and 
meetings, banning single product meetings, and requiring all other meetings and 
conferences to last a minimum of six hours and have at least two sponsors [41]. 
D. United Kingdom 
In the United Kingdom, the Medicines and Healthcare products Regulatory Agency 
(MHRA) is responsible for regulating the promotion of pharmaceutical products under 
the Medicines Act of 1968 [44]. The set of regulations used by the MHRA are based on 
the European Economic Community directives. The Association of the British 
Pharmaceutical Industry (ABPI) also plays an important role regulating the promotional 
activities of the pharmaceutical companies. 
The UK restricts the number of samples that detailers can give physicians to ten samples 
of the smallest package size per year. Furthermore, as stipulated in 92/28/EEC, detailers 
can only provide samples at written request of the physician [40]. The number of visits is 
also limited to a maximum of three cold calls per physician per year; however, detailers 
can visit more than three times if invited by the physician. Also, pharmaceutical 
companies are limited to spending no more than 9% of their turnover on all promotional 
activities, which includes detailing and advertisements [45]. 
The ABPI has provided more "guidance on marketing practices" than "any other industry 
trade association in the world" [43]. The ABPI Code of Practice for the Pharmaceutical 
Industry is formulated in accordance with British laws and "in consultation with the 
British Medical Association, the Royal Pharmaceutical Society of Great Britain and the 
Medicines Control Agency" 1451. The majority of the pharmaceutical industry in the UK 
uses this code of conduct. The ABPI rules require all detailers to pass specified ABPI 
examinations before they can begin promoting pharmaceutical products. These 
examinations are designed to ensure that pharmaceutical companies have given their 
detailers adequate training. The ABPI regulations also restrict representatives from 
providing anything beyond inexpensive promotional items [45]. 
E. Sweden 
Sweden has the tightest regulations on pharmaceutical promotional activities of all the 
five sample countries [43]. The Swedish equivalent of the FDA is the Medical Product 
Agency (MPA), which is responsible for the regulation and surveillance of the 
development, manufacturing, sale, and promotional activities of pharmaceuticals and 
other medical products [46]. Like the FDA, the MPA has the power to "intervene and 
prevent" unreliable or incorrect information to be advertised to consumers and healthcare 
professionals [46]. 
Most physicians in Sweden work in conjunction with a hospital or clinic. Detailers must 
apply to the head of a department for permission to give a promotional presentation to 
that department, are required to speak to all the physicians in the department at one time, 
and are not allowed to distribute gifts of any kind [47]. Furthermore, only detailers whose 
presentations are deemed to have had high scientific quality and content are invited back 
for future presentations. The total number of sales representative presentations is also 
capped at most hospitals and clinics to only a few presentations a year [47]. This set of 
regulations was designed to ensure that the educational component of detailer takes 
precedence over the promotional component. A similar set of rules apply to 
pharmaceutical representatives visiting medical school students, except in this case, the 
students rate detailers on the quality of their presentation [47]. 
In the case of physicians with private practices, detailers may only visit if invited by the 
physicians. Furthermore, physicians have to send a written request to pharmaceutical 
companies in order for detailers to leave samples, and detailers can only leave ten 
samples of the smallest available package size per year [40]. 
Sweden also has a unique and stringent set of regulations surrounding meetings and 
conferences organized by pharmaceutical companies. As mentioned in Chapter 1, the 
country councils are mainly responsible for providing health care in Sweden. Therefore, 
pharmaceutical companies are required to obtain approval from country councils for hold 
meetings and conferences in their regions [47]. Invitations to approved conferences are 
then sent to hospital management not individual physicians, and the management decides 
which physicians to send to the conference based on the topics to be discussed [43]. 
Furthermore, according to a national agreement, pharmaceutical companies are only 
allowed to reimburse physicians up to 50% on the cost of attending the conference (i.e., 
travel, food, accommodation expenses) and are banned fkom providing entertainment at 
these conferences [43]. Some counties felt that this national agreement was not restrictive 
enough, and therefore, chose to adopt more limiting regulations. A few counties only 
allow pharmaceutical companies to partially reimburse the expense of attending a 
conference if the country itself cannot cover the costs [47], and the most restrictive 
counties have decided to restrict all contact and cooperation between physicians and the 
pharmaceutical industry [43]. 
Chapter 3 - Data and Regression Models 
In this chapter I discuss the databases and the data used in this thesis. I also discuss the 
regression models created and the definitions of the variables used in each regression 
model. 
3.1 - Overview of the Data 
The original data in this thesis was obtained fiom three widely used databases: the IMS 
MIDAS International database, the Organization of Economic Cooperation and 
Development (OECD) 2005 OECD Health Database, and the SourceOECD 2006 
database. The data collected from these sources include: (1) quarterly sales and 
promotional data on antinausea, antipsychotic, and antihypertensive medications in the 
US, UK, Sweden, Italy and France, (2) annual population data (total population and birth 
rate data), (3) annual macroeconomic data (gross domestic product (GDP) per capita), (4) 
health indicator data (cancer incidence data), and (5) annual number of medical 
professionals (physicians and nurses). All of the data cover the time period fiom the first 
quarter 1992 to the third quarter of 2003. 
Quarterly sales and promotional data was provided by the IMS MIDAS International 
database. IMS is a private firm in Philadelphia that independently collects data on the 
sale and marketing of pharmaceutical products. Sales and promotional data are collected 
by IMS at presentational form. For example, the IMS will record how many bottles of 
100 tablets of 100-mg pills were sold in a given quarter in a country. This thesis uses 
patient days as a sales indicator, which is calculated by the IMS fiom the total grams of a 
medication sold divided by the average daily dosage for that given medication. Sales data 
in monetary terms is also provided. For the purposes of this thesis, monetary sales data 
were converted from national currencies into US dollars using exchange rates, and 
deflated by each country's Producer Price Index (PPI). The price-per-patient-day values 
were calculated from the PPI-adjusted dollar values divided by the number of patient 
days at the therapeutic class level and generational level. The number of compounds in 
the data set for each country is listed in Table 3.1. 
Promotional data on detailing, journal advertising and mail advertisements are collected 
and reported by the IMS at the aggregated local product level. In this thesis I only use 
promotional data in the form of detailing counts because detailing is the most effective 
and widely used form of promotion, and data on journal and mailing advertisements was 
not available for all five sample countries. Furthermore, because detailing visits are short, 
Table 3.1: Number of Molecules in the Sample 
COUNTRY 
France 
Italy 
Sweden 
United Kingdom 
United States 
Antihypertensives 
46 
47 
3 1 
42 
42 
Antinausea 
13 
13 
8 
10 
15 
Antipsychotics 
4 
5 
5 
6 
6 
usually lasting only a few minutes, the number of detailing counts serves as a reasonably 
reliable indicator of promotional intensity without having to consider variances in the 
length of each visit [6]. 
The population, economic, and health care system data were obtained from the 2005 
OECD Health and Source databases. The data in the OECD databases are collected &om 
OECD member countries on an annual basis. It should be noted that the method of data 
collection is not uniform across all OECD member countries. Furthermore, data has only 
been collected in certain categories over the last few years'2, and the OECD will 
sometimes extrapolate the data in these categories. Therefore, the reliability of all of the 
OECD data is uncertain. However, regardless of these possible drawbacks, the OECD 
databases are the most comprehensive sources on population and health care system data 
currently available, and therefore these sources were used to obtain data for this thesis. 
Finally, the classification of antinausea, antipsychotic, and antihypertensive medications 
into new and old generations was based on the earliest launch time and the mechanism of 
action for each compound. The necessary information for classification was gathered 
from FDA approval data, information on antipsychotic medications created by the Royal 
College of Psychiatrists [48], and consultations with Professor Ernst R. Berndt [49]. 
All the original data were processed using the STATA 7 program. The results of the 
descriptive analysis and the econometric regression model analysis are represented using 
Microsoft Excel charts and STATA regression outputs, respectively. 
3.2 - Variables and Regression Models 
Four different linear regression models are employed in this thesis. In this section I 
explain these models and define the variables used. The goal of the regression models is 
to numerically examine the relationship between sales volume (measured in patient days 
per capita) and economic, health care system, price, and promotional factors at 
therapeutic class and generation levels of aggregation. The first two models were used for 
data that was distinguished by country and therapeutic class, whereas the last four models 
were used for pooled data that included all five countries for each therapeutic class. A list 
of the dependent variables and their definitions is given in Table 3.2, and Table 3.3 lists 
and defines the explanatory variables used in the regression models. 
'' For example, cancer incidence data was only available fkom 1998, and even then it was only collected bi- 
annually. 
I I Share of the total number of patient days captured by the new I 
Table 3.2: Dependent Variables in Regression Models 
Variable Name 
totqd-lkcapita 
middle generation of medications at the country-therapeutic class- 
time level 
Variable Definition 
Total patient days per 1000 capita at the country-therapeutic class- 
time level 
share new pd 
shareqd-newrnid 
generation of medication at the country-therapeutic class-time level 
Share of the total number of patient days captured by the new and 
Table 3.3: Explanatory Variables in Regression Models 
I ( time level I 
Variable Name 
price~100gd~class 
price-ratio 
price - ratio-newmid-old I Price ratio of the new and middle generation drugs to old 
Variable Definition 
Average price per 100 patient days for the drugs at country- 
thera~eutic class-time level 
* 
Price ratio of the new generation to old and middle generation 
drugs. Prices are averaged at country-therapeutic generation- 
I generation drugs. Prices are averaged at country-therapeutic 
I time level 
tot~n~m~compound 
generation-time level 
Total number of all compounds at country-therapeutic class- 
num~new~compound 
I tot-detail-lag1 1 Lagged total detailing counts at country-therapeutic class-time I 
Number of new compounds country-therapeutic class-time 
level 
share new compound 
P ~ Y S - ~ ~ P O P  
nurse lkpop 
income capita 
time 
num new compound divided by tot num compound 
Number of physicians per 1 million population at country- 
time level 
Number of nurses per 1,000 population at country-time level 
GDP per capita at country-time level 
Denotes time lapsed in auarters with 1992 0 1 = 1 
tot-detail-lag4 
rel-detail-lag 1 
level, lagged by 1 quarter 
Lagged total detailing counts at country-therapeutic class-time 
level, lagged by 4 quarters 
Lagged ratio of new to old-middle detailing counts at country- 
rel-detail-lag4 
therapeutic class-time level, lagged by 1 quarter 
Lagged ratio of new to old-middle detailing counts at country- 
rel-detail-newmid-lag1 
therapeutic class-time level, lagged by 4 quarters 
Lagged ratio of new-middle to old detailing counts at country- 
rel-detail-newmid-lag4 
therapeutic class-time level, lagged by 1 quarter 
Lagged ratio of new-middle to old detailing counts at country- 
Country Variable 
Therapeutic Class 
therapeutic class-time level, lagged by 4 quarters 
Dummy variable for each country 
Dummy variable for each therapeutic class 
A 95% confidence interval is used for all the parameter estimates in the regressions to 
assess statistical significance. The variables tot-detail-lag1 and tot-detail-lag4 are never 
included as regressors simultaneously, but instead only one of the two appears as a 
regressor due to their high pair-wise correlation (>0.9). All variables, except the time 
trend variable and dummy variables, are used in logarithmic form in the regressions. The 
equations for the four regression models that were used for the econometric analysis in 
this thesis are given below. 
There are two levels of regression models (class-level and generation-level) in order to 
determine if there different factors effecting sales of medications between the 
therapeutic-level and the generation-level. In other words, the generation-level models 
aim at determining the factors that promote the sale of an entire therapeutic class are the 
same as the factors that promote the diffusion of new generation products. 
The regression models for antinausea are separate fkom the models for antihypertensives 
and antipsychotics because antinausea products are detailed to both physicians and 
nurses; therefore, the availability of nurses needed to be included in the antinausea 
regression models. 
Finally, because there is a middle generation in antihypertensives, the generation-level 
model is run twice for this therapeutic class. In the first regression model, the diffusion of 
the new generation relative to the old and middle generation is examined. In the second 
regression model, the diffusion of the new and middle generations relative to the old 
generation is analyzed. 
Equation 1 : Class-level Model 
Antihypertensives and Antipsychotics 
totqd-capita = a, + a1 price~100qd~class + a2 tot-nun-compound + a3 0 
phys-lmpop + a4 income-capita + as time + tot-detail-lag1 
totNcapita  = a, + a1 price 100qd-class + a2 tot-num-compound + a3 
phys-lmpop + a4 income-capita 5 as time + tot-detail-lag4 
totqd-capita = a, + a, price - 100gd-class + a2 tot-num-compound + a3 
phys-lmpop + a4 nurse-lkpop + as income - capita + a6 time + a7 
tot-detail-lag 1 
to txcap i ta  = a, + a1 price - 100qd-class + a2 tot-numumcompound + a3 0 
phys-lmpop + a4 nurseelkpop + as income-capita + a6 time + a7 0 
tot-detail-lag4 
Equation 2: Generational-level Model 
shareqd = a, + a1 price-ratio + a2 share-new-compound + a3 phys-lmpop + a4 
income - capita + as time + a6 rel-detail-lag1 
sharegd = a, + a1 price-ratio + a2 share-new-compound + a3 phys-lmpop + 
income-capita + as time + rel-detail-lag4 
Anihvvedensives - Two generation-level models are used to examine the interaction of 
the three generations in antihypertensives. 
New vs. Old-Middle 
sharegd = a, + a1 price-ratio + a2 share-new-compound + a3 phys-lmpop + a4 
income - capita + as time + a6 rel-detail-lag 1 
sharegd = a, + a] price - ratio + a2 share-new-compound + a3 phys-lmpop + a4 
income-capita + as time + a6 rel-detail-lag4 
New-Middle vs. Old 
sharegd-newrnid = a, + a1 price-ratio-newmid-old + a2 share-new-compound + 
a3 phys - lmpop + income-capita + as time + a6 rel-detail-newmid-lag1 
shareqd-newmid = a, + a1 price-ratio-newmid-old + a2 share-new-compound + 
a3 0 phys - lmpop + income-capita + a5 time + a6 rel-detail-newmid-lag4 
Antinausea - Nurses added to this model because this therapeutic class is detailed to 
physicians and nurses. 
sharegd = a, + a1 price-ratio + a2 share-new-compound + a3 phys-lmpop + a4 
nurse - 1 kpop + as income-capita + a6 time + a7 rel-detail-lag1 
sharegd = a, + a1 price-ratio + a2 share-new-compound + a3 phys-lmpop + a4 
nurse-1 kpop + a5 income-capita + a6 time + a, rel-detail-lag1 
Equation 3 : Pooled Class-level Model 
Due to the fact that there was no detailing data available for Sweden, the pooled 
regression models were created with and without the detailing variables, so that Sweden 
could be included in the cross-country analysis. 
3.1 - Wahout Detailng - Dummy variable Sweden omitted 
totqd-capita = a, + a1 l price-100qd-class + a2 l tot-n~m~compound + a3 l 
phys-lmpop + as l income-capita + as l time + a6 l US + a7 l UK + ag l France + 
a90 Italy 
3.2 - With Dehzilin~ - Dummy variable Italy omitted 
to tHcapi ta  = a, + a, l price - 100gd-class + a2 l tot-num-compound + a3 l 
phys-lmpop + as l income-capita + as l time + a6 l tot-detail-lag1 + a7 l US + ag l 
UK + a9 l France 
totqd-capita = a, + a1 l price 100qd-class + a2 l tot-num-compound + a3 l 
phys-lmpop + as l income-capita+ as l time + a6 l tot-detail-lag4 + a7 l US + a8 l 
UK + a9 l France 
Equation 4: Pooled Generational-level Model 
4.1 - Wifhout Dehzilinp - Dummy variable Sweden omitted 
shareqd = a, + a1 l price-ratio + a2 l share-new-compound + a3 l phys-lmpop + a4 
l income-capita + as l time + a6 l Italy + a7 l US + as l UK + a9 l France 
4.2 - With Detailing - Dummy variable Italy omitted 
shareqd = a, + a1 l price-ratio + a2 l share-new-compound + a3 l phys-lmpop + a4 
l income-capita + as l time + a6 l rel-detail-lag1 + a7 US + ag l UK + a9 l France 
shareqd = a, + a1 l price-ratio + a2 l share-new-compound + a3 l phys-lmpop + a4 
l income - capita + as l time + a6 0 rel-detail-lag4 + a7 l US + a8 l UK + a9 l France 
Equations 3 and 4 allow the intercepts to be different between the five sample countries; 
however, in order to determine whether there are statistically significant cross-country 
differences in the estimated parameters, Chow tests are performed in Chapter 7. The null 
hypothesis is that there are no significant cross-country differences in the parameter 
estimates. The Chow statistic follows an F-distribution and is calculated fiom the sum of 
squared residuals of the semi-constrained pooled models (SSb)  and the sum of squared 
residuals of the unconstrained country-specific regression models (SSR). Chow tests are 
performed for both the therapeutic and generation levels of aggregation. The Chow 
statistic is calculated using the following formula: 
Chow Statistic = [(SSh - SSR) / SSR] x [(N-k)/q] - F,, N-k , 
where SSR, is the total of all the sum of squared residuals for the country specific 
regression models, N is the total number of observations in the constrained (pooled) 
model, k is the total number of parameters in the unconstrained (country specific) 
models including the intercept terms, and q is the difference of k and the number of 
parameter estimates in the constrained model. 
The Chow statistic follows an F-distribution with q and N-k degrees of freedom. If the 
Chow statistic is greater than the critical value of F ,  N-L at a 5% significance level, the 
null hypothesis (Ho) is rejected. Conversely, if the critical is larger than the Chow 
statistic, the Ho cannot be rejected. 
Chapter 4 - Antinausea Medications 
In this chapter, background is provided on nausea and vomiting and the antinausea 
medications used to treat these conditions. The use and detailing of antinausea drugs in 
the United States, UK, France, and Italy follow this discussion. Then econometric models 
are used to quantify and compare the factors contributing to the sale of antinausea 
medications from 1992 to 2003. Finally, a summary of the antinausea market in the five 
sample countries is presented based on the analysis found in this chapter. 
4.1 - Symptoms and Causes of Nausea and Vomiting 
Nausea is an uneasiness of the stomach that often accompanies the urge to vomit, but 
does not always cause vomiting. Vomiting is the act of forcing the contents of the 
stomach up through the esophagus and out of the mouth [www.clevelandclinic.org]. 
Nausea and vomiting are not diseases themselves, but rather are symptoms of many 
different conditions. Nausea and vomiting can be indications of infection, food poisoning, 
blocked intestine, concussion or brain injury, appendicitis, and migraines. They can also 
be symptoms of more serious diseases like heart attacks, kidney or liver disorders, central 
nervous system disorders, brain tumors, and some forms of cancer [50]. 
People of all ages can suffer from nausea and vomiting for a variety of the causes listed 
above. In addition, people undergoing radiation therapy or chemotherapy for the 
treatment of cancer have an increased risk of nausea and vomiting. During the first 
trimester of pregnancy, over half of all women experience nausea and vomiting, which is 
commonly called "morning sickness." 
All of the countries in this study are developed countries, so factors like poor water and 
improper sanitation, which would increase the likelihood of experiencing nausea or 
vomiting, are not an issue in the United States, France, Italy or Sweden. Furthermore, due 
to the variety of causes of nausea and vomiting, and the tendency for people of all ages to 
suffer from these conditions, it is difficult to predict whether one country's population 
will have a greater demand for antinausea drugs than other. However, it may be possible 
to determine possible demand in a sample country by examining the two groups of people 
most likely to need antinausea medication prescriptions: pregnant women and cancer 
patients. Therefore, the birth rate in the sample countries was examined, as well as the 
incidence of cancer in each country. 
From the birth rate data shown in Fig.4.1, we can see that, on average, women have had 
more children in the US than in the other countries in this study. France has the next 
highest birth rate, followed by the UK and Sweden. The number of births per female is 
lowest in Italy. In 2003, the number of births per female is 7.9% higher in the US than in 
France (1.89 births verses 1.29 births). 
Figure 4.1: Birth Rate Data from 1992 to 2003 
Source: OECD Database 2005 
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Figure 4.2: Incidence of Cancer per 100,000 Population from 1998 to 2002 
Source: 2005 OECD Health Database and SEER Program 
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According to the data in Fig.4.2, the incidence rate of cancer is highest in the US, 
followed by France, with the incidence rates of Italy, Sweden, and the UK are similar and 
lower than in the other two countries. In 2002, the rate of incidence for cancer was 58% 
higher in the US than in France, 65% higher in the US than in Italy, 67% higher in the US 
than in the UK, and 73% higher in the US than in Sweden [7,5 11. 
From the data on birth rates and cancer incidence, it can be extrapolated that the demand 
for antinausea drugs will be greatest in the US, followed by France, Italy and the UK, 
with demand lowest in Sweden. However, data on per-capita sales (in patient-days) of 
antinausea drugs are found to be 321% higher in the France, 208% higher in Italy, and 
15% higher in the UK than are sales in US. Per-capita sales in the US are only higher 
than per-capita sales in Sweden, with US sales being 57% higher than Sweden's, which is 
still lower than what is predicted by the cancer incidence and birth rate data on the two 
countries. This phenomenon and possible underlying causes are discussed further later in 
this chapter in section 4.3. 
4.2 - Types of Antinausea Drugs 
Antinausea drugs control nausea and can also prevent vomiting. Drugs that are designed 
to control vomiting are referred to as antiemetic drugs. The type of antinausea drug 
prescribed to a patient depends on the causes and type of nausea and the vomiting the 
patient is experiencing. While nausea and vomiting during early stages of pregnancy are 
likely due to changing hormone levelsI3, there are multiple different causes of nausea and 
vomiting related to cancer. 
Nausea and vomiting that is caused by cancer is divided into several categories. 
Physicians use the categories to determine what antinausea drug to prescribe. The 
categories include 14: 
Anticipatory: Occurs before the start of a new chemotherapy cycle. Patients, who 
experience nausea and vomiting in previous cycles of chemotherapy, may 
anticipate these side effects with a new cycle of treatment and, consequently have 
a reaction even before the treatment begins. 
Acute-onset: Occurs within a day of chemotherapy treatment. Symptoms are 
typically the most severe several hours after treatment. 
Delayed-onset: Begins more than a day after a chemotherapy treatment. The 
occurrence is higher if a patient receives a high dose of chemotherapy or has 
previously had acute-onset nausea and vomiting. 
Chronic: Occurs in patients who have advanced cancer, and can be caused by a 
variety of factors ranging from dehydration to reaction to chemotherapy drug. 
13 The exact cause of morning sickness is unknown, but the medical belief is that it is caused by changing 
chemical levels, especially the rapid increase in estrogen and progesterone levels 
[http://www.morningsicknesshelp.codm~rning~i~kne~s~auses. html] . 
l4 The description of the categories was taken fiom the Mayo Clinic website article "Nausea and vomiting: 
Cancer-related causes and how to cope", http://www.rnayoclinic.com~healWcancer/CA00030. 
The antinausea medications work by using one, or a combination of, the following 
mechanisms to counteract nausea and vomiting: (1) blocking the vomiting center of the 
brain, (2) blocking receptors to the brain and gut, (3) encouraging the stomach to expand 
and empty, (4) interacting with the chemoreceptor trigger zone (CTZ) of the brain, (5) 
reducing swelling and pressure, (6) reabsorbing fluids into digestive system, and (7) 
tranquilizing or sedating the body. Common types of antinausea medications and the 
mechanisms by which they work are listed in Table 4.1. Pregnant women can take not all 
antinausea medications because some stronger medications may damage the fetus. The 
medications that are considered to be safe for pregnant women are marked with an astrix 
(*) in Table 4.1. 
Table 4.1: Categories and Mechanisms of Action for Antinausea Drugs 
Metoclopramide* , Domperidone 
Category 
Phenothiazines 
Expand/Empty Stomach Acts on the walls of the gut, encouraging 
the stomach to expand, and pushing 
contents downwards to bowels. 
reduce swelling around a tumor, 
allowing fluids to pass, which rehydrates 
the body and reducing nausea. 
Mechanism 
Blocks neurotransmission to the 
"vomiting center" of the brain, thereby 
suppressing the feeling of nausea. 
Serotonin or 5HT3 
Blockers 
Steroid 
Endocrine-Metabolic 
Agent 
(Fluid Absorption) 
Common Drugs in Category 
(Generic Name) 
Prochlorperazine, Piperzine* 
Encourages the body to reabsorb fluids 
from the digestive system. Helps reduce 
buildup of fluid above a blockage, which 
reduces pressure and thus nausea. 
Work by blocking either serotonin or 
5HT3 receptors in gut and brain from 
sending signals to the vomiting center or 
the CTZ. 
Reduces swelling and pressure. Also, can 
Octreotide* 
Ondansetron* , Granisetron * , 
Tropisetron 
Dexamethasone 
I brain less sensitive to neurotransmitters SedativeITranquilizer 
1 vomiting center to cause nausea and 
Slow normal brain function, making the 
Chemoreceptor Trigger 
Zone (CTZ) Interaction 
I vomiting. 
Lorazepam, Promethazine*, 
that cause nausea. 
Blocks CTZ from sending signals to the 
brain that would otherwise trigger the 
Methotrimeprazine, Haloperidol 
Domperidone, Motilium 
*Safe for pregnant women. Source: Cancer Research UK, www.cancerhelpuk.org 
Physicians prescribe antinausea medications based on the cause of the nausea. A 
vomiting center blocker is usually the first round of defense against nausea because these 
drugs are inexpensive and work on many patients [52]. However, if this does not work, 
more expensive antinausea medications are given. Medications that work via different 
mechanisms may also be combined. In fact, some antinausea medications work better in 
combination than separately. For example, the effectiveness of serotonin blockers is 
increased when they are administered with a steroid. Due to the variety of antinausea 
medications on the market, and the fact that different patients react differently to the 
same medication, there is no one antinausea medication that is considered to be the 
"most" effective. 
While antinausea medications help countless people suffering fiom nausea and vomiting, 
and have improved the lives of cancer patients undergoing radiation and chemotherapy, 
these drugs may have side effects in some patients. Most side effects are mild, ranging 
f?om dry mouth to drowsiness; however, some antinausea drugs can have more serious 
side effects. A breast cancer study found that dexamethasone, an antinausea drug that was 
given to almost all breast cancer patients undergoing chemotherapy, actually reduced the 
effectiveness of the chemotherapy 1531. Promethazine hydrochloride, a drug commonly 
prescribed for nausea and vomiting in children was issued a black box warning by the 
Food and Drug Administration (FDA) in 2004 when it was found that the drug caused 
fatal respiratory depression1' in children under the age of two [54,55]. The drug was also 
found to have respiratory depressant effects to a lesser degree in older children when 
combined with certain other medications. A list of common side effects for widely used 
antinausea drugs is shown in Table 4.2. 
Table 4.2: Common Side Effects of Antinausea Medications 
I dizziness, jitteriness, fatigue I 
Category 
Phenothiazines 
Side Effect 
Involuntary muscle spasms, 
Expand or Empty Stomach 
Serotonin or 5HT3 Blockers 
Steroid 
Common Drugs 
Prochlorperazine, Piperzine 
Endocrine-Metabolic Agent 
SedativeITranquilizer 
- 
'%espiratory depression is a condition when the rate of breathing is lowered to a point where there is not 
enough oxygen in-take [Physician's Desk Reference, 20051. 
Twitching in arms, legs or 
face 
Constipation, headache, 
fatigue, abdominal pain 
Restlessness, anxiety, 
Chemoreceptor Trigger 
Zone (CTZ) Interaction 
Metoclopramide, 
Domperidone 
Ondansetron, Granisetron, 
Tropisetron 
Dexamethasone 
confusion 
Gallstones, nausea, fatigue, 
headache 
Drowsiness, low blood 
pressure 
Octreotide 
Lorazepam, Promethazine, 
Methotrimeprazine 
Sources: Cancer Research UK, www.cancerhelpuk.org and Chemocare, www.chemocare.com 
Dry mouth Domperidone, Motilium 
4.3 - The Sale and Use of Antinausea Medications 
The overall antinausea medication market in number of patient days was compared 
amongst the sample countries and graphed. The results are shown in the graph in Fig. 4.3. 
The sale of antinausea medications rose steadily in the US until the fourth quarter of 
1996, when it reached a peak of 141.123 million patient days. Sales in Italy follow a 
similar, though slower, trend, also peaking in the fourth quarter of 1996, at sales of 63.63 
million patient days. Sales in Sweden, though much lower than sales in the other 
countries, also reached a peak in the fourth quarter of 1996, hitting a rate of 2.99 million 
patient days. Sales in the UK are relatively flat and peak in the third quarter of 1998 at 
25.4 million patient days. Data for sales in France was only available from the fourth 
quarter of 1996, and sales peak in France in the first quarter of 1997 at a level of 112.4 
million patient days. Sales in all five countries begin to drop by the end of 1998. In Italy, 
France, UK, and Sweden sales for antinausea drugs end at a lower rate in 2003 than their 
initial levels. Only in the United States do sales end higher than in the first period; 
however, even in the US, the number of patient days is 35.4% lower than at the peak 
(1 4 1.123 million patient days at the peak verses 9 1.17 million patient days in the fourth 
quarter of 2003). 
There are multiple possible reasons for the sale of antinausea drugs declining after the 
end of 1998. First, pre-medications for chemotherapy significantly improved from what 
was available in 1992 [56]. Secondly, in 1999 in the US, antiemetic guidelines were 
released by the American Society of Clinical Oncology (ASCO), which standardized 
antiemetic dosing across the country, and could help explain the drop and then steadying 
of antinausea drug usage in America [56]. Finally, newer chemotherapy drugs that 
caused less nausea and vomiting than older drugs entered the market [57]. The 
improvements in cancer treatment and standardization of antinausea medication usage 
jointly could lead to a drop in number of cancer patients needing antinausea drugs in 
conjunction with their chemotherapy. Since cancer patients represent one of the largest 
classes of patients taking antinausea medications, this led to a drop in overall sales of 
antinausea medications. 
Figure 43: Total Patient Days for Antimusea Medicatiom 
When patient-days-per-capita'6 is compared across the five countries in this study, very 
interesting results are revealed. These data, illustrated in Fig. 4.4, show that France has 
the highest use of antinausea drugs, followed by Italy, UK, the US and Sweden, 
respectively. At the end of 1996, when data on France is available, annually one French 
person consumed 54% more antinausea medications than an Italian (1.7 1 verses 1.109 
patient-days-per-capita), 33 1 % more than a British person (.4 1 55 patient-days-per- 
capita), 321% more than an American (.5321 patient-days-per-capita), and 505% more 
than a Swede (.3383 patient-days-per-capita). By the end of 2003, sales had fallen in all 
the sample countries; however, per-capita, the French consumed 249% more antinausea 
medications than Italians (1.53297 verses .61618 patient-days-per-capita), 424% more 
than the British (.3606 patient-days-per-capita), 488% more than Americans (.31402 
patient-days-per-capita), and 1053% more than a Swede (. 14558 patient-days-per-capita). 
Therefore, though sales fell in all the countries, the rate of decrease was much slower in 
France than in the other comparison countries. 
l6 Patient-days-per-capita is calculated by dividing the total patient days by the total population. 
+ Italy + USA - - - France + lM +I+ Sw eden 
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Figure 4.4: Total Patient Days per Capita for Antinausea Medications 
Despite the higher price of antinausea medications in the US in comparison to France, 
Italy, UK and Sweden, the sales in the US are higher than the other four countries. The 
graphs in Fig.4.5 and Fig. 4.6 illustrate the total sales per capita and the price per patient 
day in purchasing power parity (PPP) adjusted US dollars. From Fig. 4.5, it can be seen 
that the total sales of antinausea drugs followed the same general ups and downs in all the 
sample countries until 2000, when sales being to drop in Italy and Sweden, but start to 
rise in the US, UK and France. The per-patient-day price has risen steadily in the US 
fkom 1992 to the end of 2003, while it has fallen in France, UK and Italy. The per- 
patient-day price in Sweden followed a downward trend until the third quarter of 2001, 
when per-patient-day price began to rise and continued to rise until the end of 2003. At 
the end of the third quarter of 2003, the last period for which there are data for all five 
counties, the price of antinausea medication is $2.74 in the US, approximately 1.36 times 
higher than the price in Sweden ($2.0 I), 5.4 times the price in Italy ($0.5 14) and France 
($0.508), and 6.7 times the price in the UK ($0.412). 
Figure 4.5: Total Sales (US$ PPP) per Capita of Antinausea Drugs 
Figure 4.6: Price pes Patient Day (US$ PPP) of Antinausm Drugs 
The differences in price per-patient-day in the sample countries can be explained when 
the composition of the antinausea market and the price difference of new and old 
antinausea drugs are examined. Unlike most therapeutic classes, there is no clear method 
by which to decompose antinausea medications into new and old generations. The reason 
is that many antinausea medications were initially developed to treat other conditions, 
such as depression or allergies, and later also marketed as antinameants. Therefore, for 
the purposes of this thesis, new and old generation classification is based on the time of 
entry of a drug onto the antinausea medication market. When the percent of antinausea 
patient days captured by new drugs in each of the four sample countries is examined (See 
Fig.4.7), it shows that Sweden and the US have the highest percent of patient-day market 
share of new drugs, with 8.8% and 5.3%, respectively. In comparison, new drugs account 
less than 1% of patient days in Italy, France, and the UK. 
From the graph in Fig.4.8, illustrating the ratio of new antinausea medications to old 
antinausea medications, it can be seen that the price of new antinausea medications is 
higher in every country than old anh8usea drugs. Though the new drug premium has 
been declining over the years, it is still very significant. At the end of 2003, new 
antinausea drugs still commanded a premium of 45 times the price of old antinausea 
medications in the UK, 49 times the price of old medications in Italy, 50.6 times the price 
of old medications in France, 54.9 times the price of old medications in Sweden, and 87.7 
times the price of older medications in the US. The higher premium on new antinausea 
drugs in the US and Sweden, combined with the greater market share of new drugs in 
these countries, helps explain why the price per-patient day is higher in these two nations 
versus Italy, France, and the UK. The major reason that new antinausea drugs command 
the highest premium in the US is probably due to the fact that the other four countries all 
have centralized price controls on phamaceuticals via the natiwal government, which 
does not exist in the US. Thus, with no central authority capping the price of 
pharmaceuticals in the US, the price of new drugs is fkee to rise to whatever level the 
market demand will support. 
4.4 - The Promotion of Antinausea Medications 
This section discusses the detailing activities for the promotion of antinausea medications 
to medical professionals. As mentioned earlier, detailing is the most important of all the 
types of promotional activities in the pharmaceutical industry. Therefore, the intensity 
with which a therapeutic class is detailed is a good indicator of overall promotional 
activity for that class. Due to the control the Swedish government has over the sale of 
pharmaceuticals, through the Apoteket AB, detailing is much rarer in Sweden than the 
other four countries, and therefore, there is no detailing data available for this nation. 
Detailing activity in the US, UK, France, and Italy will be examined in this section. (Note 
that detailing data for the US is available from the first quarter of 1996, detailing data for 
France is available from the fourth quarter of 1996, and detailing data for Italy is only 
available from the fourth quarter from 1999 until the second quarter of 2003). 
One interesting fact about the detailing of antinausea medications is that they are detailed 
to physicians as well as nurses. This is because nurses more often handle patients 
suffering &om nausea and vomiting than physicians, especially in a hospital setting when 
patients are undergoing chemotherapy. Antinausea medications are promoted more 
heavily in France and Italy than in the US or UK through detailing to medical 
professionals. Figures 4.9 through 4.1 1 show the total detailing counts per capita, per 
physician and per nurse in the US, UK, France, and Italy. On the class level, the number 
of detailing visits to physicians for antinausea medications was 27 times higher in France 
than in the UK, 5 times higher in France than in the US, and 1.6 times higher in France 
than in Italy for the year 2003. One possible reason for French physicians being detailed 
the most heavily is that the French people use antinausea drugs at a greater level than the 
residents of the other three countries (Fig. 4.4), therefore, it may be more worthwhile to 
detail products to physicians of this country than the other three. 
Figure 4.9: Total Detailing Counts per Million Population for Antinausea 
Mediations in France, Italy, US aml the UK 
/+~rance +Wy +USA +UK] 
Figure 4.10: Detailing Counts per MUlion Physicians for Antinausea Medications in 
France, Italy, US and the UK 
Detailing to nurses is higher in France and Italy than in the UK or the US. In all 
countries, except the UK, the number of detailing visits to nurses was lower than the 
number of visits to physicians. In the UK, the number of details is almost equivalent 
among physicians and nurses. This is probably due to the fact that there are fewer 
physicians and nurses in the UK than the other countries, so pharmaceutical companies 
probably try to promote their products to any medical professional available. One 
possible explanation for physicians receiving a greater number of visits in most countries 
is that physicians in all four countries can write prescriptions, as well as, dispense 
medication. However, only nurse practitioners, and not general nurses, are allowed to 
write prescriptions. In proportion to the total nursing population, there are relatively few 
nurse practitioners in any country. Therefore, it is possible that pharmaceutical 
companies find it more effective to detail antinausea drugs more heavily to physicians 
than nurses because all physicians can write prescriptions, where as only a select few 
nurses have this capability. 
I g l o o -  
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Figure 4.11: Det.ubrg Counts per Million Nurses 
The number of physicians and nurses in France, Italy, UK and the US is shown in Fig. 
4.12. Italy has the greatest number of plyysiciano per capita, followed by the US, France 
and the UIC France has the greatest number-of nurses of the four countries. The UK has 
the smallest per capita number of physicians and nwses of all four countries, and the only 
country with more physicians than nurses. 
France 
USA 
I Physicians per 1000 population . Nurse per 1000 popuWon I 
Figure 4.12: Physicians and Nurses per 1000 Population 
When the share of detailing counts by generation of drug is compared (See Fig.4.13- Fig. 
4.16), an interesting pattern can be witnessed among the countries. For France, Italy and 
the UK, the old generation of antinausea medications dominates the share detailing 
counts for the entire period. However, in the US, new antinausea drugs reach and exceed 
the detailing level of old drugs. In fact, during the period examined, there is almost a 
complete reversal in detailing share of new and old antinausea medications in the US. 
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Figure 4.13: Share of Detailing Counts by Generation for Antinausea Medication in 
- Italy ' 
Figure 4.14: Share of Detailing Counts by Generation for Antinausea Medication in 
France 
- 
Figure 4.15: Share of Detailing Counts by Generation for Antinausea Medication in 
Figure 4.16: Share of Detailing Counts by Generation for Antinausea Medication in 
us 
When the results about new drug share of patient days (Fig. 4.7) is compared to the 
results on detailing of new versus old antinausea medications, it can be seen that the 
sales-to-detailing ratio of new drugs is highest in the US, followed by the UK and Italy, 
and lowest in France. This implies that the US market is more prone to new drugs' 
penetration, which is supported by the finding that the new drug "premium" (Fig. 4.8) is 
much greater in the US than the other countries. 
The descriptive analysis of the sales and promotion of antinausea drugs has shown the 
coexistence of high use and extensive promotion in France and Italy. In the US and the 
UK, the level of promotion is much lower, and so is the level of use of antinausea 
medications per capita. The promotional activity in the UK is almost equally directed at 
physicians and nurses, presumably in an attempt to have the greatest impact on this 
country's small medical workforce. The promotional activity that does occur in the US is 
primarily focusing on new antinausea drugs, presumably because new medications 
command a much higher price in the US market, and pharmaceutical companies realize 
that focuses their promotional efforts on more expensive medications will result in higher 
overall sales. This is shown to be true when the total sales of antinausea drugs were 
compared across the sample countries. 
Many previous studies have found a positive relationship between sales in the 
pharmaceutical market and promotional efforts and pricing schemes. To test whether this 
held true for antinausea medications in the US, UK, France, Italy and Sweden, the 
relationship was numerically evaluated using econometric models. These econometric 
models, and their results are discussed in the following section. 
4.5 - Econometric Analysis 
In this section, results for the regression models at the class and generation levels 
discussed in Chapter 3 are reported. The goal of the models is to quantitatively examine 
the relationship between the diffusion of medicines (sales volume and market share) and 
promotional, economic, and policy factors. The explanatory factors studied include the 
intensity of promotion (lagged detailing counts), overall wealth of the country (income 
per capita), intensity of medical services (number of physicians and nurses per capita), 
and prices of medication. The right-hand-side (RHS) variables tot-detail-capita-lag1 and 
tot detail-capita-lag4 are regressed in separate models due to their high pair-wise 
correlation ( ~ 9 ) .  
Table 4.3 reproduces the regression results of Equation 1 in Chapter 3. For this regression 
log-totqd-lkcapita is the dependent variable; price, number of compounds, number of 
physicians, number of nurses, per capita income, and detailing information are 
correspondingly calculated at the class level. The variables used in the class-level 
regression models are not sufficient to accurately determine the driving factors of the 
antinausea markets in France, Sweden or the UK, as shown by the very low adjusted R- 
squared values. The major reason for the model being inadequate is that nausea is treated 
very differently in different countries. The point at which a patient is medically treated to 
control nausea and vomiting varies from one nation to the next [58, 591, and it is not 
possible to capture such cultural differences in a quantitative model. 
The class-level regression model finds the time variable to be positive and significant in 
the US, while it is negative and significant in Italy. This is probably due to the finding in 
the descriptive analysis presented in section 4.3 that antinausea sales (in patient-days) 
have been falling over the years in Italy, while they have experienced a small rise in the 
US over the last few years (see Fig.4.4). 
Price related variables are only found to be significant in the US. The model fmds that 
price has a negative impact on sales, while income has a positive effect. It is possible that 
price related variables would only be significant in the US because the US is the only 
country in the sample without a national health care system. This implies that American 
patients have to pay for a larger portion of their medical expenses than patients in the 
other five countries. This could make the US market for antinausea medications more 
price and income sensitive than markets in the other countries. 
The relative availability of medical professionals variable is only significant in the US 
and UK. The model finds nurses to have a negative and significant effect on antinausea 
patient-days in the US. The reason for this finding is unknown. In the UK, physicians are 
found to have a significant negative effect, where as nurses are shown to have a 
significant positive effect. This difference among medical professionals in the UK may 
be due to the fact that nurses, not physicians, attend to hospital patients suffering from 
nausea. Therefore, nurses may be more likely to request an antinausea medication to stop 
a patient's vomiting than a physician. However, it should be noted that the reliability of 
the data on nurses in the OECD database is unknown. Furthermore, it was not possible to 
divide detailing counts among physicians and nurses, and this inability to separate out 
promotional efforts to these two groups of medical professionals may add measurement 
error to the regression models. Thus, it is possible that the lack of statistical significance 
in these regression models relating to medical professionals could simply reflect 
measurement error. 
log-totqd- 1 kcapita) USA UK France 
Intercept 45.71933 1 12.49'784 1 49.78964 
Table 4.3: Regression Results for Equation 1 
logprice- 1 OOqd-class 
log~tot~num~compound 
logqhy S - ~ ~ P O P  
log-nurse- 1 Kpop 
log - income-capita 
Variable 
(Dependent: 
(2.80) (0.96) (-0.06) 
time .0218327 .OO 15462 00 194 16 
(2.65) (0.60) (-0.08) 
log-tot-detail-lag 1 .13 10095 -.025066 .2 17 1067 
(1.94) (-0.74) (1.52) 
log-tot_detail_lag4* -.O 1 3254 -.0070372 .0599 1 4 
(-0.39) (-0.45) (0.97) 
Number of Observations 32 44 29 
Adjusted R-Squared .83 .57 .10 
Parameter Estimate - ANTINAUSEA 
Italv Sweden 1 
t-values are shown in the parenthesis below the parameter estimates. 
*model was run with log-tot-detail-lag1 and then replaced with log-tot-detail-lag4. 
A second regression model with the share of patient days captured by the new generation 
of drugs (log-share-newqd) as the dependent variable was run to determine what factors 
impact the sale of new antinausea medications relative to the old generation of antinausea 
medications. The results of these regressions are shown in Table 4.4. (Note that it was not 
possible to run this regression model for France because old antinausea drugs accounted 
for 99% of all patient-days, so there were not enough observations with which to run the 
generational model on this country.) 
The time variable is the only variable found to be positive and significant in all four 
sample countries. This result confirms the finding in section 4.3 (see Fig.4.7) that new 
antinausea medications are increasing their market share over time. However, other than 
the time variable, the antinausea market in the four countries reacts very differently to the 
remaining variables in the generation-level regression model. 
In the generational-level regression models the price ratio of new to old antinausea 
medications has a significant and negative effect in the US and Italy, which indicates that 
higher prices for new antinausea drugs translates to lower sales in comparison to cheaper, 
older generation antinausea drugs in these countries. However, the opposite is found in 
Sweden, where higher prices translate to higher patient-day sales. One possible 
explanation for this surprising finding in Sweden is that Swedish physicians may equate 
higher price with higher quality, and therefore be more likely to prescribe expensive 
antinausea medications than cheaper antinauseants. 
Table 4.4: Regression Results for Equation 2 
Variable I Parameter Estimate - ANTINAUSEA I 
(Dependent: 
log-sharcnew pd) 
Intercept 
log-nurse-1 Kpop 
log-income-capita 
time 
log-rel-detail-lag 1 
Number of Observations 
Adiusted R-Sauared 
USA UK France Italy Sweden 
(-2,71) 
2.810 
-5.569 
(-0.1 5) 
-a5509 
(-3.64) 
1.9256 
(1.15) 
5.259 
Not 
Enough 
Data. 
27,564 
(2.44) 
-.28003 
(- 1.73) 
-.2602 1 
(- 1.14) 
-1.9553 
(0.2 1) 
-2.422 
(- 1.99) 
,0422 
(2,Ol) 
,2154 
t-values are shown in the parenthesis below the parameter estimutes. 
(- 1.35) 
2.0889 
(4.71) 
,2901 
*model was run with log-tot-detail-lag1 and then replaced with log-tot-detail-lag4. 
-42,1124 
(=2,22) 
me842812 
(-2.46) 
-.675714 
France 
(1.12) 
-1,960 
(-2*73) 
,04887 
(6A3) 
.0072648 
The number of new compounds on the market is found to have a significant positive 
2 1.2788 
(1 .6 1) 
,165261 
(3,OS) 
,476272 
Mostly 
(0.12) 
.0713447 
effect on new drug market share in Sweden, which corresponds to the descriptive analysis 
(-0.50) 
495542 
Uses 
"Old" 
Antinausea 
finding that new antinausea medications account for a larger share of patient days in 
Sweden than in the other four sample countries (see Fig.4.7). The generational model also 
(3,06) 
.729371 
(-0.25) 
Dropped 
Medications 
shows that the number of new compounds available has a negative and significant effect 
(0.49) 
-3.0837 
4,461376 
(231) 
,0559634 
(2,86) 
-.3 10032 
on new drug market share in the US. It is possible that hysicians in the US believe that R multiple new compounds means more "me-too" drugs , and not new novel antinausea 
(- 1.26) 
-2.8377 
(-353) 
,035629 
(5.66) 
NIA 
(- 1.75) 
-,I98006 
medications, and therefore, American physicians resort to prescribing old, established 
NIA 
antinausea drugs over a plethora of newer antinausea medications. 
Income per capita is found to be significant in the UK, Italy and Sweden. In Italy, income 
has a positive effect on new antinausea drugs gaining market share, while in Sweden and 
" A "me-too9' drug is a drug that is structurally very similar to other drugs already on the market, and has 
only minor differences. 
the UK, the effect is negative. This finding is confounding because all three countries 
have national healthcare systems that cover the vast majority of the cost of prescription 
medications; patients are only responsible for a minimal copay. Therefore, residents of 
these countries should be income neutral. Furthermore, even if income does have an 
effect, it is baffling that the effect would be negative. 
The detailing variable lagged four quarters is found to have a negative effect on new drug 
sales in Italy. Though this finding seems odd, when one refers back to Fig.4.13, the 
reason for the negative effect becomes clear. New antinausea medications are barely 
detailed in Italy, almost all detailing efforts are directed towards old antinausea drugs, 
and therefore it is understandable that detailing does not have a positive effect on new 
drug sales. 
The positive effect of detailing on new drug sales in the US was clearly indicated in 
section 4.4 (See Fig.4.16) and the regression model further supports this finding as both 
promotional variables are found to be positive and significant in the US. Finally, the 
regression model also reveals that promotional efforts have a positive impact on new 
drug sales in the UK. 
4.6 - Summary of the Antinausea Medication Market 
The market for antinausea medications in the US, UK, France, Italy and Sweden has 
experienced an overall decrease in patient days for the time period examined. This 
decrease is the combined result of improvements in chemotherapy and a reclassification 
of antinausea medications in the mid- 1990s. Interestingly, although the antinausea market 
experienced a slowdown, new antinausea medications are accounting for an increasing 
share of the market. This trend towards expansion over time for new antinausea 
medications was shown in both the descriptive analysis and in the generation-level 
regression models in all the sample countries for which the model could be run (every 
sample country except France). Furthermore, detailing efforts were found to have a 
significant positive effect on new antinausea drugs gaining market share in the US and 
the UK. Thus, even though cultural differences about medically treating nausea play a 
significant and immeasurable role in antinausea drug sales, the analysis in this chapter 
reveals several factors that appear to be operative in all sample countries. 
Chapter 5 - Antihypertensive Medications 
In this chapter, background is provided on hypertension and antihypertensive 
medications, followed by a discussion of the promotion of antihypertensives in the 
United States, United Kingdom, France, and Italy. Then econometric models used to 
quantify and compare the factors contributing to the sale of antihypertensives from 1992 
to 2003 are presented. Finally, a summary of the market for antihypertensive medications 
in the sample countries is presented based, on the analysis found in this chapter. 
5.1 = Symptoms and Causes of Hypertension 
Hypertension, commonly referred to as high blood pressure, is a condition where an 
individual's systolic and diastolic pressures are abnormally high. The Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC) has defined blood pressure categories, and defines hypertension to be a blood 
pressure reading of 140190 rnm Hg or higher (See Table 5.1). Hypertension often goes 
untreated because people with high blood pressure rarely show symptoms until the 
condition has progressed. In fact, a 2003 study found that only 58% of Americans with 
hypertension ever receive treatment for their condition [60]. Untreated hypertension can 
damage organs like the heart or kidney because hypertension causes these organs to 
overwork. In turn, organ damage can cause a multitude of serious problems including 
heart attack, stroke, and kidney failure [61]. 
Table 5.1 Blood Pressure Categories by JNC I Blood Pressure (Systolic/DiastoIic) I JNC VII Category I 
< 120180 
120- 139180-89 
Source: Chobanian et al. JAMA 2003; 289:2560-71. 
Normal 
Prehypertension 
140- 1591 90-99 
> 1601100 -
Many factors can contribute to an individual's chances of developing hypertension 
including heredity, obesity, a high salt diet, stress, drinking three or more alcoholic 
beverages daily, lack of exercise, and aging [62]. Though the actual causes of 
hypertension are still under investigation, researchers have found a few identifiable 
causes of hypertension, such as sleep apnea, chronic kidney disease, renovascular disease, 
chronic steroid therapy, and thyroid or parathyroid disease [63]. 
Hypertension - Stage 1 
Hypertension - Stage 2 
Hypertension is very common in developed countries; however, the percentage of the 
population with hypertension in developing countries has been rising over the years. 
Approximately 20% of the world's adult population is estimated to be hypertensive [64]. 
A 2003 study on hypertension in eight developed countries (Canada, England, Finland, 
Germany, Italy, Spain, Sweden, and the United States) found the average hypertension 
prevalence for adults 35 to 74 years of age to be 27.6% in the North American countries 
and 44.2% in the European countries [65]. At 42%, England had the highest hypertension 
prevalence of the five countries examined in this thesis. Italy and Sweden both had a 
hypertension prevalence rate of 38%. The rate in the US was found to be 28%. The WHO 
Monica project found that hypertension prevalence in France was 20% for the overall 
adult population [66]. Given the similarity in genetics and culture in Europe and the US, 
researchers believe differences in hypertension prevalence are due to differences in 
lifestyle and dietary habits, but these have yet to be examined closely [65]. 
Using the prevalence rates found in the studies mentioned above, and assuming that 
everyone with hypertension receives treatment, the per-capita demand for 
antihypertensives in the sample counties in this thesis can be calculated. The per-capita 
demand for antihypertensives in the UK should be approximately 50% higher than the 
US and 110% higher than in France1*. However, the data in this thesis shows that the per- 
capita sales for antihypertensives were highest in Sweden, followed by the UK, Italy, 
France, and the US actually has the lowest per-capita use of antihypertensives of the five 
sample countries. Unit sales in Sweden are 8% higher than sales in the UK and 57% 
higher than sales in the US, while only 27% higher than sales in France. Possible reasons 
for the higher sales in the EU countries than the US are discussed later in this chapter. 
5.2 - Types of Antihypertensives 
Hypertension, or high blood pressure, causes the force of blood on arterial walls to be 
abnormally high, thereby overworking the heart and blood vessels. Antihypertensive 
medications thus work to reduce this pressure by one, or a combination, of the following 
mechanisms: (1) reducing the workload on the heart, (2) widening or opening the blood 
vessels or (3) preventing closing or tightening of the blood vessels [67]. Ten types of 
hypertensive medications are currently available, divided into categories based on the 
mechanism of action by which they reduce blood pressure. The categories are: diuretics, 
alpha-blockers, beta-blockers, calcium channel blockers, Angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin I1 receptor blockers (ARBs), blood vessel dilators, central 
adrenergic inhibitors, peripheral and adrengeric inhibitors [68]. 
In the data and analysis section of this chapter, only the most common categories of 
antihypertensives are included: beta-blockers, calcium channel blockers, ACE inhibitors, 
and ARBs. Due to the fact that newer medications in a therapeutic class are often sold at 
higher prices and receive more promotional efforts, the different categories of 
antihypertensives have been broken into "new", "middle" and "old" generations based on 
when they first became available. Beta blockers and calcium channel blockers are 
categorized as "old", ACE inhibitors are categorized as "middle", and ARBs are 
categorized as "new". Table 5.2 lists these four different categories of antihypertensives, 
their mechanisms of action, and a few common drugs in each category. 
18 Demand difference between the UK versus the US and France calculated using: ((42%-28%)/28% = 
135.7%) and ((42%-20%)/20% = 190%). 
The effectiveness of antihypertensives is well accepted; however, these medications do 
have side effects. A study-found an increase in cancer incidence in users of calcium 
channel blockers [69]. Another study found that smoking, combined with the use of 
antihypertensives, caused cholesterol and triglyceride levels to increase [70]. In 2000, a 
meta-analysis of randomized clinical trials found that intermediate and long long-acting 
calcium channel blockers were less effective in preventing myocardial infarction and 
congestive heart failure than other antihypertensives [7 11. Newer antihypertensives have 
fewer, or less severe, side effects than older generation drugs, which helps raise the sale 
of these medications. Table 5.3 lists the common side effects of antihypertensives. 
Table 5.2 Categories of Antihypertensive Medications and Mechanisms of Action 
1 Blockers 1 receptors and can induce a rapid 1 Penbutolol I 1 1 Beta 
Generation Generic 
Name 
Categories 
Blocks the nervous system from 
releasing chemicals that bind with beta 
Calcium 
Channel 
Blockers 
ACE 
Mechanism of Action 
Atenolol, 
Betaxolol, I Old 
inhibitors 
heartbeat, thus reducing heart's work. 
Blocks calcium ions from sending 
signals to blood vessels to constrict 
and/or tighten. 
Prevents the production of angiotensin 
11, which is a chemical that causes blood 
ARBS 
vessels to tighten. 
Inhibit the action of angiotensin 11, 
Table 5.3 Common Side Effects of Antihypertensives 
-- - 
Source: ~edicine Net, http://Svww.medicinenet.com 
AmlodipineF 
elodipine, 
Ni fedipine 
Captopril, 
Enalapril, 
Lisinopril 
Losartan, 
Source: American Heart Association, http:/hww.arnericanheart.org 
which causes blood vessels to tighten, 
by blocking it from entering the 
angiotensin receptors. 
Beta Blockers 
Calcium 
Channel 
Blockers 
ACE 
inhibitors 
ARBS 
Old 
Middle 
Generation 
Candesartan 
Valsartan 
Generic 
Name 
Categories 
Insomnia, Cold hands and feet, 
Depression, Tiredness, Slow 
heartbeat, Symptoms of asthma 
Swollen ankles, Constipation, 
Palpitations, Headache, Dizziness 
Skin rash, Chronic dry hacking cough, 
Loss of taste, Weakness 
Dizziness, Elevated potassium level, 
Headache, Cough 
New 
Common Side Effects 
Atenolol, 
Betaxolol, 
Penbutolol 
Amlodipine, 
Felodipine, 
Ni fedipine 
Captopril, 
Enalapril, 
Lisinopril 
Losartan, 
Candesartan 
Valsartan. 
Old 
Old 
Middle 
New 
Currently, there is no class of antihypertensives that is considered better than the rest. 
However, it should be noted that there is some debate over the effectiveness of ACE 
inhibitors in African American patients. In the ALLHAT study, black patients who were 
treated with ACE inhibitors had higher blood pressure and an increased risk of stroke and 
cardiovascular diseases over black patients treated with diuretics [72]. 
Physicians prescribe a medication based on a patient's characteristics, as well as the 
physician's prescribing habits. In most patients, a single antihypertensive is not sufficient 
to reduce blood pressure to normal levels, but rather combination therapy, where two to 
three drugs were taken together, is often found necessary to reduce blood pressure to 
optimal levels [73]. Regardless of what medication is prescribed, the medical community 
stresses the need for patients to change their lifestyles to control hypertension. 
5.3 - The Sale and Use of Antihypertensive Medications 
The overall antihypertensive medication market in number of patient days amongst the 
sample countries was compared and graphed. The results are shown in the graph in Fig. 
5.1. In all five sample countries, the sale of antihypertensives has been rising over the 
years. The total number of patient days is highest in the US. The UK, Italy and France 
have very similar total patient day sales of antihypertensives. Sweden has the lowest total 
patient days of all five countries. 
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Figure 5.1: Total Patient Days for Antihypertensives 
When patient-days-per-capita'g is compared (See Fig. 5.2) across the five countries in 
this study, a very different picture on usage is revealed. The fastest rate of increase has 
been in Sweden and the UK. The per capita use of antihypertensives is rising in all five 
countries. Sweden has the highest use of antihypertensives, followed by UK, Italy, France 
l9 Patient-days-percapita is calculated by dividing the total patient days by the total population. 
and the US, respectively. At the end of 2003, annually one person in Sweden consumed 
8% more antihypertensives than a British person (15.590 verses 14.372 patient-days-per- 
capita), 22% more than an Italian (12.694 patient-days-per-capita), 27% more than a 
French person (12.303 patient-days-per-capita), and 57% more than an American (9.92 
patient-days-per-capita). 
Figure 5.2: Total Patient Days per Capita for Antihypertensives 
The total sales in dollars per capita was highest in the US, followed by the UK, Italy, 
France and Sweden. The graph in Fig. 5.3 shows that at the end of 2003, the sales per 
capita in the US were $6.83, compared to $6.41 in the UK, $5.58 in Italy, $5.42 in 
France, and $5.25 in Sweden. The price per patient day in the US is $0.69, which is 53% 
higher than the price per patient day in the UK ($0.45), 57% higher than the price per 
patient day in France and Italy ($0.44), and 103% higher than the price per patient day in 
Sweden ($0.34). The fact that patients in the US pay higher prices for their 
antihypertensives helps explain why total sales per capita are highest in the US. However, 
it should be noted that the price per patient day is trending downward in the US, while it 
is trending upward in the other four sample countries, indicating a trend toward 
convergence of dollar sales across the sample countries. 
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Figure 5.3: Total Sales (US$ PPP) per Capita of Antihypertensives 
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Figure 5.4: Price (US$ PPP) per Patient Day of Antihypertensives 
The graphs in Fig.5.5 through Fig.5.9 shows that break down of patient day market share 
in the five sample countries. In all five sample countries, old antihypertensive capture the 
largest percentage of patient days and the middle generation hypertensive medications 
capture the next largest share of patient days. However, new antihypertensives have been 
gaining patient day market share in all five sample countries over the time period 
examined. These graphs show that by the end of year 2003, new drugs account for 15.7% 
of patient days in France, 13% in Italy, 10.7% in Sweden, 9.8% in the US, and 9.3% in 
the UK. For an overview of new, middle, and old generation antihypertensives, refer to 
Table 5.2. 
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Figure 5.5: Percent of Patient-Day Market Share by Generation of 
Antihypertensives in Italy 
Figure 5.6: Percent of Patient-Day Market Share by Generation of 
Antihypertensives in France 
Figure 5.7: Percent of Patient-Day Market Share by Generation of Antihypertensive 
Drugs in Sweden 
- 
Figure 5.8: Percent of Patient-Day Market Share by Generation of Antihypertensive 
Drugs in UK 
Figure 5.9: Percent of Patient-Day Market Share by Generation of Antihypertensive 
Drugs in the US 
The price ratio of new to middle and old drugs is shown in Figs.5.10 and 5.1 1. In all five 
countries, new antihypertensive drugs cost more than middle and old generation 
antihypertensive drugs. Sweden has the highest premium on new antihypertensive 
medications with a price 4.8 times higher than middle drugs and over 7 times more than 
old drugs. In the UK and new drugs sell at a premium of 3.9 times the price of middle 
generation antihypertensives and 5.5 time the price of the old generation. In France, the 
new drug premium is 2.8 times the middle generation and 5.2 times the old generation. 
New generation medications cost 3.2 times more than the middle generation and 4 times 
more than the old generation in Italy. The situation is slightly different in the US, where 
middle generation antihypertensives are cheaper than the old generation, and therefore 
new drugs cost 5.6 times more than the middle generation and 4.2 times more than the 
old generation. 
Figure 5.10: Price Ratio of New to Middle Geeeration Antihprtemives 
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Even though Sweden has the highest price difference between new and old 
antihypertensives, the price per patient day in Sweden is the lowest of all five countries. 
One cause for the low price per patient day is probably the fact that new drugs account 
for a smaller portion of total patient days in Sweden than in some of the other sample 
countries. Thus, even though the new drug premium is high in Sweden, old drugs account 
for the majority of antihypertensive use in the county, and because old drugs cost less 
than new antihypertensives, the over all cost per patient day is kept low. A similar 
process is occurring in the UK, where new drugs account for the smallest percentage of 
patient days of all five sample countries (See Fig.5.5-Fig.5.9). France and Italy have 
similar prices for antihypertensives, and this leads to the countries having similar usage 
patterns, which fall between the rates in Sweden and the US. The price of 
antihypertensives is highest in the US, which keeps the patient day per capita low 
because the high cost of antihypertensives probably causes physicians to prescribe them 
sparingly. 
5.4 - The Promotion of Antihypertensive Medications 
This section discusses the detailing activities for the promotion of antihypertensive 
medications to physicians. As previously mentioned, the unique government controlled 
pharmaceutical distribution system in Sweden keeps detailing to a much lower level in 
this country than the other four countries in this thesis, so no detailing data is available on 
Sweden. Detailing activity in the US, UK, France, and Italy will be examined in this 
section. (Note that detailing data for the US is available fkom the first quarter of 1996, 
detailing data for France is available fkom the fourth quarter of 1996, and detailing data 
for Italy is only available from the first quarter from of the year 2000). 
Antihypertensive medications are promoted more heavily in Italy and France than in the 
US or UK through detailing to physicians. Fig. 5.12 and Fig. 5.13 show the total detailing 
counts per capita and per physician in the US, UK, France, and Italy. Physicians in Italy 
were detailed 7.3 times more frequently about antihypertensives than physicians in the 
UK, 5.8 times more often than physicians in the US, and 1.7 times more frequently than 
physicians in France for the year 2003. One possible reason for Italian physicians being 
detailed the most heavily is that the regulations on detailing in Italy restrict the number of 
samples a detailer can leave a physician (see Chapter 2). It is possible that this restriction 
causes detailers in Italy to rely more heavily on their verbal messages in changing 
prescribing behavior than on samples, therefore they visit physicians in Italy more 
frequently than physicians in the other three countries. 
Figure 5.12: Total Detailing Counts per Million Population for Antihypertensive 
Medications in France, Italy, US and the UK 
Figure 5.13: Detailing Counts per MWion Pitysicism for Antihypertensive 
Mdhtiow in Fmee, Itply, US and the UK 
When the share of detailing counts by generation of antihypertensive drug is compared 
(see Fig.5.14 - Fig. 5.1 7), an interesting pattern can be witnessed among the countries. In 
Italy the new generation of antihypertensive reached and then exceeded the detailing 
level of old generation antihypertensives over the time period examined. By the end of 
2003, detailing for new antihypertensives accounts for 5 1% of all detailing counts, old 
generation antihypertensives receive 3 1% of all detailing counts, and middle generation 
antihypertensives account for only 18% of the total detailing counts. 
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Figure 5.14: Share of Detailing Counts by Generation for Antihypertensives in Italy 
In France, old and middle generation antihypertensives are detailed almost equally from 
the fourth quarter of 1996 until the third quarter of 2000, with details for new 
antihypertensives lagging behind the two older generations. However, from the third 
quarter of 2001, new antihypertensives steadily receive a greater share of detailing 
counts. By the end 2003, new and old antihypertensive medications receive almost equal 
detailing attention at 37% and 38% of total counts, respectively. 
Figure 5.15: Share of Detailing Counts by Generation for Antihypertensives in 
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Figure 5.16: Share of Detailing Counts by Generetion for Antihypertensives 
In the UK, new antihypertensives start off with a small share of detailing counts, but 
quickly meet and then exceed the detailing counts for old drugs. By the fourth quarter of 
2003, new antihypertensives account for nearly 67% of all detailing counts for the 
therapeutic class, which is the greatest share of detailing counts devoted to new 
antihypertensives of all the sample countries. While in the US, new antihypertensive 
drugs reach and exceed the detailing level of old drugs by the second quarter of 2003. By 
the fourth quarter of 2003, 49% of all detailing efforts are focused on new 
antihypertensives. 
Figure 5.17: Share of Detailing Counts by Generation for Antihypertensives in the 
US 
I ,- 
The descriptive analysis of the sales and pr6k&tion of antihypertensive drugs has shown 
the coexistence of high use and extensive promotion in France and Italy. In the UK, the 
level of promotion is much lower; however, the level of use of antihypertensive 
medications per capita is higher in the UK than in France, Italy or the US. This is most 
likely due to the fact that hypertension prevalence in the UK is the highest of all five 
sample countries [65], which would lead to higher demand, regardless of promotional 
efforts. In fact, it is possible that detailing efforts with respect to antihypertensives are 
low in the UK for this very reason; pharmaceutical companies know the demand will be 
high because of the prevalence of hypertension, so do not see the need to spend much 
money promoting antihypertensives in the UK. Promotional activity is also low in the 
US, and the promotional efforts are essentially evenly distributed among old and new 
antihypertensive medications. The middle generation antihypertensives cost less than 
both the new and old generations in the US, which makes these drugs more popular in 
America than the other four sample countries. It is possible that new and old 
antihypertensives are promoted almost equally in the US to try to encourage physicians to 
move away fiom lower cost middle generation to higher cost new and old generation 
antihypertensives. Also it is possible that the overall higher cost of antihypertensives in 
the US relative to the other sample countries results in physicians more strongly 
recommending non-medical solutions to contr( "ing blood pressure than physicians in 
other countries. This behavior may cause pharmaceutical companies to detail 
antihypertensives less heavily because they know that physicians are only prescribing 
them as a last resort, so the detailer's time is bette !wqaa. promoting medications in other 
more heavily prescribed therapeutic classes. , , , , 
Many previous studies have found a positive relationship between sales in the 
pharmaceutical market and promotional efforts and pricing schemes. To determine 
whether this held true for antihypertensive medications in the US, UK, France, Italy and 
Sweden, the relationship was tested using econometric models. These econometric 
models and their results are discussed in the following section. 
5.5 - Econometric Analysis 
In this section, the regression models at the class and generation levels discussed in 
Chapter 3 are estimated. The goal of the models is to quantitatively examine the 
relationship between the difhsion of medicines (sales volume and market share) and 
promotional, economic, and policy factors. The factors studied include the intensity of 
promotion (lagged detailing counts), overall wealth of the country (income per capita), 
availability of medical services (number of physicians per capita), and prices of 
medication. The right-hand-side (RHS) variables tot-detail-capita-lag1 and 
tot detail capita-lag4 are regressed in separate models due to their high pair-wise 
coGelatioi ( ~ 9 ) .  
Table 5.4 shows the regression results of Equation 1 in Chapter 3. For this regression 
log-totqd lkcapita is the dependent variable; price, number of compounds, number of 
physicians~per capita income, and detailing information are correspondingly calculated at 
the class level. 
The results displayed in Table 5.4 show that the time variable is positive and significant 
in the US, UK, France and Sweden. Thus, the class-level regression model shows that the 
total number of patient days has been increasing over time in these four countries. This 
finding agrees with the earlier descriptive analysis section 5.3, which found that use of 
antihypertensives had been increasing over time. 
The total number of compounds is found to have a negative and significant effect on 
patient day sales in both the UK and France. This finding suggests that the number of 
compounds available in the UK and France has been increasing faster than patient day 
sales. 
Income is found to have a positive significant effect in the UK, but a negative significant 
effect in Italy. It is unclear why income would have an effect in either one of these 
countries because both have national health care systems that provide prescription drug 
coverage. 
Detailing is found to have positive and statistically significant effects in France and Italy, 
while the detailing lagged four quarters variable is found to have a negative and 
statistically significant effect on the sale of antihypertensives in the UK. The positive 
effect of detailing in France and Italy explains why antihypertensives are detailed far 
more heavily in these two sample countries than in the UK or the US (see Fig.5.11 and 
Fig.5.12). 
To determine what factors play a role in diffusing newer generations of medications, a 
regression model with the number of new patient days being the dependent variable was 
created. Because there are three separate generations of antihypertensive medications 
(new, middle, and old), two versions of the generation-level regression model were run 
for the antihypertensive therapeutic class. The first model aims at determining what 
factors impact the diffusion the new generation of antihypertensives, so old and middle 
generation antihypertensives are combined in this model. The second model tries to 
determine what factors influence newer generation medications taking market share away 
fiom old generation drugs; therefore, in this second model new and middle 
antihypertensives are grouped and counted together. The regression results of these 
models are shown in Tables 5.5 and 5.6. 
w d  lkcapita) USA UK France 
Intercept 4.660926 9.150798 20.66256 
(2.1 1) (334) (3.16) 
logprice-1 OOqd-class .03 12038 .0229905 -.08448 16 
Table 5.4: Regression Results for Equation 1 
(0.23) (. 3 6) (- 1.79) 
1og~tot~num~compound .233 3966 -5057945 -.8432457 
Variable 
(Dependent: 
l o g q h ~ s - l m ~ o ~  
log-income-capita 
time 
log-tot-detail-lag 1 * 
Parameter Estimate - ANTIHYPERTENSIVES 
(- 1.2 1) (-2.29) (3.65) 
Number of  Observations 32 36 29 
Italv Sweden 
t-values are shown in the parenthesis below the parameter estimates. 
*model was run with log-tot-detail-lag4 and then replaced with log-tot-detail-lagl. 
As shown in Table 5.5, the time trend variable is positive and statistically significant in 
the US, UK, France and Italy. This finding indicates that over time new antihypertensives 
have been gaining patient day market share, which agrees with the finding in section 5.3 
that sales of new antihypertensives has been rising relative to the middle and old 
generations (see Figs. 5.5-5.9). 
The price of new antihypertensives relative to old and middle generation drugs if shown 
to have a statistically significant negative effect in the US and UK, while it has a 
statistically significant positive effect in Sweden. This indicates that the higher price of 
new drugs is slows down the diffision of new antihypertensives in the US and UK. The 
reason that higher prices are shown to increase patient day sales in Sweden may be due to 
the structure of the national health care system in Sweden, which helps patients pay for 
prescription medications only after they hit an annual expenditure ceiling. It is possible 
that Swedish physicians prescribe more expensive medications in order to help patients 
reach the expenditure ceiling quicker. 
The share of new compounds is shown to have a positive and statistically significant 
effect on new antihypertensives gaining market share in the US, France and Sweden. This 
indicates that the expansion of the new generation sales is accompanied by increased 
options for treatment with the generation in these three countries. 
Finally, detailing is found to have a positive and significant effect in France and the UK, 
and a negative and significant effect in the US. This suggests that higher detailing efforts 
result in higher sales of new antihypertensives in France and the UK, but heavy 
promotion fails to have a positive effect on sales in the US. 
I Intercept 1 -10.1962 1 -13.2702 1 -1.75053 1 .4490562 
Table 5.5: Regression Results for Equation 2 
(- 1.29) (- 1.03) (-0.07) (0.05) 
logqrice-ratio -.800011 -2.23839 -.4 197254 -.4982759 
Variable 
(Dependent: 
log-share-newqd) 
log - share-new-compound 
I logqhys-1 mpop 
log-income-capita 
Parameter Estimate - ANTIHYPERTENSIVES 
USA UK France Italy 
Sweden 
time 
(4.75) (2.28) (3.94) (5.40) 
log-rel-detail-lag 1 * -.059316 .7522403 .2990859 -.0060478 
(-2.66) (4.42) (8.08) (- 1.23) 
log-rel-detail-lag4 -.050038 .7805679 .2521363 -.0048253 
(- 1.95) (13.05) (4.86) (-0.47) 
Number of Observations 32 35 29 16 
Adjusted R-Squared .99 .99 .98 .98 
t-values are shown in the parenthesis below the parameter estimates. 
*model was run with log-tot-detail-lag and then replaced with log-tot-detail-lagl. 
As shown in Table 5.6, the model combining new and middle generation 
antihypertensives into a single group found the time trend variable to have a positive and 
statistically significant effect on these newer generation products gaining market share in 
all five sample countries. This finding agrees with the findings in section 5.3 about old 
antihypertensives losing market share over time to newer medications. 
The number of physicians in a country is shown to have a positive and significant effect 
in the UK and in Italy. This indicates that physicians in these two sample countries may 
be more likely to prescribe newer generation antihypertensives than physicians in the 
other three sample countries. 
The price ratio of new-middle to old generation drugs is found to have statistically 
significant and negative effects on the newer generation products gaining market share. 
This indicates that higher prices impede newer generations of drugs from gaining market 
share in Italy. It is unclear why the price ratio variable is found to have a positive and 
significant effect in the UK when new and middle generation products are combined, 
when this variable was shown to have a negative effect on the diffusion of new 
medications alone. 
Table 5.6: Regression Results for Equation 2* 
Variable I Parameter Estimate - ANTIHYPERTENSIVES I 
I (Dependent: I I 
log share pdnewmid) 
Intercept 
log-income-capita 
time 
log - re1 - detail-newmid-lag 1 * 
Number of Observations 
Adjusted R-Squared 
t-values are shown in the paren 
*model was run with log-tot-dc 
I USA UK France Italy Sweden 
-239031 1 636480 1 -.53734 1 -4.9987 1 -4.15668 
fiesis below the parameter estimates. 
tail-lag4 and then replaced with log-tot-detail-lagl. 
Income per capita is found to have a negative and statistically significant effect in Italy. It 
is possible that the copay on prescription medications in Italy causes this negative effect. 
Income is not found to have a statistically significant effect in any of the other countries. 
Detailing is again found to have a statistically significant positive effect in France, and 
also shown to have a statistically significant positive effect in Italy. This indicates that 
detailing of middle generation drugs increases sales in Italy, while detailing of only the 
new generation antihypertensives failed to have a statistically significant effect. 
5.6 - Summary of the Antihypertensive Medication Markets 
The antihypertensive markets in the US, UK, France, Italy and Sweden expanded in both 
patient days and dollar sales over the time period examined. In all five sample countries, 
the old generation of antihypertensives accounts for the largest portion of patient days; 
however, the new generation of antihypertensives has been increasing their share of the 
market. The fastest growth for new antihypertensives occurred in France and the US. 
Detailing activities for the antihypertensive therapeutic class are shown to have a 
significant positive impact in France and Italy, which explains why promotional efforts 
are heavier in these two sample countries than in the US or UK. 
Chapter 6 - Antipsychotic Medications 
In this chapter, background is provided on psychosis and the antipsychotic medications 
used to treat these conditions. The use and detailing of antipsychotic drugs in the United 
States, UK, France, and Italy follow this discussion. Econometric models are then used to 
quantify and compare the factors contributing to the sale of antipsychotic medications 
from 1992 to 2003. Finally, a summary of the antipsychotic market in the five sample 
countries is presented, based on the analysis repeated in this chapter. 
6.1 - Symptoms and Causes of Psychosis 
Psychosis is a broad psychiatric term used to describe a mental state where thought and 
perception are severely impaired. Individuals who suffer fiom psychotic episodes may 
experience hallucinations, possess delusional beliefs, undergo rapid personality changes, 
and have a disorganized thought process. Psychosis may be caused by multiple factors 
ranging from genetics to stress to illicit drug overdoses. The focus of this portion of the 
thesis is on schizophrenia, which is the most expensive and dehabilitating of the mental 
disorders leading to psychosis [74]. 
Schizophrenia is a mental disorder characterized by impairments in the perception of 
reality and by significant social or occupational dysfunction. The term "schizophrenia" is 
derived fiom Greek and means "shattered mind". The exact causes of schizophrenia are 
currently unknown; however, a few factors that increase the chances of developing 
schizophrenia have been identified. Because schizophrenia tends to run in families (See 
Fig. 6.1), the role that genes play in the development of the condition is being rigorously 
studied by various institutions including the NIMH. In addition, prenatal difficulties like 
intrauterine starvation or viral infections also appear to influence the incidence of 
schizophrenia [75]. 
The prevalence of schizophrenia is approximately 7 per 1000 adults, and predominantly 
affects people in the 15-35 year age group [76]. It is the most expensive of all mental 
disorders. It was estimated that in the year 2002, the cost of schizophrenia was $62.7 
billion, which included direct treatment, societal and family costs [77]. 
An estimated 24 million people have schizophrenia worldwide and 50% of them do not 
receive adequate treatment for their condition [76]. The reason for this deficit in 
treatment is mostly due to the lack of an objective laboratory test to diagnosis 
schizophrenia. Diagnosis of schizophrenia is therefore based on the behavior of the 
patient, and though diagnosis and treatment of schizophrenia has less cultural differences 
than other mental disorders, such as depression, there is still substantial discrepancy 
among physicians in diagnosing the condition [78]. 
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Figure 6.1: Risk of Developing Schizophrenia Based on Family History of Condition 
The most commonly used criteria for diagnosing schizophrenia in the United States is the 
American Psychiatric Association's Diagnostic and Statistical Manual of Mental 
Disorders (DSM). According to the DSM, for a person to be diagnosed as having 
schizophrenia, helshe must display the following [79] : 
(A) Characteristic symptoms: Two or more of the following20, each present for a 
significant portion of time during a one-month period (less if successfully 
treated): (1) delusions, (2) hallucinations, (3) disorganized speech, (4) grossly 
disorganized or catatonic behavior, (5) negative symptoms - lack or decline in 
emotional response, speech, or motivation; 
(B) SociaVoccupational dysfunction: For a significant portion of the time since 
the onset of the disturbance, one or more major areas of fimctioning such as work 
or interpersonal relations are markedly below the level achieved prior to the onset; 
(C) Duration: Continuous signs of the disturbance persist for at least six months. 
This six-month period must include at least one month of symptoms that meet 
Criterion A; 
(D) Schizoaffectivel Mood Disorder exclusion: Schizoaffective Disorder and 
Mood Disorder with psychotic features have been ruled out; 
(E) Substancelgeneral medical condition exclusion: The disturbance is not due to 
the direct physiological effects of a substance (illegal drugs or medication) or a 
general medical condition; 
(F) Relationship to a Pervasive Developmental Disorder: If there is a history of 
autism or another pervasive developmental disorder, the additional diagnosis of 
schizophrenia is made only if prominent delusions or hallucinations are also 
present for at least a month. 
*' According to the DSM, if a person has bizarre delusions or hallucinations that involve continuous voices, 
he/she does not need to meet two or more criteria in A) to be considered schizophrenic. 
Once a patient is diagnosed with schizophrenia, helshe is usually placed on some form of 
antipsychotic medication to control the condition. The different types of antipsychotic 
medications are discussed in the following section. 
6.2 - Types of Antipsychotic Medications 
Antipsychotic medications can be broken into two broad categories: "typical" and 
"atypical" antipsychotics. "Typical", or fust generation, antipsychotics were introduced 
in the mid-1950s and work by reducing the action of a particular chemical in the brain 
called dopamine [48]. These older medications effectively reduce the psychotic events a 
patient suffers, but they have serious side effects (See Table 6.2). 
During the last two decades, a new generation of antipsychotic medications has been 
introduced. These "atypical" antipsychotics reduce the psychotic events associated with 
schizophrenia and other mental disorders by blocking a different set of chemical 
transmitters than the "typical" antipsychotic medications (See Table 6.2). While there is a 
debate over whether the new antipsychotics are better at managing the characteristic 
symptoms of schizophrenia than the old generation of drugs [go], most agree that the 
newer antipsychotics have fewer and less severe side effects than the old medications. In 
addition, there is some evidence that the new drugs may help reduce the "negative" 
symptoms of schizophrenia, which the older drugs were not able to handle effectively 
[48]. Tables 6.1 and 6.2 list the common "typical" and "atypical" antipsychotics currently 
available globally, their mechanisms of action, and the side effects. 
Table 6.1: Categories and Mechanisms of Action for Antipsychotic Medications 
Typical Antipsychotic - 
Dopamine Antagonist 
Generation Ca@!or~ 
Block dopamine 
receptors in all 
.2 C, Q 
k 
e d  
C, 
4 
- 
0 
-a 
i? 
4 
Mechanism of 
Action 
Chlorpromazine, 
Haloperidol, Pimozide I Old 
Source: Royal College of Psychiatrists, http://www. rcpsych. ac. uk/ 
parts of the brain. 
Blocks dopamine 
and serotonin 
receptors in the 
brain. 
Only blocks a 
portion of 
dopamine 
receptors and also 
blocks serotonin 
receptors. 
Dopamine 
and Serotonin 
Antagonist 
Partial 
Dopamine 
Antagonist 
Common Drug 
(Generic) 
Fluphenazine, 
Tri fluoperazine. 
Amisulpiride, 
Clozapine, Olanzapine, 
Sertindole, Zotepine, 
Quetiapine 
Aripiprazole 
New 
New 
I Dopamine Antagonist 1 similar to 1 Fluphenazine, I I 
Table 6.2: Common Side Effects of Antipsychotic Medications 
I Parkinson's. 
Category 
Typical 
Antipsychotic - 
I Tri fluooerazine. 
Common Side 
Effects 
Restlessness, 
Stifmess and Shaking 
I Amisulpiride, Dopamine 
and 
Serotonin 
Antagonist 
Partial 
Dopamine 
Antagonist 
I Clozapine, Olanzapine, 
Common Drug 
(Generic) 
Chlorpromazine, 
Haloperidol, Pimozide 
Sleepiness and 
slowness, Weight 
gain, Increased risk 
of diabetes. 
Headaches, Nausea, 
Vomiting, Insomnia 
Restlessness 
( Sertindole, Zotepine, 
Generation 
Old 
uetia ine  
New 
New 
6.3 - The Sale and Use of Antipsychotic Medications 
The overall antipsychotic medication market in number of patient days was compared 
amongst the sample countries and graphed. The results are shown in Fig. 6.2. The sale of 
antipsychotics has been rising in all five countries; however the rate of increase is much 
greater in the United States than in the other countries. Total sales in patient days in the 
US rose fkom 5.9 million patient days in the first quarter of 1994 to 184 million patient 
days in the fourth quarter of 2003, which represents an increase of over 3 100%. 
When patient-days-per-capita is compared, the sales of antipsychotics across the five 
sample countries is shown to have risen at a much more similar rate in the different 
countries examined (See Fig.6.3). Though the US has the highest patient days per capita 
(.632 patient-days-per-capita), Sweden is a very close second (.628 patient-days-per- 
capita), followed by the UK (.428 patient-days-per-capita), France (.376 patient-days-per- 
capita), and Italy (.319 patient-days-per-capita). In all countries, except Italy, the sale of 
antipsychotics per capita rose steadily during the entire period examined. The 
introduction of atypical antipsychotics is probably the major reason for the increased use 
of antipsychotics. The lower, and less serious, side effects of atypical antipsychotics has 
led physicians to use these medications to treat other mental illness beyond psychosis, 
such as depression [8 1 1. 
Figure 6.2: Total Patient Days for Antipsychotics 
Figure a3: ToCol Patsent Days per Capita (or Antipsych&ics 
The graphs in Fig.6.4 and Fig.6.5 illustrate the total sales per capita and the price per 
patient day in purchasing power parity (PPP) adjusted US dollars. As shown in Fig. 6.4, 
the total sales of antipsychotics drugs rose in all five sample countries during the time 
period examined. The price per-patient-day has fallen slightly in all of the countries. The 
reason for the price decrease is that the majority of antipsychotics came off patent during 
the period examined, and lower cost generics became available. For example, the most 
popular atypical antipsychotic medication, Clozapine, came off patent in 1994 in the US, 
and there is a noticeable drop in the total sales per capita and price per patient day during 
this period. 
Figure 6.4: Total Sales per Capita in US$ (PPP) for Antipsychotics 
The price-per-patient-day is highest in the US, followed by the UK, with France and 
Sweden having similar per patient day prices, and Italy having the lowest price-per- 
patient-day of all five countries (See Fig.6.5). Despite the drop in per-patient-day prices 
in all five countries over the period examined, the gap in price between the US and the 
other four countries remains large. At the end of 2003, the per-patient-day price in the US 
for antipsychotics was $6.99, which was 2.1 times the price in the UK ($3.27), 2.7 times 
the price in Sweden ($2.56), 2.8 times the price in France ($2.5 l), and 3.8 times the price 
in Italy ($1.85). 
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Figure 6.5: Price per Patient Day in US$ (PPP) for Antipsychotics 
The benefits of atypical antipsychotics over typical antipsychotics are evident in looking 
at the patient day market share captured by these new drugs. As shown in Fig.6.6, new 
antipsychotic drugs account for 99% of all patient days in the UK, in France and the US 
new antipsychotics make up 97% of total patient days, in Italy they account for 93% of 
all patient days, and in Sweden 88% of all patient days are captured by the atypical 
antipsychotics. 
Figme 6.7: Rke htb d New to Old AntSpychda 
The diB-ces in market sbme of new to old drags can be exp1hed by emmiahg the 
price ratio betwm the two cr$egories of drugs in thc ~ ~ 4 3 1 ~  cauntriw (See Fig.6.7). The 
antipsycMics (stypiads) d old 
sntipsfdmtk. Tbis M g B a  prke on new ~ ~ c a t g t i ~  helps e q W  why old 
antipy~hdics are wed with marr frequency in Sweden thaa in the othn four sample 
countries. The price of new antipsychotic medications is 1.4 times the price of old drugs 
in France, Italy and the US. This lower new drug premium helps explain the higher rates 
of new antipsychotics use in these three countries. Interestingly, atypical antipsychotics 
actually sell at a lower price than typical antipsychotics in the UK. The price of atypicals 
is .75 times the price of typical antipsychotics. The reason for this phenomenon cannot be 
explained by the data that were available for this thesis, but pose an interesting question 
for further study. However, this lower price of new drugs explains why new 
antipsychotics account for 99% of all patient-days in the UK. 
6.4 - The Promotion of Antipsychotic Medications 
This section discusses the detailing activities for the promotion of antipsychotic 
medications to physicians. Due to the unique pharmaceutical distribution system in 
Sweden, there is no detailing data available for this country. Therefore, detailing activity 
in the US, UK, France, and Italy will be examined in this section. (Detailing data for the 
US is available fiom the first quarter of 1996, for the UK it is available fiom the third 
quarter of 1996, for France it is available from the first quarter of 2001, and for Italy it is 
available from the fvst quarter of 2000). 
The reduced side effects of atypical antipsychotics have led to a considerable amount of 
antipsychotic detailing effort being directed towards general practitioners, in addition to 
psychiatrists. A study examining the effect of promotional efforts for antipsychotic 
medications directed at GPs showed a three-fold increase in the number of antipsychotics 
prescriptions written by GPs after they were visited by detailers [81]. Thus, this section of 
the thesis examines total detailing effort of antipsychotics to all physicians (GPs, 
psychiatrists, ect). 
Figures 6.8 and 6.9 report the total detailing counts per capita and per physician in the 
US, UK, France, and Italy. The data show that antipsychotics are detailed most heavily in 
the US. On the class level, the number of detailing visits to physicians for antipsychotic 
medications was 3.4 times higher in the US than in France, 4.2 times higher in the US 
than in Italy, and 14.7 times higher in the US than in the UK for the year 2003. In fact, 
during the time period examined, the number of details per physician has been steadily 
rising in the US, although it has fallen in the other three sample countries. One possible 
reason for American physicians being detailed the most heavily is that the Americans use 
antipsychotic drugs at a much higher level than the residents of the other three countries 
(Fig. 6.3), therefore, it may be more worthwhile to detail antipsychotic medications to 
physicians in America over physicians in the other three countries. 
Figure 6.8: Total Detailing Counts per Million Population for Antipsychotics 
Figure 6.9: Total Detailing Counts per Million Physicians for Antipsychotics 
When the share of detailing counts for antipsychotic medications is compared by drug 
generations (See Fig.6.10- Fig. 6.13), an interesting trend is revealed. In all five 
countries, by the end of the year 2000, new antipsychotics account for over 98% of the 
detailing counts. This intense detailing of new antipsychotic medications in all sample 
countries further explains why these new generation medications captured the vast 
majority of patient days in all five countries (Fig. 6.6). The high detailing efforts ensured 
that physicians learned about the benefits of atypical antipsychotics and began 
prescribing these medications over the typical antipsychotics. 
Figure 6.10: Share of Detailing Counts by Generation for Antipsychotics in Italy 
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Figure 6.11: Share of Detailing Counts by Generation for Antipsychotics in France 
Figure 6.12: Share of Detailing Counts by Generation for Antipsychotics in the UK 
120 
roo 
Ob 
1 8 0  
I 
E W  
I! 
0 
4 3 * 4 &  4 4 4  3 4  
8 8 6  9. g ~ & a d ) ~ g d ~ 6 $ O ~ ~ b 4 ~ & 8 & @  
[+NW t o l d  I 
Figure 6.13: Share of Detailing Counts by Generation for Antipsychotics in the US 
The descriptive analysis of the sales and promotion of antipsychotic drugs reveals the 
coexistence of high use and extensive promotion in the US. Conversely, the lower level 
of promotional dE0;rt in thc UK cornsponds to a lower per-capita level of use. The data 
on detailing shows that almost (111 promotional efforts are directed t o w d  newer, atypical, 
antipsychotic medications. These promotional efforts appear to have had a dramatic 
affect as new antipsychotic medidons account for over 90% of all patientdays in every 
sample country except Sweden, which is the only country where detailing efforts are 
negligible. 
1 
Many previous studies have found a positive relationship between sales in the 
p ~ e u t i c r r l  market and promotional efforts and pricing schemes [3, 821. To 
detemine whether this held true for mtipsychotic medications in the US, UK, Fmce, 
Italy and Swtden, the relationship ww assessed empirically using e c m o d e  models. 
These econometric models and their results are discussed in the following section. 
6.5 - Econometric Analysis 
In this section, the results for regression models at the class and generation levels of 
aggregation discussed in Chapter 3 are reported. The goal of the models is to 
quantitatively examine the relationship between the diffusion of medicines (sales volume 
and market share) and promotional, economic, and policy factors. The factors studied 
include the intensity of promotion (lagged detailing counts), overall wealth of the country 
(income per capita), availability of medical services (number of physicians and nurses per 
capita), and prices of medication. The right-hand-side (RHS) variables 
tot-detail-capita-lag1 and tot-detail-capitclag4 are regressed in separate models due to 
their high pair wise correlation ( ~ 9 ) .  
Table 6.3 shows the regression results of Equation 1 in Chapter 3. For this regression 
log-totqd-lkcapita is the dependent variable; price, number of compounds, number of 
physicians, per capita income, and detailing information correspondingly calculated at the 
class level are the explanatory variables. 
Table 6.3: Regression Results for Equation 1 
Variable 1 Parameter Estimate 1 
I (Dependent: I I 
log totqd lkcapita) 
Intercept 
l o g P h ~ s - l m ~ 0 ~  
log-income-capita 
time 
log-tot-detail-lag 1 * 
USA UK France 
- 17.896 
(-2.70) 
-.55025 
(- 1.39) 
.528278 
(3.15) 
Italy Sweden 
-- - -- 
t-v&es shown inparenthesis below the parameter estimates. 
*The model was r u n  with log-tot-detail-lag4 replaced by logItottdetailI1uggl. 
2.044805 
(0.06) 
-1.05297 
(-2.40) 
-.307062 
(-0.87) 
Number of Observations 
Adjusted R-Squared 
The results displayed in Table 6.3 show that the parameter estimate for the time variable 
is positive and significant in every country except Italy, where it is still positive, but not 
significant. Thus, the class-level regression model shows that the total number of patient 
days has been increasing over time in all five sample countries. This finding agrees with 
the earlier descriptive analysis section 6.3, which found that use of antipsychotics had 
been increasing over time. 
-46.5989 
(-3.28) 
.I59069 
(2.05) 
.340747 
(5.53) 
- 13.2996 
(- 1.05) 
.05 1 129 
(0.43) 
.00175 1 
2 
The parameter estimate for the price-per-patient day variable is also significant in the 
UK, France, and Italy. One would expect that if price has any effect on use, it should be a 
negative effect, which is what is found to be the case in Italy and France; however, the 
model finds a positive effect in the UK. The reason for this is unknown. 
12.50509 
(1 .OO) 
-.582704 
(-5.60) 
.O 1 77698 
(0.22) 
(-2.12) 
32 
.99 
The total number of compounds is positive and significant in the US and the UK, which 
suggests that the number of compounds and total patient days per capita have a positive 
relationship in these two countries. One possible explanation for this result is that more 
compounds means that more drug options are available, which is important in most 
(-252) 
43 
.99 
(0.95) 
44 
.98 
(0.89) 
16 
.89 
40 
.98 
therapeutic classes, but especially important in mental health, as different patients 
respond vastly differently to the same compound. 
Income per capita is found to be positive in all five sample countries, but only significant 
in the US and the UK. This suggests that higher incomes lead to a larger number of drugs 
being purchased. This relationship is understandable in the US, where there is no national 
health care system, so a patient's ability to purchase a medication may well depend on 
their economic status; however, the positive link between income and patient-days in the 
UK is harder to explain because the NHS covers mental health expenses for residents in 
the UK. 
Finally, the effect of detailing lagged four quarters also is shown to be negative and 
significant in the UK and US. While it seems odd that promotional activities would have 
a negative affect on sales over time, this result may be indicating that promotional efforts 
wear off over time, and not necessarily that they have a negative impact on sales. 
A second regression model with the share of patient days captured by the new generation 
of drugs (log-share-newqd) as the dependent variable was run to determine what factors 
impact the sale of new antipsychotics relative to the old generation of antipsychotic 
medications. The results of these regressions are shown in Table 6.4. (Note that it was not 
possible to run this regression model for the UK because new antipsychotics account for 
99% of all patient-days, so there were not enough observations with which to run the 
generational model.) 
In these regressions, the parameter estimate for the price ratio of new to old drugs is 
found to be negative and significant in the US, France, and Italy. This suggests that the 
higher the price of the new drug, the less likely it is to be sold relative to the old drug in 
these three countries. 
In the US and Sweden the parameter estimate for the share of new compounds available 
is positive and significant, suggesting that the greater the number of new compounds, the 
greater than the share of patient days captured by the new generation of drugs. 
Both the number of physicians and the time variable have positive and significant 
parameter estimates in the US. This implies that the more physicians there are, the faster 
new drugs will capture market share. It also suggests that new drugs capture more market 
share over time, which is shown to be the case in section 6.3. However, the regression 
model also finds that the detailing variable lagged four quarters is negative and 
significant, which indicates that detailing efforts are no longer effective in promoting new 
drugs one year after the promotional effort occurs. 
Lastly, both income. per capita and detailing efforts lagged one quarter have positive 
significant effects in Italy. This suggests that a higher income level translate to newer 
drugs being purchased more frequently in Italy. While newer drugs are more expensive 
than older drugs, Italy has a national health care system that covers prescription 
medications, so it is unclear how income would play a role in diffuse new medications in 
this country. The detailing efforts having a positive effect is in agreement with studies 
that have found detailing to promote new drug sales in antipsychotics [8 11. 
6.6 - Summary of the Antipsychotic Medication Market 
Table 6.4: Regression Results 
Variable 
(Dependent: 
log share-newqd) 
Intercept 
loggrice-ratio 
log - share-new-compound 
l ~ g J ? h ~  S - ~ P O P  
log-income-capita 
time 
log-rel-detail-lag 1 * 
log-rel-detail-lag4 
Number of Observations 
Adjusted R-Squared 
t-values shown in parenthesis 
The market for antipsychotic medications in the US, UK, France, Italy and Sweden has 
experienced significant growth in both patient-days and dollar sales over the 1992-2003 
time period examined. This trend towards expansion over time was shown in both the 
descriptive analysis and in the therapeutic class regression models. In all five countries, 
new atypical antipsychotics dominated the detailing efforts of pharmaceutical companies; 
however, the regression models only found the effect of detailing to be significant and 
positive in Italy. Even though new antipsychotics are more expensive than old 
antipsychotics in every country examined, except the UK, these new drugs accounted for 
the vast majority of patient days in all five countries. The generational level regression 
model found price to be negatively related to patient-days in the US, France, and Italy, 
suggesting that sales of new antipsychotics would be even higher than current levels if 
the price of new antipsychotics were lowered. 
*The model was run with log-tot-detail-lag4 replaced by log-tot-detail-lagl. 
for Equation 2 
Parameter Estimate - ANTIPSYCHOTICS 
USA 
- 1.18562 
(-1 SO) 
-.080596 
(-6.61) 
.I472219 
(3.43) 
.2041364 
(2.60) 
-. 148003 
(- 1.75) 
.W8186 
(6.04) 
-.001036 
(-0.23) 
-.016739 
(-2.45) 
32 
.97 
below the parameter estimates. 
UK 
Not 
Enough 
Data 
Points. 
UK 
Only 
Uses 
"New" 
Drugs 
2 
- 
France 
-. 1833468 
(-0.14) 
-.0360343 
(-4.85) 
Dropped 
Dropped 
.00775 1 
(0.06) 
.0019283 
(1.16) 
.00133 13 
(0.37) 
-.0026804 
(-0.45) 
10 
.77 
Italy 
-2.970883 
(- 1.5 1) 
-.0394894 
(-6.00) 
.054989 
(0.86) 
.I574938 
(0.74) 
.I473684 
(2.08) 
.0028026 
(3.16) 
.008612 
(2.43) 
-.0006902 
(-0.22) 
16 
.96 
Sweden 
-3.87543 
(-0.25) 
-. 173855 
(-0.64) 
1.446803 
(7.56) 
-. 1 15035 
(-0.05) 
SO58676 
(0.7 1) 
.0023335 
(0.37) 
NIA 
NIA 
40 
.9 1 
Chapter 7 - Cross-country Comparison 
In this chapter, I use regression models to examine cross-country differences in factors 
affecting the diffusion of antinausea, antihypertensive, and antipsychotic medications in 
the United States, United Kingdom, France, Italy and Sweden. For the regressions 
presented in this Chapter, I pool the regression data and add country-specific dummy 
variables into the regression models. The regressions in the following sections are at the 
therapeutic class and generation levels, respectively. 
7.1 - Cross-country Therapeutic-class-level Regression 
For the regression outputs presented in this section, the dependent variable is the total 
patient days per capita at the therapeutic class level (log-totAcapita). Two different 
regressions were run at the therapeutic-class-level for each of the three therapeutic classes 
examined in this thesis. For the first regression model, Sweden is included, and therefore, 
detailing variables are removed because no detailing data was available for Sweden. In 
the second regression model, observations for Sweden are removed and the effect of 
detailing on therapeutic class level sales in the other four sample countries (US, UK, Italy 
and France) is examined. 
A. Antinauseants 
The regression outputs for the linear form of Equation 3.1 in Chapter 3 for antinausea 
medications in the five sample countries are shown in Table 7.1. The dependent variable 
is the total patient days per capita at the therapeutic class level (log-totAcapita). The 
explanatory variables for this regression are: price, number of compounds, number of 
physicians and nurses per capita, income per capita, and country dummies. Sweden is the 
omitted reference group. 
As shown in Table 7.1, the country dummy variables for Italy, France and the UK are all 
statistically significant and positive. This means that, other things equal, per capita sales 
of antinausea medications were higher in France, Italy and the UK than in Sweden. These 
finding of higher usage are consistent with by the per capita sales data in Chapter 4 (see 
Fig.4.4). 
The time trend variable in this regression is found to be negative and statistically 
significant, which agrees with the finding in Chapter 4 that overall sales of antinausea 
medications have been declining over the time period examined in this study (see Fig.4.3) 
due to a combination of improved chemotherapy and standardization of antinausea 
medication use in the US [56,57]. 
In order to fhther examine if the parameter estimates are statistically significantly 
different across the countries, a Chow test was performed (see Chapter 3 for details on 
how the Chow statistic is calculated). The null hypothesis (Ho) is that there are no cross- 
country differences in the parameter estimates, other than for the intercept terms. At the 
class-level for antinausea medications, the sum of squared residuals for the pooled 
regression (SSRp) is 4.3 17 and the total sum of squared residuals for the country-specific 
regressions is 2.9, the N value is 220, k is 35, and q is 24. The Chow statistic is 3.766 - 
F24,185. The critical F value at the 5% significance level is 1.58, which is smaller than the 
Chow statistic, so the null hypothesis can be rejected. Thus, the Chow test suggests that 
there are statistically significant cross-country differences in the sale of antinausea 
medications at the therapeutic-class level. For example, comparing the country-specific 
regressions in Table 4.3, substantial differences can be seen with respect to the time 
trend, which is found to be a significant positive factor in the US, but a significant 
negative factor in Italy. 
Table 7.1: Regression Results for Equation 3 - Antinausea 
I Dependent V&Ie: log_totgd_kcapifa I I Explanatory Variable Parameter Estimate I 
Intercept 
log - tot-num-compound 
l o g q h ~ s - l m ~ o ~  
. 
1.157476 
(5.88) 
.I82 1042 
(0.4 1) 
log-nurse- 1 Kpop 1.598225 
(1.72) 
log-income-capita .3007203 
(0.79) 
Time 
Italy 
-.0059571 
(-2.43) 
1.317776 
France 
In the second regression, data on Sweden is excluded from the pooled data set, and 
detailing variables are included as regressors. The regression outputs for the linear form 
of Equation 3.2 in Chapter 3 for antinausea medications are shown in Table 7.2. Once 
again, the dependent variable is the logarithm of total patient days per capita at the 
therapeutic class level (log-totqd_capita). The explanatory variables for this regression 
(5.06) 
1.745356 
UK 
Number of Observations 
Adjusted RSquared 
(0.57) 
1.554386 
(1.97) 
220 
.95 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Sweden 
are: price, number of compounds, number of physicians and nurses, income per capita, 
detailing variables, and country dummies. Italy is now the omitted reference group. 
As shown in Table 7.2, the dummy variable "US" has a negative and statistically 
significant parameter estimate. The parameter estimate suggests that all other variables 
held fixed, per capita sales for antinausea medications in Italy are 1.22 patient days per 
capita higher than are sales in the US. The per capita sales data in Chapter 4 show that 
sales in Italy are significantly higher than sales in the US (see Fig.4.4); however, the 
patient day difference is lower than what is suggested by the regression model. 
A Chow test was preformed to determine if the parameter estimates are significantly 
different across the sample countries. The sum of squared residuals for the pooled 
regression (SSRp) is 1.422 and the total sum of squared residuals for the country-specific 
regressions (SSRt) is 0.700, the N value is 120, k is 32, and q is 21. The Chow statistic is 
4.321 - F21,88, and the critical value at the 5% significance level is 1.68. Because the F- 
statistic from the Chow test is greater than the critical value, the null hypothesis can be 
rejected. Thus, the Chow test shows that there are statistically significant cross-country 
differences in the sale of antinausea medications at the therapeutic-class level when 
detailing is included as a regressor. 
In the pooled regression, the parameter value on the price variable is negative and 
significant. This implies that higher prices for antinausea medications lead to lower use. 
This finding is consistent with the country-specific regression result for the US. In all the 
other country-specific regressions, price was not found to be a significant factor, which 
was attributed to the existence of national health care systems in the other sample 
countries. 
Nurses per capita are found to have a positive and statistically significant parameter value 
in the pooled regression, suggesting that the availability of nurses contributes positively 
to the patient day sale of antinausea medications. Given that nurses often care for patients 
suffering with nausea and vomiting, it is reasonable that these medical professions would 
be likely to request antinausea medications for their patients. The finding that the 
parameter estimate on the nurses per capita variable is significant and positive is 
consistent with the country-specific regression model for the UK, but contrary to the 
regression for the US (see Table 4.3). 
A positive and statistically significant parameter value is also found for income per 
capita. This implies that income plays a positive role in the patient day sales of antinausea 
medications. In the country-specific regression results, income was found to have a 
positive statistically significant effect in the US, but was an insignificant factor in the 
other four sample countries. 
Coefficient estimates on the detailing variables are both positive and statistically 
significant, implying that detailing has a positive effect on the sale of antinausea 
medications. This finding of high levels of promotion leading to higher sales is in 
agreement with previous studies on promotion that have found detailing to have positive 
effects on sales volume [83, 841. 
Table 7.2: Regression Results for Equation 3 - Antinausea 
Dependent Variable: log-totgd-1 kcapita 
Explanatory Variable 
Intercept 
log-nurse- 1 Kpop 
log - income-capita 
Parameter Estimate 
-2.785839 
1.957016 
(2.05) 
1.209054 
Time 
(2.72) 
-.006593 
(-2.1 1) 
log-tot-detail-lag 1 * 
log-tot-detail-lag4 
France 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Italy 
*model was run with log-tot-detail-lag1 and then replaced with log-tot-detail-lag4 
.I128424 
(2.64) 
.0407864 
(2.33) 
.229 1669 
(0.42) 
-- 
Number of Observations 
Adjusted R-Squared 
B. Antihypertensives 
120 
.96 
The regression outputs for the linear form of Equation 3.1 in Chapter 3 for 
antihypertensive medications in the five sample countries are shown in Table 7.3. 
Sweden is included in this pooled regression model, and the "Sweden" dummy variable 
serves as the omitted reference group. 
The results in Table 7.3 indicate that the parameter estimates for the dummy variables 
"France" and Italy" are statistically significant and negative. This implies that per capita 
sales of antihypertensives are lower in these two countries than in Sweden, other things 
held equal. The qualitative analysis in Chapter 5, showing that among the five sample 
countries, per capita use of antihypertensives is highest in Sweden, are also consistent 
with this result (See Fig.5.2). 
In order to further examine if the parameter estimates are statistically significantly 
different across the countries for the antihypertensive market, a Chow test was 
performed. The null hypothesis (I&) is that there is no cross-country difference in the 
parameter estimates, other than for the intercept terms. At the class-level for 
antihypertensives, the sum of squared residuals for the pooled regression (SSb) is 0.843 
and the total sum of squared residuals (SSRJ for the country-specific regressions is 
0.433, the N value is 166, k is 30, and q is 19. The Chow statistic is 6.801 - F19, 136. The 
critical value at the 5% significance level is 1.66. The Chow statistic is greater than the 
critical value, thus the null hypothesis can be rejected. Therefore, the Chow test indicates 
that there are statistically significant cross-country differences in the sale of 
antihypertensive medications at the therapeutic-class level. Comparing the country- 
specific regressions in Table 5.4, substantial differences can be seen in the parameter 
values for the five sample countries. For example, the detailing lagged four quarters 
variable has a positive and significant parameter estimate in Italy and France; however, 
the parameter value is negative and significant in the US. 
In the pooled regression results, the parameter estimate on the number of physicians per 
capita variable is positive and significant. In the country-specific therapeutic-class-level 
regressions, physicians per capita were not found to be significant in any country (see 
Table 5.4). The finding in the pooled regression suggests that even if physicians do not 
appear to have an effect on antihypertensive use on a country-by-country basis, on a more 
aggregate level increased physician intensity fosters the diffusion of antihypertensives. 
The number of compounds on the market is found to have a negative and significant 
parameter estimate, which is consistent with the country-specific regressions (see Table 
5.4). This suggests that the number of compounds available is increasing faster than the 
number of patient days in the sample countries. This could reflect gradual saturation of 
the overall market for antihypertensives. 
Finally, the time trend variable is shown to have a positive and significant parameter 
value. This indicates that, other things held equal, patient day sales for antihypertensives 
have been increasing over time in the five sample countries. This finding is consistent 
with the country-specific regressions, where time was found to have a positive and 
significant effect in four out of five sample countries; it was found to be insignificant 
only in Italy (see Table 5.4). 
Table 7.3: Regression Results for Equation 3 - Antihypertensive 
Dependent Variable: log-totjd-1 kcapita 
Italy 
Explanatory Variable 
Intercept 
l o g q h ~ s - l m ~ o ~  
log-income-capita 
time 
Parameter Estimate 
2.82 1749 
(1.04) 
a5935494 
(2m51) 
.2302753 
(0.96) 
.0144701 
(8m39) 
- 
France 
US 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Sweden 
- 
-.I131666 
(-2m 16) 
-.2015165 
UK 
Number of Observations 
Adjusted RTSquared 
The regression outputs for the linear f o m  of Equation 3.2 in Chapter 3 for 
antihypertensive medications in the four sample countries for which there is detailing 
data are shown in Table 7.4. The dependent variable is the total patient days per capita at 
the therapeutic class level (log-totqd-capita). The explanatory variables for this 
regression are: price, number of compounds, number of physicians, income per capita, 
detailing variables, and country dummies. Italy is the omitted reference group. 
.085143 
(0.82) 
166 
.86 
As shown in Table 7.4, the dummy variables for France and the UK both have 
statistically significant and positive parameter estimates, indicating that per capita sales 
of antihypertensives are higher in the UK and France than in Italy, other things equal. 
The descriptive analysis of the antihypertensive market in Chapter 5 indicates that 
utilization of antihypertensives is higher in the UK than Italy for the time period from 
1992 to 2003 (See Fig.5.2). However, the analysis in Chapter 5 finds that while per capita 
antihypertensive sales began at a lower level in Italy than in France in 1992, by the fourth 
quarter of 2003, per capita patient day sales in Italy are actually slightly higher than 
France (1 2.694 versus 12.303 patient-days-per-capita). The reason that the pooled 
therapeutic-class-level regression model finds per capita sales to be higher in France than 
in Italy is most likely due to the fact that sales in Italy did not exceed sales in France until 
the second quarter of 2003, so for the majority of the time period examined, per capita 
sales in France did in fact out pace sales in Italy. 
Table 7.4: Regression Results for Equation 3 - Antihypertensive 
Dependent Variuble: bg-tot-pd-1 kcapita 
Explanatory Variable 
Intercept 
l o g p h ~ s - l m ~ o ~  
log-income-capita 
Parameter Estimate 
-.3980846 
(-0.14) 
.7518171 
(2.98) 
.3738717 
time .0122697 
(5.08) 
log-tot-detail-lag 1 * 
A Chow test was performed, where the sum of squared residuals for the pooled 
regression (SSb) is 0.437 and the total sum of squared residuals for the country-specific 
regressions (SSR) is 0.078, the N value is 113, k is 28, and q is 17. The Chow statistic is 
22.79 - F17, 85, and the critical value at the 5% significance level is 1.75. Thus the null 
-.0664 177 
(-0.99) 
log-tot-detail-lag4 
France 
US 
UK 
Number of Observations 
Adjusted R-Squared 
hypothesis can be rejected, suggesting that there are statistically significant cross-country 
-.0145313 
(- 1.39) 
.I822933 
(2.90) 
.0979559 
(0.47) 
.4163507 
(2.30) 
113 
.87 
differences exist in the sale of antihypertensives. 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Italy 
*model was run with log-tot-detail-lag and then replaced with log-tot-detail-lag4 
The time trend variable has a positive and significant parameter value, which is consistent 
with the country-specific regressions, and is also consistent with the descriptive analysis 
in Chapter 5, which found antihypertensive use to be increasing over time (see Fig.5.2). 
Both of the detailing variables are found to be insignificant in the pooled regression. This 
is of interest because detailing was found to have a statistically significant positive effect 
in the country-specific regressions for France and Italy, and negative and significant 
effect in the UK (see Table 5.4). 
C. Antipsychotics 
Table 7.5 shows the regression outputs for the linear form of Equation 3.1 in Chapter 3 
for antipsychotic medications in all sample countries. The dependent variable is the 
logarithm of total patient days per capita at the therapeutic class level 
(log totqd capita). The explanatory variables are: price, number of compounds, number 
ofphysiciaii, income, and country dummies. Sweden is the omitted reference group. 
Table 7.5: Regression Results for Equation 3 - Antipsychotic 
Dependent Variabe: log-totgd_Ikcapita 
I Italy I -3.095351 
Explanatory Variable 
Intercept 
Log~tot~num~compound 
l o g ~ h ~ s - l m ~ o ~  
log-income-capita 
time 
Parameter Estimate 
-65.64468 
(-6.29) 
.4250335 
(4.41) 
6.755619 
(8.83) 
1 .ti84777 
(2.08) 
.0304283 
(6.62) 
France 
The results in Table 7.5 show that the parameter values for all four country dummy 
variables are statistically significant. The parameter values for "France" and "Italy" are 
shown to be negative, indicating that per capita sales of antipsychotics are higher in 
Sweden than in France and Italy, other things held equal. On the other hand, the 
parameter values for the US and the UK are positive, meaning that per capita sales for 
(-11.11) 
-1.254662 
Number of Observations 
Adjusted R-Squared 
213 
.92 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Sweden 
antipsychotics are higher in these two sample countries than in Sweden, all other things 
held equal. The descriptive analysis of per capita sales of antipsychotics in Chapter 6 is 
also consistent with findings from the regression model for Italy and France, implying 
that per capita sales of antipsychotics are much lower in these two countries than in 
Sweden. The descriptive analysis of Chapter 6 also finds per capita sales to be higher in 
the US than in Sweden. 
A Chow test was performed to determine if, other than country-specific intercept terms, 
the parameter estimates are statistically significant different across the five sample 
countries for the antipsychotic therapeutic class. The sum of squared residuals for the 
pooled regression (SSRp) is 20.188 and the total sum of squared residuals (SSRt) for the 
country-specific regressions is 10.05, the N value is 2 13, k is 30, and q is 19. The Chow 
statistic is 9.72 - F19, 183, and the critical value at the 5% significance level is 1.64. The 
null hypothesis can be rejected, and the Chow test shows that there are statistically 
significant cross-country differences in the sale of antipsychotics. For example, when the 
country-specific regressions in Table 6.3 are examined, differences can be seen with 
regard to the price variable. The parameter estimate for price is negative and significant 
for France and Italy, indicating that high prices discourage the diffusion of antipsychotic 
drugs; however, the regression for the UK found price to have a statistically significant 
positive effect. 
Only in the case of the UK is there a discrepancy between findings for the descriptive 
analysis and that for the pooled regression model. The descriptive analysis finds that per 
capita sales in Sweden are 0.2 patient days per capita higher than sales in the UK (see 
section 6.2). The use of antipsychotics is higher in Sweden than the UK probably because 
of cultural differences about what level of psychosis requires medical treatment. The 
stigma surrounding mental health in the UK has led to the Royal College of Psychiatrists 
launching a five-year campaign to combat discrimination against the mentally ill and to 
increase public awareness of common mental illness [85, 861. This campaign was 
initiated in the autumn of 2002, so if it has measurable effects, they will probably appear 
in the data from the third quarter of 2002, and because the data for this thesis only ran 
until the end of 2003, these effects are probably small over the time period examined. 
Therefore, it is possible that sales of antipsychotics are higher in Sweden than in the UK 
because of cultural differences of how mental illness is perceived and treated, but this is 
not something that can be discerned by a typical quantitative regression model. 
The regression outputs for the linear form of Equation 3.2 in Chapter 3 for antipsychotic 
medications in the four sample countries for which there is detailing data are shown in 
Table 7.6. The explanatory variables now include the detailing variables, and Italy is the 
omitted reference group. 
The results in Table 7.6 show that the dummy variable "US" has a positive and 
statistically significant parameter value. This means that per capita sales of antipsychotics 
is higher in the US than in Italy, other things equal; the descriptive analysis in Chapter 6 
is consistent with this finding (See Fig.6.2). 
A Chow test was performed on the pooled versus country-specific regression models 
after detailing is included as a regressor. The sum of squared residuals for the pooled 
regression (SSRp) is 7.339 and the total sum of squared residuals (SSRt) for the country- 
specific regressions is 0.349, the N value is 113, k is 28, and q is 17. The Chow statistic is 
100.01 - F17, 8 5  The critical F value at the 5% significance level is 1.75. Thus, the null 
hypothesis can be rejected once again, and the Chow test reveals that statistically 
significant cross-country differences exist in the sale of antipsychotics. 
time .O533&9 
Table 7.6: Regression Results for Equation 3 - Antipsychotic 
Dependent Variable: log-tot-pd-lkeapita 
Explanatory Variable 
Intercept 
logqrice- 100qd-class 
log~to t~n~m~compound 
~ O ~ J ~ Y S - ~ ~ P O P  
log-income-capita 
Parameter Estimate 
-9.666729 
(-1.17) 
-1.46578 
(-1 .77) 
1.15578 
(7.14) 
-.3309117 
(-0.43) 
2.167276 
(3.29) 
log - tot - detail-lag 1 * 
(10.07) 
1.0687595 
log-tot-detail-lag4 
France 
Omitted Variable: Italy 
*model was run with log-tot-detail-lag1 and then replaced with log-tot-detail-lag4 
(-2.30) 
-.lo83497 
(-2.87) 
.367 1678 
Number of Observations 
Adjusted R-Squared 
Interestingly, both of the detailing variables are shown to have negative and statistically 
significant parameter values. This finding of the pooled regression model is consistent 
with the findings in the country-specific regression models (see Table 6.3). This indicates 
that the level of detailing for antipsychotics is higher than the growth rate of per capita 
sales of antipsychotic medications. The reason for this is most likely cultural because 
regardless of how heavily pharmaceutical companies promote their antipsychotics, 
(0.22) 
88 
.97 
t-values are shown in the parenthesis below the parameter estimates. 
physicians will only prescribe these medications if the patients (and patient's family 
members) want to receive such medical treatment. 
In the pooled regression model, the parameter values for income per capita and the total 
number of compounds available are both found to have positive and significant effects on 
patient day sales. The country-specific regression models for the US and UK found the 
same result. In the regressions for France, Italy and Sweden, the parameter estimate for 
both variables was insignificant (see Table 6.3). This suggests that while per capita 
income and the number of compounds available may not be significant factors in the 
diffision of antipsychotics in every country, they both foster diffision on a more 
aggregate level. 
7.2 - Cross-country Generation-level Regression 
In this section, regression results are presented for models with the patient day market 
share of new generation medications as the dependent variable (log-share-newgd). Two 
different regressions were run at the generational level for each of the three therapeutic 
classes examined in this thesis. For the first regression model, Sweden is included, and 
therefore, detailing variables are removed as regressors because no detailing data was 
available for Sweden. In the second regression model, data observations for Sweden are 
removed and the effect of detailing on therapeutic class level sales in the other four 
sample countries (US, UK, Italy and France) is examined. 
A. Antinauseants 
The regression outputs for the linear form of Equation 4.1 in Chapter 3 for antinausea 
medications in the five sample countries are shown in Table 7.7. As mentioned above, the 
dependent variable is the logarithm of the share of patient days captured by the new 
generation of antinausea medications (log-sharcnewgd). The explanatory variables for 
this regression are: price ratio of new to old generation drugs, share of new compounds 
on the market, number of physicians and nurses, income per capita, and country 
dummies. Sweden is the omitted reference case. 
As shown in Table 7.7, the country dummy variables for Italy and France and the UK are 
all statistically significant and negative. This means that new antinausea medications 
account for a smaller share of the total patient-day market share in France and Italy than 
in Sweden, other things equal. This finding that new antinausea medications are utilized 
at lower levels in France and Italy than in Sweden is also consistent with the simple 
descriptive analysis, which shows that new antinausea medications account for less than 
1% of the total patient day sales of antinausea drugs in France and Italy, while they made 
up nearly 9% of patient day sales in Sweden (See Fig.4.6). 
A Chow test was conducted to determine if there are significant cross-country differences 
in the diffision of new antinausea medications. The null hypothesis (b) is that no cross- 
country differences exist in the sale of antinausea medications at the generation-level. 
The sum of squared residuals for the pooled regression (SSRp) is 28.25 1 and the total 
sum of squared residuals (SSRt) for the country-specific regressions is 5.452, the N value 
is 220, k is 35, and q is 24. The Chow statistic is 32.09 - F24, 185. The critical F value at 
the 5% significance level is 1.58. Due to the Chow statistic being greater than the critical 
value, the null hypothesis can be rejected. The Chow test reveals that statistically 
significant cross-country differences exist at the generation-level for antinausea 
medications. For example, as shown in Table 4.4, the share of new compounds on the 
market is found to have significant and opposite effects on new antinausea sales in the 
US and Sweden (the parameter estimate is positive for Sweden and negative for the US). 
Intercept 
Table 7.7: Regression Results for Equation 4 - Antinausea 
Dependent Varidble: log- share-newgd 
Ex~lanators Variable Parameter Estimate 
logqrice-ratio 
log - sharcnew-compound 
l o g q h ~ s - l m ~ o ~  
log-rime-1 Kpop 
log - income-capita 
time 
Italy 
France 
US 
UK 
For the pooled regression, the parameter value for the price ratio variable is found to be 
negative and statistically significant. This indicates that the higher price of new 
antinausea medications impedes diffusion of new antinausea drugs relative to old drugs. 
This finding is consistent with the country-specific regressions for the US and Italy, but is 
inconsistent for Sweden (see Table 4.4). It is important to note that Sweden's unique 
pharmaceutical payment structure with minimum expenditure requirements that must be 
met before the national health care system covers prescription drug costs probably leads 
1.6829603 
(- 11.59) 
.4172968 
(2.43) 
2.380843 
(2.25) 
2.387992 
(0.98) 
-.4078343 
(-0.42) 
.0204521 
(3.09) 
-1.822468 
(3.17) 
-2.652767 
(-7.46) 
.9362042 
(1.53) 
.6467749 
(0.3 1) 
Number of Observations 
Adjusted R-Squared 
220 
.9 1 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Sweden 
to this discrepancy (see Chapter 1 for more information on the Swedish national health 
care system). 
The time trend variable has a positive and significant parameter value, suggesting that the 
patient day market share of new antinausea medications has increased fkom 1992 to 2003, 
holding other factors fixed. This is consistent with the regression results for all four 
sample countries for which the generation-level model could be run (see Table 4.4). 
Finally, the relative availability of physicians has a positive and statistically significant 
on the share of new antinausea medications. This suggests that greater physician intensity 
fosters the diffusion of new generation antinausea mediations over the old generation. In 
the country-specific regressions, the availability of physicians was not found to be 
statistically significant factor in any country. This inconsistency between the pooled and 
country-specific regressions suggests though physicians may not be a major factor in 
diffusing new antinausea medications in each country separately, but when the data are 
pooled across countries, on a more aggregate level physicians play a significant role in 
new antinausea diffusion. 
The regression outputs for the logarithmic form of Equation 4.2 in Chapter 3 are 
reproduced in Table 7.8. In this regression, the observations for Sweden were removed, 
and detailing variables were included as regressors. Italy is now the omitted reference 
case. 
A Chow test was conducted again to determine if there are significant cross-country 
differences in the diffusion of new antinausea medications, once detailing is included as a 
regressor. The null hypothesis (&) is that no cross-country differences exist in the sale of 
antinausea medications at the generation-level. The sum of squared residuals for the 
pooled regression (SSRp) is 4.425 and the total sum of squared residuals (SSRt) for the 
country-specific regressions is 0.827, the N value is 94, k is 24, and q is 13. The Chow 
statistic is 23.43- F13, 70. The critical F value at the 5% significance level is 1.86. Because 
the Chow statistic is higher than the critical value, the null hypothesis can be rejected; the 
Chow test implies that there are statistically significant cross-country differences at the 
generation-level for antinausea medications. Picking one example, in the country-specific 
regressions in Table 4.4, the parameter estimate for the income per capita variable is 
negative and statistically significant in Sweden and the UK, but is positive and 
statistically significant in Italy. 
The time trend variable has a positive and significant parameter value, which suggests 
that the market share of new antinausea medications has been increasing over time. This 
finding is consistent with the country-specific regressions, where the same relationship is 
found in the US, UK, Italy, and Sweden (see Table 4.4). There was not enough data to 
run the generation-level model for France. 
The country dummy variable for France is negative and statistically significant. This 
indicates that new antinausea medications account for a greater share of patient days in 
Italy than in France, other things equal. This finding is consistent with the descriptive 
analysis in Chapter 4 (see Fig. 4.6). 
Table 78: Regression Results for Equation 4 - Antinausea 
Dependent Vhhble: log- share-newpd 
Explanatory Variable 
Intercept 
log-nurse- 1 Kpop 
log-income-capita 
time 
, 
Parameter Estimate 
34.37099 
(2.03) 
(-0.44) 
1.600466 
(0.4 1) 
-3.67931 1 
(-2.52) 
.0541144 
(4.26) 
log-rel-detail-lag 1 * 
log-rel-detail-lag4 
France 
The relative detailing lagged four quarters variable (rel-detail-lag4) has a statistically 
significant positive effect, which implies that heavier detailing of new antinausea 
medications relative to old generation antinausea medications has a positive effect on the 
patient day market share of new antinausea drugs, but the full effect of this higher 
detailing takes approximately one year to be realized. This finding is also consistent with 
the country-specific regressions for the US and the UK (see Table 4.4). 
.0557219 
(1.65) 
.049444 
(2.40) 
1.9262073 
(-2.14) 
UK 
Number of Observations 
Adjusted R-Squared 
-.0690008 
(-0.03) 
57 
.96 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Italy 
*model was run with log-rel-detail-lag1 and then replaced with log-rel-detail-lag4 
B. Antihypertensives 
The regression outputs for the linear form of Equation 4.1 in Chapter 3 for 
antihypertensive medications in the five sample countries are shown in Table 7.9. Data 
for Sweden is included in this pooled regression model. Sweden also serves as the 
omitted reference group. 
For the pooled generational regressions, a two generation split was used for 
antihypertensives, which divides antihypertensives into a "new" and a "old-middle" 
categories. The reason for using a two generation split for the pooled generation-level 
regressions is that this makes the results for antihypertensives easier to compare to the 
pooled generational regressions for antipsychotics and antinauseants because these latter 
two therapeutic classes only have two generations. 
Table 7.9: Regression Results for Equation 4 - Antihypertensive 
Dependent V d e :  log_ share_newgd 
Explanatory Variable 
Intercept 
log~share_new~compound 
l o g J h ~ s - l m ~ 0 ~  
log-income-capita 
time 
Parameter Estimate 
-47.001 14 
(- 1.78) 
.6750595 
(3.04) 
-2.482 10 1 
(- 1.20) 
6.19081 
(2.94) 
.0498583 
Italy 
(3.81) 
1.963006 
France 
As shown in Table 7.9, the coefficients on the dummy variables for Italy and France have 
positive and statistically significant values. This implies that new generation 
antihypertensives have a larger patient day market share in France and Italy than in 
(2.38) 
1.27941 1 
Number of Observations 
Adjusted R-Squared 
166 
.77 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Sweden 
Sweden, other factors held equal. The descriptive analysis in Chapter 5 is consistent with 
this finding as well (See Figs.5.5-5.7). 
A Chow test was conducted again to determine if there are significant cross-country 
differences at the generation-level of aggregation for antihypertensives. The null 
hypothesis (Ho) is that no cross-country differences exist at the generation-level. The sum 
of squared residuals for the pooled regression (SSRp) is 62.153 and the total sum of 
squared residuals (SSRt) for the country-specific regressions is 30.00, the N value is 166, 
k is 30, and q is 19. The Chow statistic is 7.671- F19, 136 The critical F value at the 5% 
significance level is 1.66, which is smaller than the Chow statistic, and therefore, the null 
hypothesis can be rejected. Thus, the Chow test suggests that there are statistically 
significant cross-country differences at the generation-level for antihypertensives. 
Turning to the country-specific regressions (See Table 5.5), the share of new compounds 
has a positive and significant impact in Sweden, the US and France; however, the 
absolute value for the parameter is much greater in Sweden than for the other two sample 
countries. 
The regression outputs for the linear form of Equation 4.2 in Chapter 3 for 
antihypertensive medications in the four sample countries for which there is detailing 
data are shown in Table 7.10. The dependent variable is the total patient days per capita 
at the therapeutic class level (log-share-newqd). The explanatory variables for this 
regression are: price ratio of new to old generation medications, share of new compounds 
on the market, number of physicians, income per capita, relative detailing variables, and 
country dummies. Italy is the omitted reference group. 
Table 7.10 shows that all three country variable dummies have statistically significant 
and positive parameter estimates. This means that holding other factors equal, new 
antihypertensive medications account for a larger portion of patient day sales in France, 
UK, and the US than in Italy. The descriptive analysis in Chapter 5 only finds that France 
has a higher percentage of patient-day sales for new antihypertensives than Italy (see 
Fig.5.5 and Fig.5.6). The new drug patient day market share in the US and UK, though 
very close to the new drug market share in Italy, is lower than that of Italy (See Figs 5.5, 
5.8, and 5.9). The analysis in Chapter 5 reveals that the middle generation of 
antihypertensives (ACE inhibitors) account for a much greater patient day market share 
in the US and UK than in Italy over the entire time period examined by this thesis. This 
suggests that physicians in the US and UK prefer the middle generation antihypertensives 
to the new generation, and this explains why the regression model overestimates the new 
drug share of patient days in these two countries in comparison to Italy. 
A Chow test was conducted to determine if significant cross-country differences exist at 
the generation-level of aggregation for antihypertensives (other than for the intercept 
term) after observations for Sweden are removed and detailing is added as a regressor. 
The null hypothesis (Ho) is that no cross-country differences exist at the generation-level. 
The sum of squared residuals for the pooled regression (SSRp) is 6.405 and the total sum 
of squared residuals (SSRt) for the country-specific regressions is 0.62, the N value is 
112, k is 28, and q is 17. The Chow statistic is 46.06- Fly, 84. The critical F value at the 
5% significance level is 1.74, which is smaller than the Chow statistic, and therefore, the 
null hypothesis can be rejected once again. Table 5.5 reveals one such cross-country 
difference in the time trend, which has positive and significant parameter values in all 
country-specific regressions including detailing as a regressor, but vastly different 
absolute values in the four sample countries. 
Table 7.10: Regression Results for Equation 4 - Antihypertensive 
Dependent Variable: log- share-newgd 
Explanatory Variable 
Intercept 
logqrice-ratio 
log - share-new-compound 
The number of physicians per capita has a positive and significant parameter estimate. 
Because the coefficient estimate on physicians was insignificant in the pooled generation- 
level regression model including Sweden, this suggests one of two things. First, either 
physicians in the other sample countries play a more important role in diffusing new 
antihypertensives than do physicians in Sweden, or second, that it is the interaction 
between detailing and physicians that produces the positive statistically significant 
parameter value for physicians in the second regression model and not the first regression 
model. In the country-specific regression model, the number of physicians was only 
statistically significant in the US, where it was found to have a negative effect on the 
Parameter Estimate 
-53.86462 
(-4.20) 
-2.721782 
(-7.49) 
.6915782 
(5.48) 
log-income-capita 
time 
log-rel-detail-lag 1 * 
log-rel-detail-lag4 
France 
US 
UK 
Number of Observations 
Adjusted R-Squared 
.67 18788 
(0.62) 
.0336402 
(5.01) 
.OW3308 
(2.61) 
.I188452 
(5.75) 
1.892699 
(6.59) 
2.94545 
(3.68) 
4.178265 
(4.91) 
112 
.94 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Italy 
*model was run with log-rel-detail-lag1 and then replaced with log-rel-detail-lag4 
diffusion on new antihypertensives. This discrepancy may be due to the fact that middle 
generation (ACE inhibitors) are used more extensively by American physicians than 
physicians in the other four sample countries (see Figs.5.5 - 5.9), and this preference for 
the middle generation antihypertensives may delay the diffusion of new generation drugs 
in the US relative to the aggregate market for antihypertensives. 
In the pooled regression, both of the detailing variables are positive and statistically 
significant, which implies that higher detailing of new generation antihypertensives 
increases the patient day sales of new generation antihypertensives relative to the middle 
and old generations. 
C. Antipsychotics 
The regression outputs for the linear form of Equation 4.1 in Chapter 3 for antipsychotic 
medications in the five sample countries are shown in Table 7.1 1. Because this regression 
attempts to quantify factors influencing new antipsychotic diffision in the market, the 
dependent variable is the patient day market share of new antipsychotic medications 
(log share-newgd). The detailing variables are not included as regressors in this model 
because data on Sweden was included in this pooled regression, and there is no detailing 
data available on Sweden. Sweden is the omitted reference group. 
First of all, it should be noted that the generation-level regression model for Equation 4.1 
does not do a very good job of modeling the diffision of new antipsychotic medications 
in the five sample countries. The low R-squared value of 0.39 indicates that the 
explanatory variables included in this model are not the major determining factors 
impacting the diffision of new antipsychotic medications. Therefore, the findings of this 
model should not necessarily be considered indicative of the antipsychotic market in the 
sample countries. 
As shown in Table 7.1 1, in the pooled antipsychotic regressions, none of country dummy 
variables has a statistically significant parameter value. This is understandable because 
the descriptive analysis in Chapter 6 found that new antipsychotics dominate the patient 
day market share in all five sample countries, and the percentage market share captured 
by new antipsychotics in all five countries is comparable (reference Section 6.3). 
The time trend variable has a positive and significant parameter estimate, suggesting that 
the use of new antipsychotics has risen in the time period from 1992 to 2003. This 
finding is consistent with the simple descriptive analysis (see Fig.6.6) and the country- 
specific regression result for the US (see Table 6.4). Time was not found to be a 
significant factor in the other country-specific regressions. 
A Chow test was conducted to determine if, other than for country-specific intercept 
terms, parameter estimates for Equation 4.1 are statistically different across the sample 
countries with respect to antipsychotics. The null hypothesis (Ho) is that no cross-country 
differences exist at the generation-level for antipsychotic medications, other than for the 
intercept terms. The sum of squared residuals for the pooled regression (SSRp) is 32.96 
and the total sum of squared residuals (SSRt) for the country-specific regressions is 
26.34, the N value is 166, k is 30, and q is 19. The Chow statistic is 1.798- FI9, 136. The 
critical F value at the 5% significance level is 1.66. The Chow statistic is higher than the 
critical value; therefore, the null hypothesis is rejected and the Chow test suggests that 
there are statistically significant cross-country differences in the diffusion of new 
antipsychotics. For instance, in the country-specific regressions for all three sample 
countries on which the generation-level regression could be performed (US, France, 
Italy), the parameter estimate for the price ratio of new to old generation antipsychotics 
was statistically significant and negative; however, although the absolute values for 
France and Italy are similar, the value for the US is much larger (see Table 6.4). This 
suggests that the high price of new antipsychotics is slowing the diffusion of new 
antipsychotics relative to old antipsychotics in all three countries, but the slowdown is 
more pronounced in the US. 
Table 7.11: Regression Results for Equation 4 - Antipsychotic 
Dependent Variable: bg- share-newgd 
Ex~lanato N Variable I Parameter Estimate 
Intercept 3 1.90582 
(1.81) 
logprice-ratio -.6558334 
log - income-capita 
time 
(-7.17) + 
-1.119022 
(-0.85) 
.0300732 
Italy 
(3049) 
.4121646 
France 
In the pooled regression results, the share of new compounds has a positive and 
(0.74) 
-.lo41043 
Number of Observations 
Adjusted R-Squared 
statistically significant impact on the new antipsychotic patient day market share in both 
pooled generation-level regressions. This indicates that the expansion in the number of 
166 
.39 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Sweden 
new antipsychotics has helped the new generation drugs to gain market share. This 
finding is consistent with the country-specific regression results (see Table 6.4). 
The regression outputs for the linear form of Equation 4.2 in Chapter 3 for antipsychotic 
medications are shown in Table 7.12. This regression model does not include data on 
Sweden; therefore, the explanatory variables now include the detailing variables. Italy is 
the omitted reference group. 
Table 7.12: Regression Results for Equation 4 - Antipsychotic 
Dependent Variable: log- share-newgd 
Explanatory Variable 
Intercept 
log - share-new-compound 
Parameter Estimate 
- 1.004236 
(- 1.47) 
.2382404 
(10.19) 
l o g q h ~ s - l m ~ o ~  
log-income-capita 
time 
-.085224 
(- 1.07) 
.I495986 
(2.23) 
.0050288 
log - rel-detail-lagl* 
I Number of  Observations I 46 I 
(6.02) 
-.0025678 
log-rel-detail-lag4 
France 
US 
UK 
., I 1 Adjusted R-Squared I .97 
(- 1.50) 
-.0004702 
(-0.4 1) 
.0104777 
(0.40) 
-.0570618 
(-0.94) 
.0602926 
t-values are shown in the parenthesis below the parameter estimates. 
Omitted Variable: Italy 
*model was run with log-rel-detail-lag1 and then replaced with log-rel-detail-lag4 
I note that with an adjusted R-square value of .97, this second regression model is a 
decent predictor of the factors influencing the diffusion new antipsychotic medications in 
Italy, France, UK and the US. It should also be noted that this second regression model 
has 46 observations compared to 166 observations for the first regression model. The 
smaller number of observations is due to the fact that during most quarters in the four 
sample countries new antipsychotics accounted for 100% of detailing counts. Therefore, 
there are very few observations in the data set where there is a relative difference in 
detailing counts of new and old antipsychotics. 
As in the regression for Equation 4.1, none of the country dummies has a statistically 
significant parameter value for Equation 4.2. In fact, the only difference between the two 
regression models is the finding that per capita income has a positive and significant 
effect on new antipsychotics gaining market share, whereas in the first regression model 
income was not a significant factor. 
A final Chow test is performed to determine if statistically significant cross-country 
differences exist (other than for the intercept term) when observations for Sweden are 
removed and relative detailing is included as a regressor. The null hypothesis (Ho) is that 
no cross-country differences exist at the generation-level for antipsychotic medications. 
The sum of squared residuals for the pooled regression (SSRp) is 0.003 16 and the total 
sum of squared residuals (SSRt) for the country-specific regressions is 0.0023, the N 
value is 57, k is 2 1, and q is 10. The Chow statistic is 1.253- Flo, 36. The critical F value 
at the 5% significance level is 2.106. The critical value is greater than the Chow statistic. 
Thus, the null hypothesis cannot be rejected, and the Chow test shows that there are no 
statistically significant cross-country differences in the diffusion of new antipsychotics 
when observations for Sweden are excluded and relative detailing is added as a regressor. 
The main reason for the inability to reject the null hypothesis is probably due to the fact 
that all the sample countries predominantly use new generation antipsychotics (see Fig. 
6.6), so cross-country differences in the diffusion of new generation antipsychotics 
relative to the old generation may in fact not exist. 
7.3 - Summary of Cross-Country Comparisons 
The pooled regressions revealed there are significant cross-country differences in the 
diffusion of antinausea, antihypertensive, and antipsychotic medications. For example, 
the relative availability of physicians, which was not a significant factor in most of the 
country-specific regressions, is found to be significant at the pooled regression level of 
aggregation for both antihypertensives and antipsychotics. This finding implies that even 
if physicians are not playing a major part in diffusing these medications in every country, 
at a more global level, the role of the physician is important. 
The Chow tests showed that the parameter estimates at the therapeutic-class regression 
models have statistically significant cross-country differences for all three therapeutic 
classes. At the generation-level, Chow tests found both antinausea and antihypertensive 
medications to have significant cross-country differences in parameter estimates. In the 
case of antipsychotics, the Chow test failed to reject the null hypothesis at the generation- 
level, suggesting that there are no statistically significant cross-country differences in the 
parameter estimates for this therapeutic class. Given the fact that all five sample countries 
predominantly use new generation antipsychotics, a finding that there are no statistically 
significant cross-country generation-level differences in antipsychotic medications is 
reasonable. 
Chapter 8 - Conclusion 
The purpose of this study has been to examine the effects of promotion on antinausea, 
antihypertensive, and antipsychotic medications in the United States, United Kingdom, 
France, Italy and Sweden between the first quarter of 1992 and the fourth quarter of 
2003. In particular, the thesis tries to answer the following questions: How do detailing 
regulations vary across the sample countries? How do these differences in regulation 
affect the detailing of pharmaceutical products? What effect do these differences have on 
the sale of antinausea, antihypertensive and antipsychotic medications? What other 
factors, such as culture, income, population, and price, play a role in the sale and use of 
pharmaceuticals? These questions were qualitatively and quantitatively addressed in this 
thesis. In this final chapter, I summarize the findings regarding these questions and 
elaborate upon the health care policy implications of the findings. 
8.1 - Market Overview 
This thesis finds that the overall markets for antinausea, antihypertensive, and 
antipsychotic medications follow the same general trends in the US, UK, Italy, Sweden 
and France. In all five countries, the market for antinausea medications has decreased 
slightly over the time period covered by this thesis. This decrease was likely caused by 
multiple factors, including improvements in chemotherapy and reclassification of 
antinausea medications [56,57]. Old generation drugs dominate the antinausea market in 
all five sample countries. New generation medications are gaining market share in the US 
and Sweden, but these medications account for less than 1% of patient day sales in 
France and Italy. New drugs also sell at a higher premium to old generation antinausea 
medications in Sweden and the US, versus France, Italy and the UK. Although the US 
has the greatest variety of antinausea medications, per capita usage is much higher in 
France and Italy. 
The antihypertensive market has expanded both in terms of volume (patient days) and 
revenue (US$) in all five sample countries from the first quarter of 1992 to the last 
quarter of 2003. Per capita use of antihypertensives was highest in Sweden, followed by 
the UK, France and Italy, and lastly, the US. The total per capita dollar sales of 
antihypertensives also revealed a trend toward convergence among the sample countries. 
Like the antinausea medication market, the old generation medications account for the 
largest share of patient day sales in antihypertensives, and middle generation medications 
claim the next largest percentage of patient days. However, the new generation of 
antihypertensives has shown a significant growth rate in all five sample countries, and 
may capture a majority of the patient day market share in the coming years. 
Finally, the antipsychotic medication market showed expansion in patient day and dollar 
sales over the time period studied in this thesis. The per capita use of antipsychotic 
medications is highest in the US and Sweden, which appears to be due more to cultural 
differences in how mental illness is perceived and treated in the five sample countries 
than economic factors. Unlike the other two therapeutic classes examined in this thesis, 
the new generation of antipsychotic medications dominates the patient day market share. 
In four out of the five sample countries, new antipsychotics account for over 90% of all 
sales. This is a result of both heavy detailing and a reduced side effect profile associated 
with the new generation of atypical antipsychotics. 
8.2 - Economic and Cultural Factors 
The GDP per capita of each sample country was used as an economic indicator 
(income capita) in the regression models in this thesis. In the therapeutic-class-level 
regressions, income is found to have a positive statistically significant effect in the US for 
both antinausea and psychotic medications. This finding is reasonable because the US 
does not have national health care system, so income may play a part in whether or not 
medications are purchased by patients. For most of the other sample countries, the 
income variable is insignificant the majority of the time, or has inconsistent signs when it 
is significant. Given that Italy, Sweden, France, and the UK all have national health care 
systems, it is understandable that individual income is not a significant factor in 
medication sales. 
Cultural factors are likely to have an effect on the sales of both antinausea and 
antipsychotic medications. The different sample countries have different cultural 
preferences of when to treat a patient for nausea and vomiting or psychosis [59, 871. In 
France, nausea and vomiting are medically treated sooner than in the other sample 
countries. This cultural difference explains why per capita sales for antinausea 
medications are so much higher than what cancer incidence and birth rate data predict. 
Likewise, mental health conditions receive more attention and medical treatment in the 
US and Sweden than in the other three sample countries. Mental health is treated less 
frequently in Europe than in America, with an estimated 3645% of schizophrenia 
sufferers not receiving medical treatment in Europe [88]; however, mental illness seems 
to receive medical attention sooner in Sweden than in the other sample countries as 
shown in both the descriptive and quantitative analysis in this thesis. These cultural 
differences help explain why actual utilization of antipsychotic medications in the five 
sample countries do not correspond with the findings of the regression models. 
8.3 - Health Care System Factors 
The thesis finds that the lack of a national health care system that sets price controls on 
pharmaceutical products causes the price per patient day for all medications in all three 
therapeutic classes to be higher in the US than in the four other sample countries, all of 
which have national health care systems with price controls. This higher cost of 
medication in the US helps explain why per capita patient day sales are lower in the US 
for antinausea and antihypertensive medications than most of the EU. Only in the case of 
antipsychotics do American patients use more medications per capita, which, as 
discussed above, probably has more to do with cultural differences than with the health 
care system factors. The US is the only country in the sample that allows direct-to- 
consumer (DTC) marketing of prescription medications, and this difference in policy may 
also help explain the differences in detailing frequency discussed in the following 
section. 
The price controls used in Italy, France, Sweden and the UK may help explain why the 
US is the only country where the price variable ever shows a statistically significant 
positive effect at the therapeutic-class level (see Table 4.3). As expected, the price ratio 
of new to old generation medications has a negative effect almost every time it is found 
to be statistically significant in the regression models for the sample countries. The only 
exception occurs in the case of Sweden; however, this discrepancy between Sweden and 
the other four sample countries is probably an effect of the expenditure ceiling the 
national health care system of Sweden places on patients. Because patients are not 
covered for prescription medications until they reach the ceiling, this may be providing 
incentives for physicians to prescribe more expensive medications than physicians in 
other countries. 
8.4 - Effects of Detailing 
The effect of promotion across the three therapeutic classes is mixed. In the case of 
antinausea and antihypertensive medications, detailing is heaviest in France and Italy and 
relatively low in the US and the UK. The existence of DTC in the US probably also plays 
a role in the lower levels of detailing for antihypertensives and antinausea medications in 
the US. DTC allows pharmaceutical companies another method by which to promote 
their products, and thereby lower detailing efforts in America relative to other countries 
where DTC is not an option for promoting pharmaceutical products. 
On the other hand, detailing is heaviest in the US for antipsychotics, which is probably an 
effect of schizophrenia and other mental conditions being treated more heavily in the US 
than in European countries. These differences in detailing level across therapeutic classes 
seem to indicate that pharmaceutical companies cater detailing efforts to the cultural 
preferences of a country. Given the high cost of detailing, such strategic promotional 
efforts are entirely plausible, and should lead to more efficient payoffs for promotional 
efforts than uniform levels of detailing in all countries. 
The regression models do not find detailing to have significant effects on drug sales at the 
therapeutic-class level. However, detailing is found to have a positive and statistically 
significant impact in the generation-level models, where it is shown to help the sale of 
new antinausea medications in the US and UK, and new antihypertensive medications in 
France and the UK. The detailing results are mixed for antipsychotics, which is probably 
due to the undeniable role of culture in this therapeutic class. 
8.5 - Cross-country Differences 
For the most part, the cross-country regressions found patient day use levels across the 
sample countries that were consistent with the regression results and descriptive analysis 
found in earlier chapters of the thesis. The cross-country analysis found that France and 
Italy use more antinausea medications than Sweden and the US. Antihypertensives were 
used more intensely in the European countries than in the US, and antipsychotics had the 
highest level of patient day per capita use in the US. 
The Chow tests showed that the parameter estimates at the therapeutic-class regression 
models have statistically significant cross-country differences for all three therapeutic 
classes. At the generation-level, Chow tests found both antinausea and antihypertensive 
medications to have significant cross-country differences in parameter estimates. This 
suggests that antinausea and antihypertensive markets, there are at least some differences 
of the demand elasticities for the economic and health care system factors in the US, UK, 
France, Italy and Sweden. 
In the case of antipsychotics, the Chow test failed to reject the null hypothesis at the 
generation-level, suggesting that there are no statistically significant cross-country 
differences in the parameter estimates for this therapeutic class. Given the fact that all 
five sample countries predominately use new generation antipsychotics, a finding that 
there are no statistically significant cross-country generation-level differences in 
antipsychotic medications is reasonable. 
The pooled regressions revealed there are significant cross-country differences in the 
diffusion of antinausea, antihypertensive, and antipsychotic medications. For example, 
the relative availability of physicians, which was not a significant factor in most of the 
country-specific regressions, is found to be significant at the pooled regression level of 
aggregation for both antihypertensives and antipsychotics. This finding implies that even 
if physicians are not playing a major part in diffising these medications in every country, 
at a more global level, the role of the physician is important. Due to the nature of 
hypertension, which has few visible symptoms, it is understandable that a physician 
would play a significant part in helping a patient treat this condition. In the case of 
psychosis, the physician's role in diffising medication may be a significant factor 
because physicians are likely to help patients overcome the cultural stigma that often 
surrounds mental illness and seek treatment. 
Furthermore, the income per capita variable, which had parameter values with 
inconsistent signs in the country-specific regressions, is found to have positive and 
statistically significant parameter values in the pooled regressions. This finding suggests 
that income and the diffusion of medications in the three therapeutic classes examined in 
this thesis have a positive relationship, which is the finding that would be expected. 
8.6 - Policy Recommendations 
This thesis has found that while there are major differences in promotional regulations 
across the five sample countries examined in this thesis, the effect of promotion is not 
necessarily what one would predict given those regulation differences. One might predict 
that stricter regulations on detailing would make detailing less significant in the 
promotion of pharmaceutical products; however, quite the opposite is found. 
For antihypertensive and antinausea medications, detailing is shown to be intense, and 
has a positive statistically significant effect in France and Italy, even though both France 
and Italy have tighter regulations on detailing activities than the US. The reason for this 
finding may be that the tighter restrictions have caused detailers in these countries to 
become more efficient than detailers in America. For example, the limited number of 
samples detailers can leave French and Italian physicians may actually cause detailers in 
these countries to be more effective in their verbal messages than detailers in the US, 
where detailers can rely more heavily on samples doing the talking for them, so to say. 
Thus, a surprising discovery is made; stricter regulations enhance, rather than diminish, 
the effectiveness of detailing activities. 
Furthermore, in Sweden, where detailing is limited to very low levels, and required to be 
almost purely educational in nature by a combination of regulations and physician 
preferences [47], the thesis finds that new generation medications account for a larger 
share of patient days than in counties where detailing is more frequent and promotional. 
It is possible that the highly educational aspect of detailing in Sweden causes 
pharmaceutical companies to only detail new generation products, which would lend 
themselves better to a more scientific sales pitch than well understood old generation 
medications. The focus on new generation medications gives physicians a better 
understanding of these newer products. This increased comfort with new generation 
drugs may in turn lead to Swedish physicians feeling more comfortable prescribing these 
new generation medications than physicians in France, Italy, and the UK where new 
medications are not usually the focus of detailing efforts. 
Detailing is shown to have some effect on sales of pharmaceutical products in all sample 
countries, and tighter regulations are not found to decrease detailing efforts or detailing 
effectiveness. Therefore, governments may want to try other policies to reduce 
unnecessary prescribing of medications than simply restricting the detailing efforts of 
pharmaceutical companies, especially given the educational value detailing brings to 
physicians [47, 881. An interesting policy consideration would be government funded 
academic detailing, or anti-detailing, programs. Studies on such academic detailing 
programs at medical schools, nursing homes, and hospitals have been shown have a 
positive effect on changing the prescribing behavior of physicians [89, 90, 91, 921. The 
state of Philadelphia recently began a small state-wide academic detailing program to 
help reduce the pharmaceutical expenses incurred by the state. The program was started 
in 2005, currently only employs eight detailers, and has a budget of a few million dollars, 
but officials are hopefbl about its ability to alter prescribing behavior [33]. This academic 
detailing program should be tracked, and if it proves to be successful, the efforts should 
be duplicated in other states and countries. 
Appendix - STATA Outputs of the Regression Results 
STATA Output of Table 4.3 - Antinausea 
Log-log regression for antinausea medications in France 
Dependent Variable: 10gtot~pd~lkcapita 
Detailing variable l m e d  1 auader 
Source I SS df MS Number of obs = 29 
--I----------+------------------------------ F( 7, 21)= 1.45 
Model 1 .223804592 7 .03 1972085 Prob > F = 0.2370 
Residual 1 .46 1709428 2 1 .02 1986 163 R-squared = 0.3265 
Adj R-squared = 0.1020 
Total 1 .6855 1402 28 .024482644 Root MSE = .I4828 
log-totqd-a I Coef Std.Err. t P>ltl [95%Conf.Interval] 
time 1 .0019416 ,0246812 0.08 0.938 -.0493859 
loggrice -s 1 4750389 .29 15 168 - 1.97 0.062 - 1.18 128 1 
log - tot - nu-d 1 -1.021344 1.46927 -0.70 0.495 -4.076858 
l ~ g ~ h y ~ - l - p  1 -5.338566 6.054 198 -0.88 0.388 - 17.92896 
log nurse--p 1 -2.300595 7.994094 -0.29 0.776 -1 8.92522 
log income-a 1 .047656 1.484094 0.03 0.975 -3.038686 
loitot-de-1 1 .23228 18 .I552553 1.50 0.149 -.0905894 
cons 1 56.20394 48.05234 1.17 0.255 -43.72636 
- 
Detailing vaniable laaaed 4 ouarters. 
Source I SS df MS Number of obs = 29 
-------------+------------------------------ F( 7, 21)= 1.21 
Model / .I96702563 7 .028 100366 Prob > F = 0.341 8 
Residual 1 .4888 1 1456 21 .023276736 R-squared = 0.2869 
-------------+------------------------------ Adj R-squared = 0.0493 
Total 1 .6855 1402 28 .024482644 Root MSE = .I5257 
log-totgd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 -.O 165468 .022696 1 -0.73 0.474 -.063746 .0306523 
logqrice -s 1 -.3707283 .278346 -1.33 0.197 -.9495805 .2081238 
log-tot-nu4 1 -.5478564 1.457539 -0.38 0.7 1 1 -3.578975 2.483262 
l ~ g ~ h y ~ - l - p  1 -2.735361 5.981554 -0.46 0.652 - 15.17468 9.703962 
log-nursee-p 1 4.0025 17 8.070883 0.50 0.625 - 12.78 18 20.78684 
log-income-a 1 -.7440675 1.380572 -0.54 0.596 -3.615 124 2.126989 
log-tot-de4 ) .0599 14 .06 1472 1 0.97 0.34 1 -.0679242 .I877522 
- cons 1 36.67777 48.55899 0.76 0.458 -64.30617 137.6617 
STATA Output of Table 4.3 - Antinausea 
Log-log regression for antinausea medications in the UK 
Dependent Variable: logtot-pd-1 kcapita 
Detailina variable lamed 1 uuarter 
Source 1 SS df MS Number of obs = 44 
-------------+------------------------------ F( 7, 36) = 9.14 
Model 1 .lo5678501 7 .015096929 Prob > F = 0.0000 
Residual 1 .059442532 36 .00165 1 181 R-squared = 0.6400 
-------------+------------------------------ Adj R-squared = 0.5700 
Total 1 .I65 12 1033 43 .003840024 Root MSE = .04063 
.............................................................................. 
log - totgd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 ,0015462 .0025705 0.60 0.551 -.0036672 .0067595 
loggrice--s 1 .I2967 18 .0695428 1.86 0.070 -.0113674 .2707111 
10gphys 1-p 1 -1.546137 .4732622 -3.27 0.002 -2.505957 0.5863 167 
log nu&--p 1 1.824486 .5521664 3.30 0.002 .7046401 2.944331 
logjncome-a 1 .427853 1 .4456871 0.96 0.343 -.4760422 1.33 1749 
log tot nu-d 1 -.0304587 .I962583 -0.16 0.878 -.4284889 .3675715 
logItocde-1 1 -.025066 .0337798 -0.74 0.463 -.0935745 .0434426 
cons 1 12.49784 5.1 18544 2.44 0.020 2.1 1695 1 22.87873 
- 
Detailing variable l m e d  4 auarters 
Source I SS df MS Number of obs = 44 
-------------+------------------------------ F( 7, 36) = 9.33 
Model 1 .117910503 7 .016844358 Prob > F = 0.0000 
Residual 1 .0649635 15 36 .OO 1804542 R-squared = 0.6448 
-------------+------------------------------ Adj R-squared = 0.5757 
Total 1 .I8287401 8 43 .004252884 Root MSE = .04248 
.............................................................................. 
log - totqd-a I Coef. Std. En. t P>ltl (95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .002224 ,0034024 0.65 0.5 17 -.0046764 .0091244 
logqrice-s 1 .I657946 .067 1557 2.47 0.01 8 .0295965 .3019926 
l~gqhy~- l -p  1 - 1.65707 .56 1 1322 -2.95 0.006 -2.795099 -.5 190412 
log-nurse--PI 1.946339 .6164611 3.16 0.003 .6960979 3.19658 
log-income-a ( .368 1561 .3378308 1.09 0.283 -.3 169965 1.053309 
log-tot-nu-d 1 -. 160424 1 .I857202 -0.86 0.393 -.537082 .2162339 
log-tot-de-4 1 -.0070372 ,0155607 -0.45 0.654 -.0385958 .02452 14 
- cons 1 14.06809 4.789199 2.94 0.006 4.355 141 23.78103 
STATA Output of Table 4.3 - Antinausea 
Log-log regression for antinausea medications in Italy 
Dependent Variable: logtot-pd-1 kcapita 
Source I SS df MS 
Model 1 .356325547 6 .059387591 
Residual 1 .017991303 8 .0022489 13 
Total 1 ,37431685 14 .026736918 
Number of obs = 15 
F( 6, 8) = 26.41 
Prob > F = 0.0001 
R-squared = 0.95 19 
Adj R-squared = 0.9159 
Root MSE = .04742 
log-tot* I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 -.0577289 .0188305 -3.07 0.015 -. 101 152 -.0143057 
logprice--s 1 -.2464976 .2673846 -0.92 0.384 -.8630877 .3700925 
log-tot-nu4 1 .080303 1 1.028424 0.08 0.940 -2.29 1247 2.45 1 854 
log~hys-1-p 1 4.35302 1 3.064047 1.42 0.193 -2.7 12685 1 1.41 873 
l0g-nrnee-p I (dropped) 
log-income-a 1 -1.75 1705 1.45997 1 -1.20 0.265 -5.1 18404 1.614995 
log-tot-de-1 1 .O 174759 .0734959 0.24 0.8 1 8 -. 1520059 .I869578 
cons l -9.095906 19.61 3 18 -0.46 0.655 -54.32398 36.132 17 
DetQilina variable laaaed 4 ~uarters 
Source I SS df MS 
-------------+------------------------------ 
Model 1 .357640705 6 .059606784 
Residual 1 ,016676145 8 .0020845 18 
Total 1 .37431685 14 .026736918 
Number of obs = 15 
F( 6, 8) = 28.59 
Prob>F = 0.0001 
R-squared = 0.9554 
Adj R-squared = 0.9220 
Root MSE = .04566 
log-totjd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 -.05358 1 1 .0144945 -3.70 0.006 -.0870055 -.0201566 
loggrice--s 1 -. 1 107047 .2118765 -0.52 0.615 4992927 .3778832 
log-tot-nu4 1 .8575017 1.301365 0.66 0.528 -2.14345 1 3.858454 
logjhys-1-p 1 7.276924 3.8495 1 1 1.89 0.095 - 1.600065 16.1539 1 
log-income-a 1 - 1.15759 1.592 146 -0.73 0.488 -4.829084 2.5 13905 
log-tot-de-4 1 .0587463 .0706242 0.83 0.430 -. 104 1 135 .22 1606 
cons l -42.47798 39.16933 - 1.08 0.3 10 - 132.8026 47.84665 
STATA Output of Table 4.3 - Antinausea 
Log-log regression for antinausea medications in the USA 
Dependent Variable: lotot-pd-lkcapita 
Detailing variable lamzed I quarter 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 7, 24) = 22.62 
Model 1 1.06265853 7 .15 1808361 Prob > F = 0.0000 
Residual 1 .I61039389 24 .006709975 R-squared = 0.8684 
-------------+------------------------------ Adj R-squared = 0.8300 
Total 1 1.22369792 3 1 ,039474 126 RootMSE = .08191 
log-totgd-a I Coef. Std. Em. t P>ltl [95% Conf. Interval] 
-------------+------------------------------------------------------.--------- 
time 1 .0218327 .0082392 2.65 0.014 .0048278 .0388376 
logqrice--s 1 -.5996972 .2870549 -2.09 0.047 - 1.192 149 -.007245 
log tot-nu-d 1 -.29 13269 ,3545983 -0.82 0.41 9 - 1.023 1 82 .440528 1 
l ~ ~ ~ h ~ s ~ l - ~  1 -3.460289 1.014476 -3.41 0.002 -5.554065 -1.3665 13 
log nurse--p 1 -3 1.0138 1 10.36334 -2.99 0.006 -52.40269 -9.624926 
logincome-a ( 1.723526 .6147206 2.80 0.01 0 ,4548053 2.992247 
logtot - - de-1 ( .13 10095 .067521 1.94 0.064 -.008347 .2703661 
cons l 45.71933 15.76526 2.90 0.008 13.18144 78.25723 
Detailing variable lagwed 4 quarters 
Source1 SS df MS Number of obs = 32 
-------------+------------------------------ F( 7, 24)= 19.23 
Model 1 1.03857171 7 .I48367388 Prob > F = 0.0000 
Residual 1 .I85 126203 24 .0077 1 3592 R-squared = 0.8487 
-------------+------------------------------ Adj R-squared = 0.8046 
Total 1 1.22369792 3 1 .039474126 Root MSE = .08783 
log - totgd-a I Coef. Std. Em. t P>ltl [95% Conf. Interval] 
-------------+------------------------------------------------------.--------- 
time 1 .0216395 .0088339 2.45 0.022 ,0034073 ,0398717 
loggrice--s 1 -.403658 .2876327 - 1.40 0.173 -.9973027 .I899867 
log-tot-nu-d 1 -. 1779583 .437298 1 -0.4 1 0.688 - 1.080497 .7245807 
10gqhy~-l-p 1 -4.63771 .9710159 -4.78 0.000 -6.641788 -2.633632 
log nurse--p 1 -40.9061 9 10.26729 -3.98 0.00 1 -62.09684 - 19.7 1555 
logincome-a 1 1.1 803 87 ,7773908 1.52 0.142 -.424069 1 2.784842 
log~tot-de-4 1 -.O 132538 .03397 17 -0.39 0.700 -.Of333679 ,0568604 
- cons 1 68.21595 16.15997 4.22 0.000 34.86341 101.5685 
STATA Output of Table 4.3 - Antinausea 
Log-log regression for antinausea medications in Sweden 
Dependent Variable: logtot-pd-1 kcapita 
No Detailing V d l e s  
Source ( SS df MS Number of obs = 48 
-------------+------------------------------ F( 6, 41) = 3.81 
Model 1 .664824919 6 .I108041 53 Prob > F = 0.0041 
Residual 1 1.19190049 41 .029070744 R-squared = 0.3581 
-------------+----.------------------------- Adj R-squared = 0.2641 
Total 1 1.85672541 47 .039504796 Root MSE = .I705 
log-totjd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 -.0019076 .0100801 -0.19 0.85 1 -.0222648 .OM4496 
logprice--s 1 .I395729 .2427527 0.57 0.568 -.3506761 .6298218 
log-tot-nu4 1 2.092647 .4898002 4.27 0.000 1.103475 3.08 18 18 
l~gphhy~-l-p 1 -.9898699 2.324 16 -0.43 0.672 -5.683607 3.703867 
log nme--p 1 .3397772 3.341868 0.10 0.920 -6.409262 7.088816 
logIincome-a1 1.019245 1.310578 0.78 0.441 -1.627521 3.666011 
cons 1 -2.598249 25.24664 -0.10 0.919 -53.58487 48.38837 
- 
STATA Output of Table 4.4 - Antinausea 
Log-log regression for antinausea medications in the UK 
Dependent Variable: logshare-pd 
Detailing variable lagged I ouarter 
Source I SS df MS 
Model ( 10.934353 1 7 1.56205045 
Residual 1 .4090536 16 36 .0113626 
Total 1 1 1.3434067 43 .263800157 
Number of obs = 44 
F( 7, 36) = 137.47 
Prob>F = 0.0000 
R-squared = 0.9639 
Adj R-squared = 0.9569 
Root MSE = .I066 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
logqrice--o 1 -.28005 .I620265 -1.73 0.092 -.608655 1 .048555 
log-share-+ 1 -.2602084 .22766 - 1.14 0.261 -.72 19243 .20 15076 
time 1 .0488739 .0075981 6.43 0.000 .0334642 .0642836 
10gqhys 1-p 1 - 1.955325 1.448297 - 1.35 0.185 -4.892607 .98 19566 
log nurse--p 1 2.088932 1.860389 1.12 0.269 -1.6841 12 5.861976 
logIincome-a 1 -1.960492 .7181704 -2.73 0.010 -3.417009 -SO39752 
rel-detail-1 ( .0072648 .0624099 0.12 0.908 -. 1 193083 ,1338378 
- cons 1 27.56433 1 1.30179 2.44 0.020 4.643227 50.48542 
Detailing variable laaaed 4 uuarters 
Source I SS df MS Number of obs = 44 
-------------+------------------------------ F( 7, 36)= 104.24 
Model 1 10.4564301 7 1.49377572 Prob > F = 0.0000 
Residual 1 .5 15862161 36 .014329504 R-squared = 0.9530 
-------------+------------------------------ Adj R-squared = 0.9438 
Total 1 10.9722922 43 .255 169586 RootMSE = .I1971 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
logqrice-Q 1 -.792 1493 .18 17403 -4.36 0.000 - 1.160736 -.4235628 
log-share-+ 1 .0024427 ,35982 1 1 0.01 0.995 -.7273083 .7321938 
time 1 .0608567 .0081805 7.44 0.000 .0442658 .0774476 
10gghys 1-p 1 -4.454044 1.579 1 14 -2.82 0.008 -7.656635 - 1.25 1454 
10~-nurs~_-~ 1 1 A32433 2.055327 0.89 0.379 -2.335962 6.000829 
log-income-a 1 -1.036468 .7520159 -1.38 0.177 -2.561627 .4886911 
rel-detail4 1 .07 13447 .0299484 2.38 0.023 .O 106065 .I320829 
cons 1 39.21902 12.98828 3.02 0.005 12.87756 65.56048 
- 
STATA Output of Table 4.4 - Antinausea 
Log-log regression for antinausea medications in Italy 
Dependent Variable: logshareqd 
Detailing variable laaned 1 auarter 
Model 1 .3042977 1 1 6 .0507 16285 
Residual 1 .033213678 8 .00415 17 1 
-------------+------------------------------ 
Total ( .3375 1 1389 14 .024107956 
Number of obs = 15 
F( 6, 8) = 12.22 
Prob>F = 0.0012 
R-squared = 0.9016 
Adj R-squared = 0.8278 
Root MSE = .OM43 
l o g - s h q d  I Coef. Std. Err. t P>ltJ [95% Conf. Interval] 
logqrice--o ( -3428 1 16 .3420089 -2.46 0.039 - 1.63 1485 -.054 1377 
log-share -s 1 -.6757144 1.362741 -0.50 0.633 -3.8182 2.466771 
time? .0559634 .0195905 2.86 0.02 1 .0107876 .lo1 1393 
10gghys 1-p 1 -3955423 3.5333 13 -0.25 0.806 -9.043376 7.252291 
10~-nurse--~ I (dropped) 
log income-a 1 4.461376 1.931375 2.3 1 0.050 .0076175 8.915 135 
rel_hetail-1 1 -.3 1003 15 .I773 14 1 - 1.75 0.1 19 -.7 189 1 84 .0988554 
- cons 1 -42.1 1239 18.93871 -2.22 0.057 -85.785 14 1.560363 
Source I SS df MS 
Model ( .325648996 6 .054274833 
Residual 1 .Oil862392 8 .001482799 
Total 1 .3375 11389 14 .024107956 
Number of obs = 15 
F( 6, 8) = 36.60 
Prob>F = 0.0000 
R-squared = 0.9649 
Adj R-squared = 0.9385 
RootMSE = .03851 
log-sharegd 1 Coef. Std. Err. t P>(tl [95% Conf. Interval] 
logprice -o 1 -.97 14309 .I81 71 5 -5.35 0.001 -1.390467 -323952 
log-sharer-s 1 .2945 138 ,835432 0.35 0.734 -1.63 1996 2.221024 
time 1 .0432868 .0117696 3.68 0.006 .0161461 .0704276 
10g~hys-1-p 1 -2.275082 2.085 135 - 1.09 0.307 -7.083412 2.533247 
log-nme--p I (dropped) 
log-income- 1 3.502274 1.150428 3.04 0.0 16 34938 16 6.155 165 
rel-detail4 1 -. 1980055 .0413236 -4.79 0.001 -.293298 -. 1027 13 1 
cons 1 - 18.70567 12.75072 -1.47 0.18 1 -48.1089 10.69755 
- 
STATA Output of Table 4.4 - Antinausea 
Log-log regression for antinausea medications in the USA 
Dependent Variable: logshare-pd 
Detailing variable b e d  1 auarter 
Source) SS df MS Number of obs = 32 
-------------+------------------------------ F( 7, 24) = 55.01 
Model 1 9.22175506 7 1.3 1739358 Prob > F = 0.0000 
Residual 1 .574761781 24 .023948408 R-squared = 0.9413 
-------------+------------------------------ Adj R-squared = 0.9242 
Total 1 9.7965 1684 3 1 .3 16016672 Root MSE = .I5475 
.............................................................................. 
log-shareqd I Coef. Std. Err. t P>(tl [95% Conf. Interval] 
time 1 .0422089 .0210313 2.01 0.056 -.0011976 .0856153 
log-sharee-s 1 -.9256 133 .34 172 18 -2.7 1 0.0 12 - 1.630892 -.2203343 
logqrice-Q 1 -.550861 .15 14868 -3.64 0.001 -3635144 -.2382077 
logghys-1-p 1 2.810266 2.438617 1.15 0.261 -2.222791 7.843323 
log nurse--p 1 5.259764 24.86522 0.2 1 0.834 -46.05952 56.57905 
logincome-a 1 -2.42 179 1 1.2 17057 - 1.99 0.058 -4.933674 ,09009 15 
logrel-de-1 - 1 .215427 .0457002 4.71 0.000 .I21 1064 .3097476 
cons 1 -5.568888 36.92439 -0.15 0.88 1 -81.77709 70.6393 1 
- 
Detailing variable lagged 4 auarters 
Source1 SS df MS Number of obs = 32 
-------------+------------------------------ F( 7, 24) = 108.92 
Model 1 9.49754789 7 1.35679256 Prob > F = 0.0000 
Residual 1 .298968946 24 .012457039 R-squared = 0.9695 
-------------+------------------------------ Adj R-squared = 0.9606 
Total 1 9.7965 1684 3 1 .3 160 16672 Root MSE = ,11161 
.............................................................................. 
log - sharegd I Coef. Std. Err. t P>ltJ [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0330704 .0152535 2.17 0.040 ,0015887 .0645521 
log-sharee-s 1 -.5236915 .257585 -2.03 0.053 - 1.05532 1 .0079379 
loggrice-Q 1 -.4702685 .lo71 193 -4.39 0.000 -.691352 -.249185 
l ~ g g h y ~ - l - p  ( 1.67 134 1.765462 0.95 0.353 -1.972394 5.3 15074 
log nurse--p ( 3 1.92538 18.25362 1.75 0.093 -5.74825 1 69.599 
logIincome-a 1 -.9594482 .924 1732 - 1.04 0.3 10 -2.866848 ,94795 15 
log-rel-de-4 1 .2901328 .0360256 8.05 0.000 .2 157795 .3644861 
- cons 1 -35.6526 27.0997 1 -1.32 0.201 -91 .58365 20.27845 
STATA Output of Table 4.4 - Antinausea 
Log-log regression for antinausea medications in Sweden 
Dependent Variable: logshare-pd 
No Detailing V d l e s  
Source I SS df MS Number of obs = 48 
F( 6, 41) = 86.42 
Model 1 8.18377494 6 1.36396249 Prob > F = 0.0000 
Residual 1 .ti47093 1 18 4 1 .O 15782759 R-squared = 0.9267 
-------------+-----------------.---------.-- Adj R-squared = 0.9 160 
Total ( 8.83086806 47 .I878908 1 Root MSE = .I2563 
-----------------------------------------------.-------.----------.----------- 
log-sharegd ( Coef. Std. Err. t P>(tl [95% Conf. Interval] 
-------------+---.----------.------------------------------------------------- 
time 1 .0356287 .0062996 5.66 0.000 .0229064 .04835 1 1 
log-sharee-s 1 .4762715 .I557801 3.06 0.004 .I616672 .7908758 
logqrice-Q 1 .I6526 14 .0542443 3.05 0.004 .0557129 .2748099 
logjhys-1-p 1 .7293705 1.4942 1 0.49 0.628 -2.288248 3.746989 
log-nursee-p 1 -3.0837 12 2.44401 1 - 1.26 0.2 14 -8.0 1949 1 1.852068 
log-income-a 1 -2.837657 .8045587 -3.53 0.001 -4.462497 -1.2 128 18 
cons 1 2 1.27886 13.20899 1.6 1 0.1 15 -5.39723 47.95495 
- 
STATA Output of Table 5.4 - Antihypertensives 
Log-log regression for antihypertensives in France 
Dependent Variable: loptotpd-1 kcapita 
Detailing vaduble b e d  1 auarter 
-------------+------------------------------ 
Model 1 .0998 1 1049 6 .016635 175 
Residual ( .O 132 18 14 22 .000600825 
-------------+------------------------------ 
Total 1 .11302919 28 .004036757 
Number of obs = 29 
F( 6, 22) = 27.69 
Prob > F = 0.0000 
R-squared = 0.8831 
Adj R-squared = 0.8512 
Root MSE = .0245 1 
.............................................................................. 
log - totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0106768 ,0024043 4.44 0.000 .0056905 .015663 1 
logqrice-s 1 -.060275 .0527959 - 1.14 0.266 -. 1697669 .0492 169 
log-tot-nu4 1 -.634452 .3023933 -2.10 0.048 - 1.26 1577 -.0073266 
10gqhy~-l-p 1 -1.241376 .9443764 - 1.3 1 0.202 -3.199893 .7171409 
log income-a 1 .3 125289 .2315338 1.35 0.191 -. 1676428 .7927006 
log-tot  - de-1 1 -. 1 147276 .0458953 -2.50 0.020 -.2099086 -.0195467 
cons 1 18.80133 7.471961 2.52 0.020 3.305428 34.29722 
- 
Detailing v a ~ b l e  laaaed 4 auarters 
Source1 SS df MS Number of obs = 29 
-------------+------------------------------ F( 6, 22) = 35.50 
Model 1 .lo2448256 6 .0 17074709 Prob > F = 0.0000 
Residual 1 .010580934 22 .000480952 R-squared = 0.9064 
-------------+------------------------------ Adj R-squared = 0.8809 
Total 1 .11302919 28 .004036757 Root MSE = .02 193 
.............................................................................. 
log-totqd-a I Coef. Std. Err. t P>ltJ [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0139296 .0020783 6.70 0.000 .0096195 .OH2397 
logqrice-s 1 -.0844816 .0471273 -1.79 0.087 -. 1822176 ,0132545 
log-tot-nu4 1 -3432457 .2674774 -3.15 0.005 - 1.39796 -.28853 15 
10gqhys-1-p ( -1.522763 .8238873 - 1.85 0.078 -3.23 140 1 ,1858746 
log-income-a 1 .352642 ,206954 1 1.70 0.102 -.0765546 .78 18386 
log-tot-de-4 1 .0650297 .0178384 3.65 0.001 .0280352 .lo20243 
- cons ( 20.66256 6.53098 3.16 0.004 7.1 18 133 34.20698 
STATA Output of Table 5.4 - Antihypertensives 
Log-log regression for antihypertensives in Italy 
Dependent Variable: log,tottpd-1 kcapi ta 
Detailing variable laaned 1 cruarter 
Source I SS df MS 
Model 1 .071503166 6 .011917194 
Residual1 .029395121 9 .003266125 
-------------+------------------------------ 
Total 1 .lo0898287 15 .006726552 
Number of obs = 16 
F( 6, 9) = 3.65 
Prob > F = 0.0405 
R-squared = 0.7087 
Adj R-squared = 0.5144 
Root MSE = .05715 
.............................................................................. 
log-totjd-a I Coef. Std. Err. t P>(tJ [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 -.018885 1 .0138937 -1.36 0.207 -.0503 149 .0125448 
logprice -s 1 -.2208954 .7822102 -0.28 0.784 -1.990378 1.548587 
log-tot-nu4 1 .4694848 2.09494 1 0.22 0.828 -4.26960 1 5.20857 
logqhys-1-p 1 5.405469 2.508176 2.16 0.060 -.2684183 1 1.07936 
log-income-a 1 -2.2 14526 1.255636 -1.76 0.1 12 -5.05497 .6259192 
log-tot-de-1 1 -.0773767 .3225484 -0.24 0.8 16 -.80703 17 ,6522784 
cons l -13.5953 1 1.94224 -1.14 0.284 -40.61053 13.41994 
Detailina variable laaaed 4 cruarters 
Source I SS df MS Number of obs = 16 
-------------+------------------------------ F( 6, 9) = 7.66 
Model 1 .084372339 6 .014062056 Prob > F = 0.0039 
Residual 1 .016525948 9 .001836216 R-squared = 0.8362 
-------------+------------------------------ Adj R-squared = 0.7270 
Total 1 .I00898287 15 .006726552 Root MSE = .04285 
log-totjd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time1 -.0175089 .0101103 -1.73 0.117 -.0403799 .0053621 
logprice--s 1 -.280 1042 .44648 -0.63 0.546 -1.2901 12 .7299037 
log-tot-nu4 1 .1110103 1.203 16 0.09 0.929 -2.610726 2.832747 
logjhys-1-p 1 1.197241 2.102244 0.57 0.583 -3.558364 5.952847 
log-income-a 1 -3.606077 1.006005 -3.58 0.006 -5.88 18 18 - 1.330337 
log-tot-de-4 1 .0862548 .032346 1 2.67 0.026 .O 130829 .I594267 
cons l 36.30821 20.86065 1.74 0.1 16 -10.881 86 83.49828 
STATA Output of Table 5.4 - Antihypertensives 
Log-log regression for antihypertensives in the UK 
Dependent Variable: logtotpd-1 kcapita 
Detailing variable b m e d  I auarter 
Source I SS df MS Number of obs = 36 
-------------+------------------------------ F( 6, 29) = 466.94 
Model ( 1.8125081 5 6 .302084692 Prob > F = 0.0000 
Residual 1 .O 1876 1437 29 .000646946 R-squared = 0.9898 
-------------+------------------------------ Adj R-squared = 0.9876 
Total ( 1.83 126959 35 .052321988 Root MSE = .02544 
.............................................................................. 
log-totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0283285 .0020144 14.06 0.000 .0242086 .0324485 
logqrice--s 1 .0487689 .068 1068 0.72 0.480 -.0905252 .I88063 
log-tot-nu4 1 -.4 155355 ,1570686 -2.65 0.0 13 -.7367769 -.094294 1 
10gqhys 1-p 1 -.6409228 ,3213294 -1.99 0.056 -1.2981 15 .0162696 
log income-a 1 .2020507 .2083925 0.97 0.340 -.2241599 .6282613 
logtoot-de-1 - 1 .026 1722 .I140675 0.23 0.820 -.207 122 .2594664 
- cons 1 12.41831 2.5541 17 4.86 0.000 7.194558 17.64207 
Detailing variable laaaed 4 auarters 
Source I SS df MS Number of obs = 36 
-------------+------------------------------ F( 6, 29) = 550.91 
Model 1 1.81534279 6 .302557131 Prob > F = 0.0000 
Residual ( .0159268 29 .0005492 R-squared = 0.9913 
-------------+------------------------------ Adj R-squared = 0.9895 
Total 1 1.83126959 35 .052321988 Root MSE = .02344 
.............................................................................. 
log-totqd-a I Coef. Std. Err. t P>(t( [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0271656 .0019253 14.1 1 0.000 .0232279 .03 1 1033 
logqrice--s ( .0229905 ,0637683 0.36 0.72 1 -. 1074304 ,15341 13 
log tot-nu4 1 -.5057945 .I494406 -3.38 0.002 -.8 1 14348 -.2001542 
1 0 ~ > h ~ s - l - ~  1 -.3272742 .32227 14 - 1.02 0.3 18 -.9863933 .33 18449 
log-income-a 1 .39602 17 .I876346 2.1 1 0.044 .0122659 .7797775 
log-tot-de-4 1 -. 1062 182 .0464753 -2.29 0.030 -.2012709 -.0111656 
- cons 1 9.150798 2.736917 3.34 0.002 3.553 174 14.74842 
STATA Output of Table 5.4 - Antihypertensives 
Log-log regression for antihypertensives in the USA 
Dependent Variable: logtot-pd-1 kcapita 
Detailing variuble lagged I quarter 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 69.73 
Model 1 .289713799 6 .048285633 Prob > F = 0.0000 
Residual 1 .0173 1 174 25 .00069247 R-squared = 0.9436 
-------------+------------------------------ Adj R-squared = 0.930 1 
Total 1 .307025539 3 1 .00990405 Root MSE = .0263 1 
--------------..--------------------------------------------------------------- 
log - totgd-a I Coef. Std. Err. t P>Jtl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0063056 .003001 2.10 0.046 .000125 .0124863 
logprice-- 1 .058208 .I461945 0.40 0.694 -.2428852 .3593013 
log tot-nu4 1 .I426842 .2136661 0.67 0.510 -.2973693 St327378 
l ~ ~ ~ h ~ s ~ l - ~  1 .4502395 .306 1 146 1.47 0.154 -. 1802 153 1.080694 
log incomea 1 -. 1 1328 1 .2894338 -0.39 0.699 -.7093809 .4828 19 
log~tot-de-1 1 .00364 17 .0459466 0.08 0.937 -.090987 1 .0982705 
cons 1 5.78208 2.055034 2.81 0.009 1.549658 10.0145 
- 
Detailing variable laaned 4 ouarters 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 74.02 
Model 1 .29066348 1 6 .048443913 Prob > F = 0.0000 
Residual 1 .O 16362058 25 .000654482 R-squared = 0.9467 
-------------+--------------------I---------- Adj R-squared = 0.9339 
Total 1 .307025539 3 1 .00990405 Root MSE = ,02558 
.............................................................................. 
log-totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time( .0061881 ,0028435 2.18 0.039 .0003317 .0120444 
loggrice--s 1 .03 12038 .I354933 0.23 0.820 -.2478498 .3 102575 
log tot-nu-d 1 .2333966 -2208861 1.06 0.301 -.2215269 ,6883201 
1 0 ~ ~ h ~ s - l ~ ~  1 .415645 1 .2808291 1.48 0.15 1 -. 1627332 .9940233 
log income-a 1 .0130292 .28 14847 0.05 0.963 -.5666993 .5927576 
logtot-de-4 1 -.O 18479 .O 153054 - 1.2 1 0.239 -.05000 1 1 .O 13043 1 
- cons 1 4.660926 2.203993 2.1 1 0.045 .I2171 73 9.200135 
STATA Output of Table 5.4 - Antihypertensives 
Log-log regression for antihypertensives in Sweden 
Dependent Variable: logtot-pd-lkcapita 
No Detailing Variables 
Source I SS df MS Number of obs = 38 
---I---------+------------------------------ F( 5, 32) = 18.84 
Model 1 .953858206 5 .I90771641 Prob > F = 0.0000 
Residual 1 .32404506 1 32 .O 10 126408 R-squared = 0.7464 
-------------+------------------------------ Adj R-squared = 0.7068 
Total ( 1.27790327 37 .034537926 Root MSE = ,10063 
.............................................................................. 
log-totgd-a I Coef. Std. En: t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0141083 ,0040994 3.44 0.002 .0057581 .0224586 
loggrice--s 1 .34743 18 .2765648 1.26 0.2 18 -.2 159122 .9107757 
log-tot-nu4 1 -.3859828 .303 1883 -1.27 0.212 -1.003557 .23 15914 
logqhys-1-p 1 2.562302 1.521722 1.68 0.102 -.537344 5.661948 
log - income-a 1 SO21483 1.007462 0.50 0.622 -1.549985 2.554282 
- cons 1 - 16.44901 18.08 101 -0.9 1 0.370 -53.27882 20.3808 
STATA Output of Table 5.5 - Antihypertensives 
Log-log regression for antinausea medications in France 
Dependent Variable: logshare-pd 
Detailing variable laaaed 1 auarter 
Source ( SS df MS Number of obs = 29 
-------------+------------------------------ F( 6, 22) = 569.37 
Model 1 8.72252505 6 1.45375418 Prob > F = 0.0000 
Residual 1 .056172126 22 .002553278 R-squared = 0.9936 
-------------+------------------------------ Adj R-squared = 0.99 1 9 
Total 1 8.77869718 28 .3 13524899 Root MSE = .05053 
l o g - s h q d  I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 .0168505 .0025409 6.63 0.000 .01158 1 .022 1 199 
log-share--s 1 .3049914 .071888 1 4.24 0.000 .I559046 .454078 1 
logqrice--o 1 -2.796594 1.06752 -2.62 0.0 16 -5.0 10495 -.5826936 
10g~hys-1-p 1 -1.972191 2.233 17 1 -0.88 0.387 -6.603503 2.659121 
log-income-a 1 -.35529 1 1 .5454279 -0.65 0.522 - 1.486439 .7758572 
log-rel-de-1 ( ,2990859 .037027 8.08 0.000 .2222966 .3758752 
cons l 19.18393 17.38675 1.10 0.282 -16.87399 55.24185 
Detailing variable laaned 4 auarters 
Source I SS df MS Number of obs = 29 
-------------+------------------------------ F( 6, 22) = 296.01 
Model 1 8.67128654 6 1.4452 1442 Prob > F = 0.0000 
Residual 1 .lo74 10635 22 .004882302 R-squared = 0.9878 
-------------+------------------------------ Adj R-squared = 0.9844 
Total 1 8.778697 18 28 .3 13524899 Root MSE = .06987 
log-sharegd ( Coef. Std. Err. t P>(tl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0155618 .0039493 3.94 0.001 .0073715 .0237522 
log-share--s 1 .3473528 .lo29144 3.38 0.003 .I339214 .5607843 
logqrice -0 ( -.4197254 1.325828 -0.32 0.755 -3.169323 2.329873 
l ~ ~ ~ h ~ s ~ l - ~  1 -.7677403 3.282639 -0.23 0.8 17 -7.5755 17 6.040037 
log-incomea 1 .5961955 .710063 1 0.84 0.410 -3763853 2.068776 
log-rel-de4 1 .252 1363 .05 1872 4.86 0.000 ,1445603 .3597 124 
cons 1 -1.75053 25.76624 -0.07 0.946 -55.18643 5 1.68537 
- 
STATA Output of Table 5.5 - Antihypertensives 
Log-log regression for antinausea medications in Italy 
Dependent Variable: logsharegd 
Detailing variuble lagged I auarter 
Source1 SS df MS Number of obs = 16 
-------------+------------------------------ F( 6, 9) = 136.33 
Model 1 .270752882 6 .045 12548 Prob > F = 0.0000 
Residual / ,002978984 9 .000330998 R-squared = 0.9891 
-------------+------------------------------ Adj R-squared = 0.9819 
Total 1 .27373 1866 15 .018248791 RootMSE = .01819 
............................................................................. 
log - shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .033472 1 .006061 5.52 0.000 .0197611 .047 183 1 
log-share--s 1 .O 174203 .I804684 0.10 0.925 -.3908276 .425668 1 
loggrice--o 1 -.3879918 .382 1433 -1.02 0.336 -1.25246 .4764763 
logghys-1-p 1 -.72 1834 .7477 13 1 -0.97 0.360 -2.41 3279 ,9696106 
log-income-a 1 .6503661 .3498644 1.86 0.096 -. 1410822 1.441814 
log-rel-de-1 1 -.0060478 .00492 - 1.23 0.250 -.017 1777 ,005082 1 
- cons 1 -3.8305 1 4.143616 -0.92 0.379 - 13.20402 5.543001 
Detailing v a ~ b l e  laaaed 4 uuarters 
Source I SS df MS Number of obs = 16 
-------------+------------------------------ F( 6, 9) = 1 19.40 
Model 1 .270335817 6 .04505597 Prob > F = 0.0000 
Residual 1 .003396049 9 .000377339 R-squared = 0.9876 
-------------+------------------------------ Adj R-squared = 0.9793 
Total 1 .27373 1866 15 .018248791 Root MSE = .01943 
.............................................................................. 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0345 15 .006395 5.40 0.000 .0200484 .04898 15 
log-share--s 1 .0616069 .I983095 0.3 1 0.763 -.3870003 .5 102 141 
loggrice-Q 1 -.4982759 .429372 -1.16 0.276 -1.469583 ,47303 1 1 
10g~hys-1-p 1 - 1.102485 .go634 - 1.22 0.255 -3.152768 .9477987 
log income-a 1 ,553 1305 .52463 1 1.05 0.3 19 -.6336672 1.739928 
logIrel-de-4 1 -.0048253 .O 102839 -0.47 0.650 -.0280892 .O 184386 
- cons 1 .4490562 8.666156 0.05 0.960 -19.15515 20.05326 
STATA Output of Table 5.5 - Antihypertensives 
Log-log regression for antinausea medications in the UK 
Dependent Variable: logshare-pd 
Detailing variable lamed I auarter 
Source I SS df MS Number of obs = 35 
-------------+------------------------------ F( 6, 28) = 185.95 
Model 1 59.7581698 6 9.95969496 Prob > F = 0.0000 
Residual 1 1.49973707 28 .053562038 R-squared = 0.9755 
-------------+------------------------------ Adj R-squared = 0.9703 
Total 1 61.2579068 34 1.801 703 14 Root MSE = .23 143 
.......................... --- 
log-shareqd I Coef. Std. Err. t P>lt) [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .043 1249 .0176744 2.44 0.021 .0069205 .0793293 
log-share--s ( .I400407 .278 1052 0.50 0.619 -.429632 .7097133 
logqrice-Q 1 -3.474274 1.295229 -2.68 0.012 -6.12743 -32 1 1 178 
10gqhys-1-p 1 -2.146394 2.854293 -0.75 0.458 -7.993 147 3.70036 
log-income-a 1 3.570985 1.77 1443 2.02 0.054 -.05765 12 7.199621 
log-rel-de-1 1 .7522403 .I702564 4.42 0.000 .4034858 1.100995 
cons l -20.86806 26.38859 -0.79 0.436 -74.92263 33.1865 1 
Detailing v d l e  lapped 4 ouarters 
Source I SS df MS Number of obs = 35 
-------------+------------------------------ F( 6, 28) = 790.25 
Modell 60.8982843 6 10.1497141 Prob>F = 0.0000 
Residual 1 .3596225 1 1 28 .01284366 1 R-squared = 0.994 1 
-------------+------------------------------ Adj R-squared = 0.9929 
Total 1 6 1.2579068 34 1.80 1703 14 Root MSE = .I1333 
.............................................................................. 
log-shareqd I Coef. Std. Err. t P>(tl [95% Conf. Interval] 
time 1 .0204534 .0089782 2.28 0.031 .0020625 .0388444 
log-share--s 1 .I288445 .I206762 1.07 0.295 -. 1 183495 .3760385 
loggrice-Q 1 -2.238398 .647 17 19 -3.46 0.002 -3.56407 -.9 127269 
l~gqhy~-l -p  1 .5988802 1.391402 0.43 0.670 -2.25 1279 3.449039 
log-income-a 1 .6 156 15 1 .9093084 0.68 0.504 - 1.2470 19 2.478249 
log-rel-de-4 1 .7805679 .0598355 13.05 0.000 .6580004 .903 1353 
- cons 1 -13.27024 12.91809 -1.03 0.313 -39.73174 13.19127 
STATA Output of Table 5.5 - Antihypertensives 
Log-log regression for antinausea medications in the USA 
Dependent Variable: logshare-pd 
Detailing variable lagged 1 quarter 
Source1 SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 406.88 
Model 1 13.1614884 6 2.19358139 Prob > F = 0.0000 
Residual 1 .I34779036 25 .005391161 R-squared = 0.9899 
Adj R-squared = 0.9874 
Total 1 13.2962674 3 1 .4289 1 1852 Root MSE = .07342 
log-sharegd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 .0550686 .0110572 4.98 0.000 .0322958 .0778414 
log-share-+ 1 .6240734 .0944029 6.6 1 0.000 .4296469 .8 184999 
loggrice--0 1 -.61773 .3269568 -1.89 0.070 -1.291 1 1 .0556501 
logghys 1-p 1 -1.656298 .739445 -2.24 0.034 -3.1792 13 -. 1333823 
log income-a 1 1.967389 .7463028 2.64 0.014 .4303498 3.504429 
logIrel-de-1 1 -.0593 156 .022295 1 -2.66 0.0 13 -. 1052333 -.O 133979 
cons 1 - 10.72532 7.357233 - 1.46 0.157 -25.87783 4.4271 8 1 
Detailing variable lamed 4 auarters 
Source1 SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 365.03 
Modell 13.1462086 6 2.19103477 Prob > F = 0.0000 
Residual 1 .I50058788 25 .006002352 R-squared = 0.9887 
-------------+------------------------------ Adj R-squared = 0.9860 
Total 1 13.2962674 3 1 .428911852 Root MSE = .07747 
.............................................................................. 
log-sharegd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0635835 .0133976 4.75 0.000 ,0359907 .0911763 
log-share--s 1 SO38226 ,1093059 4.61 0.000 ,2787028 .7289423 
logqrice--0 1 -.8000108 .3732617 -2.14 0.042 -1.568758 -.0312639 
10gqhys 1-p 1 -1.838741 .7977529 -2.30 0.030 -3.481744 -. 1957382 
log-income-a 1 2.015284 .7871502 2.56 0.017 .3941177 3.63645 
log-rel-de-4 1 -.0500382 .0256294 - 1.95 0.062 -. 102823 .0027466 
cons l - 10.19623 7.88538 - 1.29 0.208 -26.43647 6.0440 17 
STATA Output of Table 5.5 - Antihypertensives 
Log-log regression for antinausea medications in Sweden 
Dependent Variable: logshare-pd 
No Detailing V d l e s  
Source I SS df MS Number of obs = 38 
-------------+------------------------------ F( 5, 32) = 26.66 
Model 1 83.5922826 5 16.7184565 Prob > F = 0.0000 
Residual 1 20.069729 32 .62717903 R-squared = 0.8064 
-------------+------------------------------ Adj R-squared = 0.7761 
Total ) 103.662012 37 2.80167599 Root MSE = .79195 
--------------II-------------------------------------------------------------- 
log-shareqd ( Coef. Std. Err. t P>(tl [95% Conf Interval] 
-------------+---------------------------------------------------------------- 
time 1 -.0397753 .050 194 -0.79 0.434 -. 1420 17 1 .0624665 
log-share--s ( 1.37134 .6099223 2.25 0.032 .I289687 2.61371 1 
logprice--o 1 7.377343 1.352668 5.45 0.000 4.622049 10.13264 
logqhys-1-p 1 2.537228 10.2934 0.25 0.807 -1 8.42974 23.504 19 
log - income-a 1 5.46362 6.736542 0.8 1 0.423 -8.258267 19.1855 1 
cons l -79.6901 5 95.73587 -0.83 0.41 1 -274.6977 1 15.3 174 
STATA Output of Table 5.6 - Antihypertensives 
Log-log regression for antinausea medications in France 
Dependent Variable: logshare-pd-newmid 
With Detailing v d l e  lugged 1 ouarter 
Source1 SS df MS Number of obs = 29 
-------------+------------------------------ F( 7, 21) = 162.04 
Model 1 .I110483 1 7 .015864044 Prob > F = 0.0000 
Residual 1 .002055952 2 1 .000097902 R-squared = 0.9818 
-------------+------------------------------ Adj R-squared = 0.9758 
Total 1 .I13 104262 28 .004039438 Root MSE = .00989 
.............................................................................. 
log-share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
logqrice-ld 1 -.5260202 .3207734 -1.64 0.116 -1.193105 .I410645 
log - share-nd 1 -.0562336 .2696225 -0.2 1 0.837 -.6169444 .5044772 
time 1 .0033153 .001401 2.37 0.028 .0004017 ,0062288 
l~gghy~- l -p  1 .I617926 .4890643 0.33 0.744 -3552724 1 .I78858 
log income-a 1 .0181058 .I25608 0.14 0.887 -.2431104 .279322 
logIrel-de-1 1 .0673907 .0171655 3.93 0.001 .03 1693 ,1030883 
cons I -2.3 19992 3.816882 -0.61 0.550 -10.25763 5.617649 
With Detailing variable laaned 4 auarters 
Source I SS df MS Number of obs = 29 
-------------+------------------------------ F( 7, 21)= 111.50 
Model 1 .I10140869 7 ,01573441 Prob > F = 0.0000 
Residual 1 .002963393 21 .000141114 R-squared = 0.9738 
-------------+------------------------------ Adj R-squared = 0.965 1 
Total 1 .I13 104262 28 .004039438 Root MSE = .01188 
.............................................................................. 
log - share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
logqrice-ld 1 .2829009 .3074893 0.92 0.368 -.356558 ,9223598 
log-share-nd 1 -.0868701 .3273504 -0.27 0.793 -.7676326 .5938923 
time 1 .0038104 .0016706 2.28 0.033 .0003362 .0072847 
1 0 g ~ h y s ~ l - p  1 -.3735915 .552 1626 -0.68 0.506 -1.521877 .7746936 
log-income-a 1 .I596988 .I472098 1.08 0.290 -. 1464407 .4658382 
log-rel-de-4 1 .0278028 .0134662 2.06 0.052 -.0002018 .0558073 
- cons 1 -.5373397 4.528222 -0.12 0.907 -9.954294 8.879614 
STATA Output of Table 5.6 - Antihypertensives 
Log-log regression for antinausea medications in Italy 
Dependent Variable: logshare-pd-newmid 
With Detailing variable lamed 1 auarter 
Source I SS df MS 
-------------+------------------------------ 
Model 1 .007504176 7 .OO 1072025 
Residual 1 7.526 1 e-06 8 9.4077e-07 
Total 1 .0075 1 1702 15 .00050078 
Number of obs = 16 
F( 7, 8) = 1 139.52 
Prob > F = 0.0000 
R-squared = 0.9990 
Adj R-squared = 0.9981 
Root MSE = .00097 
.............................................................................. 
log-share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+--------------.----------------------------------------------.-- 
logqrice-ld 1 -.0789624 .0260152 -3.04 0.016 -. 1389535 -.01897 13 
log-share-nd ( .0050129 .0276659 0.18 0.861 -.0587847 .0688 106 
time 1 .000283 .0003 122 0.91 0.391 -.0004368 .0010029 
logjhys-1-p 1 .7669707 .0389036 19.7 1 0.000 -6772587 3566826 
log-income-a 1 -.4080708 .O 19004 -2 1.47 0.000 9.45 1 894 -.3642476 
log-rel-de-1 1 -.0000249 .0003 15 1 -0.08 0.939 -.00075 15 .0007018 
cons 1 -3.066057 .234 1665 - 13.09 0.000 -3.606046 -2.526068 
- 
With Detailing v d l e  lamed 4 uuarters 
Source I SS df MS 
Model 1 .0075 10827 7 .001072975 
Residual 1 8.7496e-07 8 1.0937e-07 
Total 1 .0075 1 1702 15 .00050078 
Number of obs = 16 
F( 7, 8) = 9810.55 
Prob > F = 0.0000 
R-squared = 0.9999 
Adj R-squared = 0.9998 
Root MSE = .00033 
---------------------9----------------------------------------------.--------- 
log-share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+----------------------------------------.----------------------- 
logqrice-ld 1 -.0341598 .0105582 -3.24 0.012 -.058507 -.0098 126 
log-share-nd1 -.0575853 .0123808 -4.65 0.002 -.0861354 -.0290352 
time 1 .0003 192 .0001052 3.03 0.01 6 .0000765 .0005619 
logghys 1-p 1 3795419 .0195248 45.05 0.000 3345 176 .9245662 
log-income-a 1 -.3361968 .0112041 -30.01 0.000 -.3620335 -.3 103601 
log-rel-de-4 1 .002 1473 .0002752 7.80 0.000 .OO 15 126 .00278 19 
cons I -4.998682 .2603688 - 19.20 0.000 -5.599094 -4.39827 1 
STATA Output of Table 5.6 - Antihypertensives 
Log-log regression for antinausea medications in the UK 
Dependent Variable: logshare-pdnewmid 
With Detailing variable lagged 1 auarter 
Source I SS df MS Number of obs = 35 
-------------+------------------------------ F( 7, 27) = 357.87 
Model 1 .625205271 7 .0893 15039 Prob > F = 0.0000 
Residual 1 .006738494 27 .000249574 R-squared = 0.9893 
-------------+------------------------------ Adj R-squared = 0.9866 
Total 1 .63 1943766 34 .018586581 Root MSE = .0158 
log - share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
logqrice-ld 1 .2890045 .I35 1803 2.14 0.042 .0116374 ,5663716 
log - share-nd 1 -.3804563 .2033049 -1.87 0.072 -.7976034 .0366908 
time 1 .0095009 .0017194 5.53 0.000 .005973 .0130288 
logqhys 1-p 1 .5971166 .I958263 3.05 0.005 .I953 143 .9989189 
log income-a 1 ,0085985 .I244207 0.07 0.945 -.2466917 .2638888 
logIrel-de-1 1 -.0496358 .0311906 -1.59 0.123 -.I136337 .0143621 
- cons 1 -7.741413 1.94639 -3.98 0.000 - 1 1.73507 -3.74775 1 
With Detailing variable laaaed 4 auarters 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 7, 24) = 287.53 
Model ( .45 1076055 7 .064439436 Prob > F = 0.0000 
Residual 1 .0053788 1 1 24 .000224 1 17 R-squared = 0.9882 
-------------+------------------------------ Adj R-squared = 0.9848 
Total 1 .456454866 3 1 .01472435 1 Root MSE = .01497 
.............................................................................. 
log-share-id I Coef. Std. Err. t P>ltl [95% Conf Interval] 
-------------+---------------------------------------------------------------- 
loggrice-ld 1 .3092976 .13 12916 2.36 0.027 .0383251 .5802701 
log-share-nd 1 -.25843 1 1 .I94463 1 - 1.33 0.196 -.6597833 .I4292 1 1 
time 1 .0058152 .0021777 2.67 0.013 .0013206 .0103098 
logjhys-1-p 1 .68705 1 .I954375 3.52 0.002 .2836879 1.090414 
log income-a / -.OM2625 .I3969 13 -0.61 0.547 -.37357 12 .2030462 
logIrel-de-4 1 .0511397 .0322332 1.59 0.126 -.0153864 .I176658 
- cons 1 -6.96480 1 1.89149 -3.68 0.00 1 - 10.86864 -3.060957 
STATA Output of Table 5.6 - Antihypertensives 
Log-log regression for antinausea medications in the USA 
Dependent Variable: logshare-pd-newmid 
With Detailing Variable lanaed 1 auarter 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 7, 24) = 267.98 
Model 1 .I70925499 7 .0244 1 7928 Prob > F = 0.0000 
Residual 1 .002 186854 24 .000091119 R-squared = 0.9874 
-------------+------------------------------ Adj R-squared = 0.9837 
Total 1 .I73 1 12354 3 1 .005584269 Root MSE = .00955 
.............................................................................. 
log-share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
loggrice-ld 1 -.003525 .0595509 -0.06 0.953 -. 126432 .I19382 
log-share-nd 1 .I112053 .I626067 0.68 0.501 -.2243984 .446809 
time 1 .0057059 .0017996 3.17 0.004 .0019917 .0094201 
logphys-1-p 1 ,1972365 .0975555 2.02 0.054 -.0041082 .39858 12 
log income-a 1 .0449082 .098 1523 0.46 0.65 1 -. 1576682 .2474846 
log>el-de-1 1 .0057887 .0055529 1.04 0.308 -.005672 .0172494 
- cons 1 -2.780545 1.175491 -2.37 0.026 -5.20664 -.3544502 
With Detailing Varidle laaaed 4 auartem 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 7, 24) = 256.22 
Model 1 .170826505 7 .024403786 Prob > F = 0.0000 
Residual ( .002285848 24 .000095244 R-squared = 0.9868 
-------------+------------------------------ Adj R-squared = 0.9829 
Total 1 .I73 112354 3 1 .005584269 Root MSE = .00976 
log-share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
logqrice-ld 1 -.0127506 .0662659 -0.19 0.849 -. 1495 167 .I240154 
l o g - s e n d  1 .15 14357 .I615597 0.94 0.358 -. 1820072 .4848787 
time 1 .0061147 .0020393 3.00 0.006 .0019058 .0103237 
logphys-1-p 1 .I869226 .lo09302 1.85 0.076 -.021387 .3952323 
log-income-a 1 .0280439 .lo00778 0.28 0.782 -. 1785066 .2345944 
log-rel-de-4 ( .0000898 .0055262 0.02 0.987 -.0113 156 .0114952 
cons l -2.390308 1.1732 14 -2.04 0.053 -4.8 1 1703 .03 1087 1 
STATA Output of Table 5.6 - Antihypertensives 
Log-log regression for antinausea medications in Sweden 
Dependent Variable: logshare-pd-newmid 
No Detailing Variables 
Source1 SS df MS Number of obs = 38 
-------------+------------------------------ F( 6, 3 1) = 135.03 
Model 1 .592510187 6 .09875 1698 Prob > F = 0.0000 
Residual 1 .022670532 3 1 .00073 1307 R-squared = 0.963 1 
-------------+------------------------------ Adj R-squared = 0.9560 
Total 1 .6 15 18071 8 37 .016626506 Root MSE = .02704 
.............................................................................. 
log - share-id I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
loggrice-ld 1 .0986257 .065 1408 1.5 1 0.140 -.0342298 .23 148 12 
log - share-nd 1 -.2475332 .2 16033 - 1.15 0.26 1 -.688 1353 .I93069 
time 1 .0101774 .0019173 5.31 0.000 .0062669 .0140878 
10gghys 1-p 1 -.3 19054 1 .3790867 -0.84 0.406 -1.092207 ,4540984 
log income-a 1 .4129377 .2309353 1.79 0.084 -.058058 .8839334 
logInurn-ne-d 1 .209275 1 .I733524 1.2 1 0.236 -. 1442794 .5628295 
cons l -4.156682 3.350952 - 1.24 0.224 - 10.99099 2.677629 
STATA Output of Table 6.3 - Antipsychotics 
Log-log regression for antipsychotics in France 
Dependent Variable: logtottpddlkcapita 
With detailing variuble laaned 1 auarter 
Source I SS df MS 
-------------+-.---------------------------- 
Modell 2.31021568 5 .462043136 
Residual ( .0040057 16 4 .001001429 
Total 1 2.31422139 9 ,25713571 
Number of obs = 10 
F( 5, 4)= 461.38 
Prob > F = 0.0000 
R-squared = 0.9983 
Adj R-squared = 0.996 1 
Root MSE = .03 165 
- - - - - - - - 
log-totgd-a I Coef. Std. Err. t P>ltl [95% Conf Interval] 
time 1 .0570594 .013639 4.18 0.014 .0191914 .0949274 
logprice--s 1 -.27 17005 .38999 14 -0.70 0.524 - 1.35449 .8 1 10893 
log-tot-nu4 1 -.3343667 .368235 1 -0.91 0.41 5 -1.35675 1 .6880177 
l o g g h ~ s - l - ~  I (dropped) 
log-income-a 1 -.5339355 1.269396 -0.42 0.696 -4.058345 2.990474 
log-tot-de-1 1 -.0233829 .05 1 13 14 -0.46 0.67 1 -. 1653463 .I185805 
cons l 10.56302 13.4861 1 0.78 0.477 -26.88042 48.00646 
With detailing variable la~ned 4 auarters 
Source I SS df MS Number of obs = 44 
F( 6, 37) = 385.07 
Model 1 13.4913235 6 2.24855392 Prob > F = 0.0000 
Residual 1 .216057576 37 .005839394 R-squared = 0.9842 
-------------+--------------.------------.-- Adj R-squared = 0.98 1 7 
Total 1 13.707381 1 43 .3 18776305 Root MSE = .07642 
log-totgd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
------------.+--------------.------------------------------------------------- 
time 1 .05869 .0046164 12.71 0.000 .0493363 .0680437 
loggrice--s 1 -332704 .lo39726 -5.60 0.000 -.7933725 -.3720354 
log-tot-nu4 1 .O 177698 .079 1784 0.22 0.824 -. 1426609 .I782005 
10g~hys-1-p 1 -1.546295 1.675236 -0.92 0.362 -4.940646 1.848057 
log-income- 1 .6162782 .5438195 1.13 0.264 -.4856048 1.7 18 161 
log-tot-de-4 1 .0250082 .026435 0.95 0.350 -.0285543 .0785707 
cons 1 12.50509 12.53 187 1.00 0.325 -12.88688 37.89706 
- 
STATA Output of Table 6.3 - Antipsychotics 
Log-log regression for antipsychotics in the UK 
Dependent Variable: logtot-pd-lkcapita 
With detailing variable lugged 1 quarter 
Source I SS df MS Number of obs = 30 
-------------+------------------------------ F( 6, 23) = 475.64 
Model 1 24.6344205 6 4.10573676 Prob > F = 0.0000 
Residual 1 .I98535895 23 ,00863 1995 R-squared = 0.9920 
-------------+------------------------------ Adj R-squared = 0.9899 
Total 1 24.8329564 29 356308843 Root MSE = .09291 
.............................................................................. 
log - totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time ( .0504574 .0072558 6.95 0.000 .0354475 .0654672 
logqrice-s 1 -.65 18885 .2 135299 -3.05 0.006 - 1.093609 -.2 10 1682 
log-tot-nu4 1 1.141336 .I847158 6.18 0.000 ,7592219 1.523449 
logqhys-1-p 1 3.107629 1.1 13395 2.79 0.010 .8043962 5.410861 
log income* 1 1.43842 .8440506 1.70 0.102 -.30763 15 3.184472 
logItot-de-1 1 -.064 1 1 12 .069265 -0.93 0.364 -.2073969 .079 1744 
cons 1 -33.00528 1 1.91396 -2.77 0.01 1 -57.65 1 18 -8.359385 
With detailing variable lamed 4 quarters 
Source I SS df MS Number of obs = 43 
-------------+------------------------------ F( 6, 36)= 1024.04 
Model 1 79.8020202 6 13.3003367 Prob > F = 0.0000 
Residual 1 .467570329 36 .012988065 R-squared = 0.9942 
-------------+------------------------------ Adj R-squared = 0.9932 
Total 1 80.2695905 42 1.9 1 1 18073 Root MSE = .I1397 
.............................................................................. 
log-totgd-a 1 Coef. Std. Err. t P>Jt( [95% Conf. Interval] 
- - - - - - - - - 
time 1 .0791932 .0065501 12.09 0.000 ,065909 .0924774 
loggrice--s 1 .I590686 .0774287 2.05 0.047 .002036 .3 161013 
log-tot-nu4 1 .3407466 .06 1 574 5.53 0.000 .2 1 58686 .4656245 
logqhys-1-p 1 2.98061 1 .I39937 2.61 0.013 .6687113 5.292508 
log income-a 1 2.482542 1.138469 2.18 0.036 .I736197 4.791464 
logItot-de-4 1 -. 1308258 .05 18 192 -2.52 0.016 -.23592 -.02573 15 
cons l -46.59894 14.2 1732 -3.28 0.002 -75.43301 -1 7.76487 
STATA Output of Table 6.3 - Antipsychotics 
Log-log regression for antipsychotics in Italy 
Dependent Variable: logtot-pd-lkcapita 
With detailing variable laaned 1 auarter 
Source I SS df MS Number of obs = 16 
-------------+---------------------------.-- F( 6, 9)= 25.11 
Model 1 .234520348 6 .039086725 Prob > F = 0.0000 
Residual 1 .014009383 9 .001556598 R-squared = 0.9436 
-------------+------------------------------ Adj R-squared = 0.9061 
Total 1 .24852973 1 15 .016568649 Root MSE = .03945 
log-totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 .0374869 .0172557 2.17 0.058 -.0015482 .076522 
loggrice--s 1 -.I3359534 .3268587 -2.56 0.03 1 -1.575359 -.0965476 
log-tot-nu4 1 - 1.9 17882 1.04528 1 - 1.83 0.100 -4.282472 .4467068 
l o g ~ h y s ~ l - p  1 .4198069 2.000383 0.2 1 0.838 -4.105374 4.944988 
log income-a 1 1.636668 .7777344 2.10 0.065 -. 1226897 3.396025 
logItot-de-1 1 .093 1433 .0552869 1.68 0.126 -.03 19244 .2 182 1 1 
cons l -8.755427 13.95326 -0.63 0.546 -40.3 1989 22.80904 
With detailing variuble lamed 4 uuarters 
Source I SS df MS Number of obs = 16 
-------------+---------------------------.-- F( 6, 9) = 20.51 
Model 1 .23 1594396 6 .038599066 Prob > F = 0.0001 
Residual 1 .016935335 9 .001881704 R-squared = 0.9319 
Adj R-squared = 0.8864 
Total 1 .24852973 1 15 .016568649 Root MSE = .04338 
log-totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+----------------------------------------.----------------------- 
time 1 .0259575 .0166491 1.56 0.153 -.0117054 .0636203 
logqrice--s 1 - 1.052968 .439 1534 -2.40 0.040 -2.046402 -.059534 
log-tot-nu4 1 -.307062 .3522 102 -0.87 0.406 - 1.1038 17 .4896928 
10g~hys-1-p 1 .3705034 3.124604 0.12 0.908 -6.697842 7.438849 
log-income-a 1 .5 191295 1.221608 0.42 0.681 -2.244339 3.282598 
log-tot-de-4 1 .0437277 .049105 1 0.89 0.396 -.0673559 .I548 1 12 
cons l 2.044805 33.92087 0.06 0.953 -74.68954 78.77915 
STATA Output of Table 6.3 - Antipsychotics 
Log-log regression for antipsychotics in the USA 
Dependent Variable: loetot-pd-lkcapita 
With detailing variable b e d  1 auarter 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 346.10 
Model 1 1 1.03 14539 6 1.83857566 Prob > F = 0.0000 
Residual 1 ,132805818 25 .0053 12233 R-squared = 0.9881 
-------------+------------------------------ Adj R-squared = 0.9852 
Totall 11.1642598 31 .360137412 Root MSE = .07289 
----------------.------------------------------------------------------------- 
log-totgd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time ( .0592064 .0069607 8.5 1 0.000 .0448706 .0735423 
logprice--s 1 -.6862359 .398 158 -1.72 0.097 -1 SO6258 .I337858 
log-tot-nu4 1 .493 1805 .17 17697 2.87 0.008 .I394 143 3469468 
10gghys-1-p ( -.5619799 .773526 -0.73 0.474 -2.155087 1.03 1 127 
log-income-a 1 2.62 105 .6618384 3.96 0.001 1.257969 3.9841 32 
log - tot - de-1 1 -.0471769 .030357 -1.55 0.133 -.lo96982 .0153444 
- cons 1 - 15.05626 6.779784 -2.22 0.036 -29.0 1949 - 1.09303 1 
With detailing variable b e d  4 auarters 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 372.42 
Model 1 1 1.0407344 6 1.8401224 Prob > F = 0.0000 
Residual 1 .I23525372 25 .004941015 R-squared = 0.9889 
-------------+------------------------------ Adj R-squared = 0.9863 
Totall 11.1642598 31 .360137412 Root MSE = .07029 
----------------.------------.------------------------------------------------ 
log-totgd-a I Coef Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .064437 .0072541 8.88 0.000 .0494969 .079377 
logprice--s 1 -302487 .3957485 -1.39 0.177 -1.365308 .2648 105 
log-tot-nu4 1 .5282783 .I674902 3.15 0.004 .I833257 .8732309 
10gphy~-1-p 1 -.600497 .7423505 -0.81 0.426 -2.129396 .9284025 
log-income-a 1 2.844404 .624 1685 4.56 0.000 1.558905 4.129903 
log-tot-de-4 1 -. 123 1643 .0582232 -2.12 0.045 -.2430773 -.00325 13 
- cons 1 - 17.89636 6.624866 -2.70 0.012 -3 1.54053 -4.252194 
STATA Output of Table 6.3 - Antipsychotics 
Log-log regression for antipsychotics in Sweden 
Dependent Variable: log,tottpddlkcapita 
No Detailing Variables 
Source1 SS df MS Number of obs = 40 
-------------+-----.------------------------ F( 5, 34) = 495.22 
Model 1 19.0806675 5 3.8161335 Prob>F = 0.0000 
Residual 1 .262004221 34 .007706006 R-squared = 0.9865 
--,,-,-----o,+-----o------------------------ Adj R-squared = 0.9845 
Totall 19.3426717 39 .495965942 Root MSE = .08778 
~ ~ o ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ - - - ~ ~ ~ ~ ~ - - ~ - ~ ~ ~ ~ - - - - o ~ ~ ~ ~ - - - - o ~ ~ ~ ~ - ~ - - ~ ~ ~ ~ ~ ~ ~ ~ - ~ ~ ~ ~ o ~ ~ ~ o ~ ~ ~ ~ ~  
log - totgd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 .0547833 .0048905 1 1.20 0.000 .0448446 .064722 1 
logprice--s 1 .05 1 1292 .I182652 0.43 0.668 -. 1892 146 .29 1473 
log-tot-nu4 1 .00175 12 .I209406 0.01 0.989 -.2440297 .247532 1 
10gghys-1-p 1 1.309094 1.473 155 0.89 0.380 - 1.6847 17 4.302905 
log-hcome-a 1 .64653 13 .547548 1 1.18 0.246 -.4662203 1.759283 
- cons 1 -13.29956 12.7067 -1.05 0.303 -39.12269 12.52356 
STATA Output of Table 6.4 - Antipsychotics 
Log-log regression for antipsychotics in France 
Dependent Variable: logshare-pd 
With detailing varidle laaned 1 auarter 
Source I SS df MS 
-------------+------------------------------ 
Model 1 .000330864 4 .000082716 
Residual 1 ,0000 1984 1 4 4.9602e-06 
Total 1 .000350705 8 .000043838 
Number of obs = 9 
F( 4, 4) = 16.68 
Prob > F = 0.0092 
R-squared = 0.9434 
Adj R-squared = 0.8869 
Root MSE = .00223 
.............................................................................. 
log-sharegd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 .0024693 .0010977 2.25 0.088 -.0005786 .0055 171 
log-share-+ I (dropped) 
logqrice--0 1 -.035694 .0055343 -6.45 0.003 -.05 10597 -.0203282 
l0g~hys-l-p I (dropped) 
log-income-a 1 .0527402 .0938894 0.56 0.604 -.2079387 .3 13419 
log - tot-de-1 1 .0013313 .0036394 0.37 0.733 -.0087734 .011436 
cons l -.6702896 .9939185 -0.67 0.537 -3.42985 2.08927 1 
With detailing variable l m e d  4 auarters 
Model 1 .000467257 4 .000116814 
Residual 1 .000068425 5 .000013685 
Total 1 ,000535682 9 .00005952 
Number of obs = 10 
F( 4, 5) = 8.54 
Prob>F = 0.0185 
R-squared = 0.8723 
Adj R-squared = 0.770 1 
Root MSE = .0037 
.............................................................................. 
log-shareqd ( Coef Std. Err. t P>Jt( [95% Conf Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0019283 ,0016599 1.16 0.298 -.0023386 ,0061953 
log-share--s I (dropped) 
logqrice -o 1 -.0360343 ,0074351 -4.85 0.005 -.0551468 -.0169218 
log-Phys3-P I (dropped) 
log-income-a 1 .00775 1 .I250238 0.06 0.953 -.3 136329 .3291349 
log-tot-de-4 1 -.0026804 ,0058944 -0.45 0.668 -.0178324 .01247 15 
- cons 1 -. 1833468 1.3 12356 -0.14 0.894 -3.556865 3.190172 
STATA Output of Table 6.4 - Antipsychotics 
Log-log regression for antipsychotics in Italy 
Dependent Variable: log-share-pd 
With detailing variuble lamed 1 auarter 
Source1 SS df MS Number of obs = 16 
-------------+------------------------------ F( 6, 9) = 93.54 
Model 1 .003324105 6 .000554018 Prob > F = 0.0000 
Residual 1 .000053305 9 5.9228e-06 R-squared = 0.9842 
-------------+------------------------------ Adj R-squared = 0.9737 
Total 1 .00337741 15 .000225 161 Root MSE = .00243 
.............................................................................. 
l o g - s h q d  / Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time 1 .0043655 .0009044 4.83 0.001 .0023 196 .0064115 
log-sharee+ 1 -.4699004 .2229063 -2.1 1 0.064 -.9741496 .0343488 
logprice-+ 1 -.036683 1 .0049755 -7.37 0.000 -.0479384 -.0254278 
10g~hys-1-p 1 -.0737775 .I229668 -0.60 0.563 -.35 19477 .2043927 
log-income-a 1 .I630734 .0459853 3.55 0.006 .0590473 .2670994 
log-tot-de-1 1 .008612 .0035479 2.43 0.038 .0005859 .016638 
cons l - 1.406796 .6550562 -2.15 0.060 -2.888636 .0750438 
With detailing variable lamed 4 auarters 
Source I SS df MS 
-------------+------I------------------------ 
Model ( .003289692 6 ,000548282 
Residual 1 .0000877 19 9 9.7465e-06 
-------------+------------------------------ 
Total 1 .00337741 15 .000225 161 
Number of obs = 16 
F( 6, 9) = 56.25 
Prob > F = 0.0000 
R-squared = 0.9740 
Adj R-squared = 0.9567 
Root MSE = .003 12 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf Interval] 
-------------+---------------------------------------------------------.------ 
time 1 .0028026 .0008868 3.16 0.012 .0007966 .0048086 
log-sharee-s 1 .054989 .0637442 0.86 0.41 1 -.0892104 .I991 884 
logqrice--o 1 -.0394894 .0065779 -6.00 0.000 -.0543697 -.024609 1 
10g~hys-1-p 1 .I574938 .2137466 0.74 0.480 -.3260347 .6410222 
log-income-a 1 .I473684 .0709941 2.08 0.068 -.01323 13 .307968 1 
log-tot-de-4 1 -.0006902 .003 1008 -0.22 0.829 -.0077048 .0063244 
cons l -2.970883 1.965303 - 1.5 1 0.165 -7.4 16708 1.474942 
STATA Output of Table 6.4 - Antipsychotics 
Log-log regression for antipsychotics in the USA 
Dependent Variable: logshare-pd 
With detailing variable b e d  1 puarter 
Source1 SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 144.20 
Model 1 .076853079 6 .012808847 Prob > F = 0.0000 
Residual 1 ,00222061 7 25 .000088825 R-squared = 0.9719 
-------------+------------------------------ Adj R-squared = 0.9652 
Total 1 ,079073696 31 .002550764 Root MSE = .00942 
.............................................................................. 
log - shareqd I Coef. Std. Err. t P>lt/ [95% Conf. Interval] 
logqrice--o 1 -.0846893 .01349 -6.28 0.000 -. 1 124725 -.0569061 
log share--s 1 .2317788 .0289308 8.01 0.000 .I721946 .2913629 
logincome-a 1 ,1641596 .Of35302 1.92 0.066 -.0115232 .3398425 
log3hYs 1-p 1 -. 1200171 .0932559 -1.29 0.210 -.3 12081 1 ,0720469 
time1 .00564 16 .0010704 5.27 0.000 .003437 1 .007846 
log - re1 - de-1 1 -.0010361 .0044748 -0.23 0.819 -.010252 .0081799 
- cons 1 -.9740263 37173 19 -1.12 0.274 -2.769392 .8213391 
With detailing variable Zagged 4 auarters 
Source I SS df MS Number of obs = 32 
-------------+------------------------------ F( 6, 25) = 179.47 
Model 1 .077279558 6 .012879926 Prob > F = 0.0000 
Residual 1 .001794138 25 .000071766 R-squared = 0.9773 
-------------+------------------------------ Adj R-squared = 0.97 19 
Total 1 .079073696 3 1 .002550764 Root MSE = .00847 
.............................................................................. 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
logqrice--0 1 -.0805958 .012189 1 -6.61 0.000 -. 1056997 -.05549 18 
log-share-+ 1 .I472219 .0429711 3.43 0.002 .0587212 .2357226 
log-income-a 1 .204 1364 .0784059 2.60 0.01 5 .0426564 .3656 164 
10g~hys-1-p 1 -. 1480033 .Of344896 -1.75 0.092 -.3220128 .0260062 
time 1 .0078186 .0012948 6.04 0.000 .005152 .0104852 
log-rel-de-4 1 -.0167389 .0068285 -2.45 0.022 -.0308025 -.0026754 
- cons 1 - 1.18562 .7880684 - 1.50 0.145 -2.808678 .4374369 
STATA Output of Table 6.4 - Antipsychotics 
Log-log regression for antipsychotics in Sweden 
Dependent Variable: logsham-pd 
No Detailing VariQbles 
Source I SS df MS Number of obs = 40 
-------------+------------------------------ F( 5, 34)= 81.15 
Model 1 3.94264 5 ,788527999 Prob > F = 0.0000 
Residual 1 .33038995 34 .0097 1735 1 R-squared = 0.9227 
----------.--+------------------------------ Adj R-squared = 0.9113 
Total 1 4.27302995 39 .lo956487 Root MSE = .09858 
--------------.----------------.---------------------------------------------- 
l o g - s h q d  I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
------------- . ----- -- - 
time 1 .0023335 .0063081 0.37 0.714 -.0104862 .0151532 
log share -s 1 1.446803 .I914875 7.56 0.000 1.057653 1.835952 
log>rice> 1 -. 173855 .2712205 -0.64 0.526 -.7250413 .37733 14 
10g~hys-1-p 1 -.I150352 2.239685 -0.05 0.959 -4.666623 4.436553 
log-income-a 1 SO58676 .7 13797 0.7 1 0.483 -.9447424 1.956478 
cons l -3.875425 15.6 1958 -0.25 0.806 -35.6 1822 27.86737 
STATA Output of Table 7.1 
Log-log regression for antinausea medications in all five sample countries 
Omitted country: Sweden 
Dependent Variable: logtot-pd-lkcapita 
No detailing variable 
Source1 SS df MS Number of obs = 220 
-------------+------------------------------ F( 10, 209) = 409.46 
Model 1 84.5768052 10 8.45768052 Prob > F = 0.0000 
Residua1 1 4.3 1706272 209 .020655803 R-squared = 0.95 14 
-------------+------------------------------ Adj R-squared = 0.949 1 
Total ( 88.8938679 219 .405908073 Root MSE = .I4372 
log-totgd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 -.005957 1 .0024501 -2.43 0.016 
loggrice-.-s 1 -.0040197 .046455 1 -0.09 0.93 1 
log - tot - nu-d 1 1.157476 .I967288 5.88 0.000 
logghys-1-p 1 .I821042 ,4402568 0.41 0.680 
log nurse -p 1 1.598225 .9301745 1.72 0.087 
logjncom&a 1 .3007203 .3820257 0.79 0.432 
france 1 1.745356 -1719573 10.15 0.000 
uk 1 1.554386 .788388 1.97 0.050 
italy 1 1.3 17776 .2603074 5.06 0.000 
us 1 .I44365 1 .2550671 0.57 0.572 
cons l -3.013042 4.742725 -0.64 0.526 
STATA Output of Table 7.2 
Log-log regression for antinausea medications in US, UK, France and Italy 
Omitted country: Italy 
Dependent Variable: logtot-pd-1 kcapita 
With detailing variable l m e d  1 quarter 
Source I SS df MS Number of obs = 120 
F(10, 109)= 306.14 
Model 1 39.941 9991 10 3.99419991 Prob > F = 0.0000 
Residual 1 1.422 13322 109 .O 13047094 R-squared = 0.9656 
-------------+------------------------------ Adj R-squared = 0.9625 
Total 1 41.3641323 1 19 .34759775 1 Root MSE = .I1422 
.............................................................................. 
log-totjdd- I Coef. Std. Em. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time ( -.006593 .003 12 19 -2.1 1 0.037 -.0127806 -.0004054 
logjrice--s 1 -.2049567 .0861966 -2.38 0.0 19 -.3757955 -.034 1 18 
log-tot-nu4 1 -.600523 1 .29889 12 -2.0 1 0.047 - 1.1929 16 -.008 1305 
10g~hys-1-p 1 -.2004709 .5464375 -0.37 0.7 14 - 1.283492 .8825505 
log-nurse--p 1 1.95701 6 .9542408 2.05 0.043 .06574 17 3.84829 
log-income-a 1 1.209054 .4438407 2.72 0.008 .3293766 2.088732 
log - tot-de-1 1 .I128424 .0427651 2.64 0.010 .0280832 .I976015 
fiance 1 .2291669 .I618092 1.42 0.160 -.0915337 .5498675 
uk 1 .lo83607 .702859 0.15 0.878 -1.284683 1 SO1404 
US 1 - 1.2 19935 .4864559 -2.5 1 0.0 14 -2.184075 -.2557953 
- cons 1 -2.785839 5.53771 5 -0.50 0.61 6 -1 3.76141 8.189732 
STATA Output of Table 7.2 
Log-log regression for antinausea medications in US, UK, France and Italy 
Omitted country: Italy 
Dependent Variable: logtot-pd-lkcapita 
With detailing variable lamed 4 auarters 
Source I SS df MS Number of obs = 120 
-------------+------------------------------ F( 10, 109) = 306.00 
Mode1 1 40.2210342 10 4.02210342 Prob > F = 0.0000 
Residual 1 1.4327 1548 109 .O 13 144 179 R-squared = 0.9656 
-------------+------------------------------ Adj R-squared = 0.9624 
Total 1 41.6537497 119 ,35003151 Root MSE = .I1465 
log - totgd-a ( Coef. Std. Err. t P>(t( [95% Conf. Interval] 
time 1 -.00702 1 .003 1497 -2.23 0.028 -.O 132636 -.0007783 
logqrice-s 1 -.0977 138 .Of333794 -1.17 0.244 -.262969 .0675413 
log-tot-nu4 1 -.50050 16 ,2904099 - 1.72 0.088 - 1.076085 .07508 14 
logghys 1-p 1 -.2291089 .5464521 -0.42 0.676 -1.3 12159 $539413 
log n~rs<. -~(  2.106104 .9638229 2.19 0.031 .I958389 4.01637 
log incomema 1 1.056548 .4406474 2.40 0.0 18 ,183 1988 1.929896 
loLtot-de-4 ( .0407864 .017528 2.33 0.022 .0060464 ,0755263 
fiance 1 ,2303239 .I61 1 1 19 1.43 0.156 -.0889945 .5496424 
uk 1 .I32 165 .7 169937 0.18 0.854 - 1.288893 1.553223 
US ( - 1.38828 1 .482823 -2.88 0.005 -2.34522 -.43 134 14 
- cons 1 -1.757996 5.642055 -0.3 1 0.756 -12.94036 9.424373 
STATA Output of Table 7.3 
Log-log regression for antihypertensives in all five sample countries 
Omitted country: Sweden 
Dependent Variable: log,tot-pd-lkcapita 
No detailing variuble 
Source I SS df MS Number of obs = 166 
--o-----o----+--II-----o-------------------- F( 9, 156) = 116.27 
Model 1 5.66020954 9 ,628912172 Prob > F = 0.0000 
Residual 1 .ti443784038 156 .005408872 R-squared = 0.8703 
Adj R-squared = 0.8628 
Total 1 6.50399358 165 .039418143 Root MSE = .07355 
~ ~ o ~ ~ ~ ~ ~ o ~ ~ ~ ~ ~ ~ o ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ o ~ ~ ~ ~ ~ ~ - o ~ ~ ~ ~ ~ - - ~ ~ ~ ~ - - - - ~ ~ ~ - - - - - ~ - - - - - - - - - ~ - - -  
log-totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+--------------------------------- 
time) .0144701 .0017238 
logqrice--s 1 .02 158 1 1 .0689034 
log-tot-nu-d 1 -.2910302 .I436908 
logphys-1-p ( .5935494 .23669 13 
log - income-a 1 .2302753 .2399459 
h c e  1 -. 1 13 1666 .0524837 
uk 1 .OM143 .lo44662 
italy 1 -.3061653 .0984229 
US 1 -.2015165 .I239354 
cons 1 2.821749 2.709697 
- 
STATA Output of Table 7.4 
Log-log regression for antihypertensives in the US, UK, France and Italy. 
Omitted country: Italy 
Dependent Variable: logtot-pd-lkcapita 
Detailing v a ~ b l e  lamed 1 auarter 
Source1 SS df MS Number of obs = 1 13 
-------------+------------------------------ F( 9, 103) = 86.54 
Model 1 3.30667469 9 .367408298 Prob > F = 0.0000 
Residual 1 .437292253 103 .004245556 R-squared = 0.8832 
-------------+------------------------------ Adj R-squared = 0.8730 
Total 1 3.74396694 1 12 .033428276 Root MSE = .065 16 
logtotqd-a1 - Coef. Std.Err. t P>ltl [95%Conf.Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0122697 .0024143 5.08 0.000 .0074814 .017058 
logqrice-s 1 .0426548 .08 19124 0.52 0.604 -. 1 19799 .205 1087 
log-tot-nu-d 1 -. 1870 14 .248 1497 -0.75 0.453 -.679 1604 .305 1324 
logqhys-1-p 1 .75 18 171 .252275 2.98 0.004 .25 14891 1.252145 
log-income-a 1 .37387 17 .2698227 1.39 0.169 -. 16 12579 .go900 14 
log-tot-de-1 1 -.0664 177 .0673675 -0.99 0.326 -.2000252 .067 1898 
france 1 .I822933 .0627704 2.90 0.005 .057803 .3067836 
uk 1 .4163507 .I812585 2.30 0.024 .0568672 ,7758343 
US 1 .0979559 .2089884 0.47 0.640 -.3165233 .5124351 
cons l -.3980846 2.778 132 -0.14 0.886 -5.907854 5.1 1 1685 
STATA Output of Table 7.4 
Log-log regression for antihypertensives in the US, UK, France and Italy. 
Omitted country: Italy 
Dependent Variable: logtot-pd-lkcspita 
Detailing variable lugged 4 auarters 
Source1 SS df MS Number of obs = 1 13 
-------------+------------------------------ F( 9, 103) = 87.45 
Mode1 ( 3.31069805 9 .367855339 Prob > F = 0.0000 
Residual 1 .433268887 103 .OM206494 R-squared = 0.8843 
-------------+------------------------------ Adj R-squared = 0.8742 
Total 1 3.74396694 1 12 .033428276 Root MSE = .06486 
log - totgd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
time) .0133444 .0023649 
loggrice--s 1 .0630327 .0824274 
log-tot-nu4 1 -.3063838 .2552622 
logjhys-1-p 1 ,7727649 .2484624 
log income-a 1 .4926582 .2828 188 
loltot-de-4 1 -.01453 13 .0104396 
h c e  1 .2065298 .0645766 
uk 1 .4736691 .I83438 
us 1 .0719785 .205963 
cons 1 -1.5461 15 2.972768 
- 
STATA Output of Table 7.5 
Log-log regression for antipsychotics in all five sample countries 
Omitted country: Sweden 
Dependent Variable: logtotpd-lkcapita 
No detailing vahble 
Source I SS df MS Number of obs = 2 13 
-------------+------------------------------ F( 9, 203) = 250.70 
Mode1 1 224.380381 9 24.931 1534 Prob > F = 0.0000 
Residual 1 20.1874838 203 ,099445733 R-squared = 0.9175 
-------------+------------------------------ Adj R-squared = 0.9138 
Total 1 244.567864 212 1.153622 Root MSE = .3 1535 
.............................................................................. 
log-totgd-a ( Coef. Std. Err. t P>ltJ [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0304283 .004598 6.62 0.000 .0213624 .0394943 
loggrice-s 1 -. 1704038 .lo0924 - 1.69 0.093 -.3693976 .02859 
log tot-nu-d 1 .4250335 .0964546 4.41 0.000 .2348522 .6152149 
l ~ ~ ~ h ~ s - l - ~  1 6.755619 .8108341 8.33 0.000 5.156883 8.354356 
log - income-a 1 1.684777 .8081166 2.08 0.038 .0913985 3.278 156 
h n c e  1 - 1.254662 .I343843 -9.34 0.000 - 1.5 1963 -.989694 
uk 1 1.466975 .3370784 4.35 0.000 .a023513 2.131599 
italy 1 -3.09535 1 .2785578 -1 1.1 1 0.000 -3.644588 -2.5461 13 
us 1 1.39309 .3775996 3.69 0.000 .6485699 2.13761 
- cons ( -65.64468 10.434 12 -6.29 0.000 -86.2 1784 -45.07 153 
STATA Output of Table 7.5 
Log-log regression for antipsychotics in the US, UK, France and Italy. 
Omitted country: Italy 
Dependent Variable: logtot-pd-lkcapita 
Detailing variuble laaaed I auarter 
Source1 SS df MS Number of obs = 88 
-------------+------------------------------ F( 9, 78) = 275.30 
Model 1 51.5028275 9 5.72253638 Prob > F = 0.0000 
Residual 1 1.62 13448 78 .020786472 R-squared = 0.9695 
-------------+----------------------ow------ Adj R-squared = 0.9660 
Total 1 53.1241723 87 .61062267 RootMSE = .I4418 
log-totqd-a I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+-------------------------------------------------.-----.-------- 
time 1 .05335 19 .0053 10.07 0.000 .0428005 .0639034 
logprice-as 1 - 1.46578 .I24496 - 1 1.77 0.000 - 1.7 13632 - 1.2 17927 
log-tot-nu41 1.15578 .I61865 7.14 0.000 3335319 1.478029 
10gghys-lap 1 -.3309 1 17 .7734916 -0.43 0.670 -1.8708 15 1.208992 
log-income-a 1 2.167276 .6583264 3.29 0.001 3566491 3.477904 
log-tot-deal 1 -.0687595 .029912 1 -2.30 0.024 -. 1283098 -.0092091 
h c e  1 ,3671678 .2121205 1.73 0.087 -.0551316 .7894672 
uk 1 .I166491 .519487 0.22 0.823 -.91757 1.150868 
us 1 1.886608 .5631771 3.35 0.001 .7654086 3.007808 
cons 1 -9.666729 8.25039 1 - 1.17 0.245 -26.09 199 6.758537 
- 
STATA Output of Table 7.5 
Log-log regression for antipsychotics in the US, UK, France and Italy. 
Omitted country: Italy 
Dependent Variable: logtot-pd-lkcapita 
Detailing variable lugged 4 auarters 
Source I SS df MS Number of obs = 135 
-------------+------------------------------ F( 9, 125) = 295.56 
Model ( 156.179046 9 17.3532274 Prob > F = 0.0000 
Residual 1 7.33903 198 125 .058712256 R-squared = 0.9551 
-------------+------------------------------ Adj R-squared = 0.95 1 9 
Total 1 163.5 18078 134 1.22028417 Root MSE = .2423 1 
.............................................................................. 
log-totgd-a I Coef. Std. Err. t P>ltl 195% Conf. Interval] 
-------------+---------------------------------------------------------------- 
time 1 .0361217 .0057341 6.30 0.000 .024773 1 .0474703 
loggrice--s 1 -.3674853 ,1127357 -3.26 0.001 -.5906033 -. 1443674 
log tot-nu-d 1 .4488964 .0937152 4.79 0.000 .2634224 .6343704 
l ~ ~ ~ h ~ s - l - ~  1 6.500228 .8076803 8.05 0.000 4.90 1728 8.098727 
log-income-a 1 3.588037 ,859741 4.17 0.000 1 .I386503 5.289571 
log - tot de-4 1 -. 1083497 .0376976 -2.87 0.005 -. 1829579 -.0337415 
fiance 1 1.677236 .I877233 8.93 0.000 1.305709 2.048764 
uk 1 4.443521 ,5745908 7.73 0.000 3.306334 5.580707 
us 1 4.154601 .5669034 7.33 0.000 3.032629 5.276573 
cons l -84.65535 10.57044 -8.01 0.000 -105.5756 -63.735 14 
STATA Output of Table 7.7 
Log-log regression for antinausea medications in all five sample countries 
Omitted country: Sweden 
Dependent Variable: logsharegd 
No detailing variable 
Source 1 SS df MS Number of obs = 220 
-------------+------------------------------ F( 10, 209) = 228.05 
Modell 307.176521 10 30.7176521 Prob > F = 0.0000 
Residua1 1 28.15 13 105 209 .I34695266 R-squared = 0.9160 
-------------+------------------------------ Adj R-squared = 0.9 120 
Total 1 335.327831 219 1.531 17731 Root MSE = .36701 
log-sharegd I Coef. Std. Err. t P>Itl [95% Conf. Interval] 
log share -s 1 .4172968 .I71 7459 2.43 0.016 
log$ce-+ 1 -.6829603 .0589088 -1 1.59 0.000 
time 1 .0204521 .0066113 3.09 0.002 
logjhys-1-p 1 2.380843 1.058255 2.25 0.026 
log-nurse--p 1 2.387992 2.432261 0.98 0.327 
log-income-a ( -.4078343 .97 1 147 -0.42 0.675 
uk 1 .6467749 2.057145 0.3 1 0.754 
b c e  1 -2.652767 .3556215 -7.46 0.000 
italy 1 - 1 A22468 .5742433 -3.17 0.002 
us 1 .9362042 .6112854 1.53 0.127 
- cons 1 -18.1742 11.4573 -1.59 0.1 14 
STATA Output of Table 7.8 
Log-log regression for antinausea medications in US, UK, France and Italy 
Omitted country: Italy 
Dependent Variable: logshare-pd 
With detailing variable lagged 1 uuarter. 
Source1 SS df MS Number of obs = 57 
-------------+------------------------------ F( 10, 46)= 151.54 
Model 1 89.2300407 10 8.92300407 Prob > F = 0.0000 
Residual 1 2.70857645 46 .058882097 R-squared = 0.9705 
-------------+------------------------------ Adj R-squared = 0.964 1 
Total 1 91.9386172 56 1.64 1761 02 Root MSE = .24266 
.............................................................................. 
1 og-shareqd I Coef. Std. Err. t P>(tl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
log-share--~ 1 -.3984796 .2877432 -1.38 0.173 -.9776767 .I807174 
loggrice-Q 1 -.0455368 .I309491 -0.35 0.730 -.3091236 .21805 
time 1 .0541144 .0127136 4.26 0.000 .0285232 .0797056 
10gghy~-1-p 1 -.7013443 1.61 183 1 -0.44 0.666 -3.945792 2.543 103 
log-nurse--p 1 1.600466 3.9054 0.4 1 0.684 -6.260697 9.46 1628 
log income-a 1 -3.6793 1 1 1.458843 -2.52 0.01 5 -6.61 58 1 1 -.7428 12 
lo&el-de-1 1 .0557219 .0338038 1.65 0.106 -.0123217 .I237654 
uk 1 -.0690008 2.569527 -0.03 0.979 -5.24 1 19 5.103 188 
fiance 1 -.9262073 .43322 12 -2.14 0.038 - 1.798236 -.054 1782 
US 1 1.748868 1.204204 1.45 0.153 -.675069 4.172805 
- cons ( 34.37099 16.96436 2.03 0.049 .2235048 68.5 1848 
STATA Output of Table 7.8 
With detailing variable lagged 4 quarters. 
Log-log regression for antinausea medications in US, UK, France and Italy 
Omitted country: Italy 
Dependent Variable: logsharegd 
Source I SS df MS Number of obs = 94 
----I--------+------------------------------ F( 10, 83) = 204.98 
Model ( 109.269286 10 10.9269286 Prob > F = 0.0000 
Residual 1 4.42461244 83 .053308584 R-squared = 0.96 1 1 
-------------+------------------------------ Adj R-squared = 0.9564 
Total 1 1 13.693899 93 1.2225 1504 Root MSE = .23089 
.............................................................................. 
log-shareqd I Coef. Std. Err. t P>(tl [95% Conf. Interval] 
log-share-~~ 1 -.020489 .2509685 
logprice-Q 1 -.0776797 .lo95242 
time 1 .0409066 .0080335 
logjhys-1-p 1 -. 1979373 1.093427 
log-nurse--p 1 5.719426 2.520486 
log-income-a 1 -2.460543 .94450 12 
log - rel-de-4 1 .049444 .0205645 
uk 1 2.339863 1.599842 
france 1 -1.225523 .3 168267 
us1 1.001951 .8771834 
- cons 1 16.03958 1 1.02943 
STATA Output of Table 7.9 
No detailing variable. 
Log-log regression for antihypertensives in all five sample countries 
Omitted country: Sweden 
Dependent Variable: logshare-pd 
Source1 SS df MS Number of obs = 166 
-------------+------------------------------ F( 9, 156)= 61.54 
Model 1 220.68 1 107 9 24.520123 Prob > F = 0.0000 
Residual 1 62.1532439 156 .39841823 R-squared = 0.7802 
-------------+------------------------------ Adj R-squared = 0.7676 
Total1 282.834351 165 1.71414758 Root MSE = .6312 
.............................................................................. 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
loggrice -o 1 1.832608 .5834915 3.14 0.002 .6800443 2.985 171 
log - share:-s 1 .6750595 .22 196 1 1 3.04 0.003 .2366225 1.1 13497 
time1 .0498583 .0130839 3.81 0.000 .0240137 .0757028 
10g~hys-1-p 1 -2.482101 2.06421 1 -1.20 0.23 1 -6.5595 12 1.5953 1 
log - income-a1 6.19081 2.104477 2.94 0.004 2.033862 10.34776 
fiance 1 1.27941 1 .3617452 3.54 0.001 .5648602 1.993962 
uk 1 -1.379823 .8375213 - 1.65 0.101 -3.034169 .2745222 
italy 1 1.963006 3264292 2.38 0.019 .3305706 3.595441 
US 1 -1.840937 .9461953 -1.95 0.053 -3.709945 .0280703 
- cons 1 -47.001 14 26.43789 -1.78 0.077 -99.22357 5.221296 
STATA Output of Table 7.10 
With detailing variable lagged 1 quarter. 
Log-log regression for antihypertensives in US, UK, France and Italy 
Omitted country: Italy 
Dependent Variable: logsharegd 
Source1 SS df MS Number of obs = 1 12 
--.-------.--+------------.----------------. F( 9, 102)= 205.11 
Model 1 115.912322 9 12.8791469 Prob > F = 0.0000 
Residual 1 6.40469397 102 ,062791 1 17 R-squared = 0.9476 
Adj R-squared = 0.9430 
Total 1 122.317016 11 1 1.1019551 Root MSE = .25058 
------ ---- ------ ------- 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
log-share-~~ 1 .6915782 .I262791 5.48 0.000 .4411042 .9420523 
logqrice -o 1 -2.721782 .3634295 -7.49 0.000 -3.442643 -2.00092 1 
&e 1 .0336402 .0067211 5.01 0.000 .0203089 .0469714 
l o g ~ h y s ~ l - p 1  5.5505 13 1.063792 5.22 0.000 3.440488 7.660539 
log-income-a 1 .67 18788 1.0857 1 0.62 0.537 - 1.48 1622 2.82538 
log-rel-de-1 1 .0973308 .0368259 2.64 0.0 10 .0242868 .I703749 
uk 1 4.178265 .85 14606 4.91 0.000 2.489397 5.867133 
fiance 1 1 A92699 .2870807 6.59 0.000 1.323276 2.462 122 
us 1 2.94545 .7994257 3.68 0.000 1.359793 4.53 1 107 
cons 1 -53.86462 12.81 178 -4.20 0.000 -79.27673 -28.4525 1 
- 
STATA Output of Table 7.10 
With detailing variable lagged 4 quarters. 
Log-log regression for antihypertensives in US, UK, France and Italy 
Omitted country: Italy 
Dependent Variable: logshare-pd 
Source I SS df MS Number of obs = 1 12 
-------------+------------------------------ F( 9, 102) = 256.99 
Model 1 1 17.150684 9 13.0167427 Prob > F = 0.0000 
Residual 1 5.16633 189 102 ,0506503 13 R-squared = 0.9578 
-------------+------------------------------ Adj R-squared = 0.9540 
Total 1 122.317016 11 1 1.1019551 Root MSE = .22506 
.............................................................................. 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
log share--~ 1 .5933658 .I11104 5.34 0.000 .3729914 .8137401 
log~rice--o 1 -2.59674 1 .3267294 -7.95 0.000 -3.244807 - 1.948674 
time 1 ,0315798 .0059385 5.32 0.000 ,0198009 .0433588 
logjhys-1-p 1 6.562 147 .975 1201 6.73 0.000 4.628001 8.496293 
log income-a 1 1.652262 ,99457 15 1.66 0.100 -.3204656 3.62499 
log-rel-de-4 1 .I188452 .0206542 5.75 0.000 .0778777 .I598126 
uk 1 5.061417 .785 181 6.45 0.000 3.504014 6.61882 
fiance 1 2.245637 .2674901 8.40 0.000 1.715072 2.776202 
us 1 3.396088 .7229904 4.70 0.000 1.96204 4.830136 
cons 1 -72.62803 12.1 1487 -5.99 0.000 -96.6578 1 -48.59825 
- 
STATA Output of Table 7.11 
No detailing variable. 
Log-log regression for antipsychotics in all five sample countries 
Omitted country: Sweden 
Dependent Variable: logshareqd 
Source I SS df MS Number of obs = 166 
-------------+------------------------------ F( 9, 156) = 12.81 
Mode1 1 24.3571507 9 2.70635008 Prob > F = 0.0000 
Residual 1 32.9574876 156 .2 1 1265946 R-squared = 0.4250 
-------------+----------------------------- Adj R-squared = 0.3918 
Totall 57.3146383 165 .347361444 Root MSE = .45964 
log-shareqd I Coef. Std. Err. t Pltl  [95% Conf. Interval] 
loggrice--0 1 -.6558334 .0915 13 1 
log-share--s ) .75 12456 .3442783 
time 1 .0300732 .0086165 
l o g ~ h y s ~ l - p  1 -2.665408 1.535 156 
log-incornea 1 - 1.1 19022 1.323 12 1 
h c e  1 -.lo41043 .2064979 
I&( -1.220405 .6428022 
italyl .4121646 .5547038 
US 1 -.7684408 .6492134 
cons l 3 1.90582 17.6478 1 
STATA Output of Table 7.12 
Log-log regression for antipsychotics in the US, UK, France and Italy. 
Omitted country: Italy 
Dependent Variable: loeshare-pd 
Detailing variable &ed 1 auarter. 
Source I SS df MS Number of obs = 46 
-------------+------------------------------ F( 9, 36) = 139.33 
Model 1 .09045726 9 .010050807 Prob > F = 0.0000 
Residual 1 ,002596998 36 .000072 139 R-squared = 0.9721 
-------------+------------------------------ Adj R-squared = 0.965 1 
Total 1 .093054258 45 .002067872 Root MSE = .00849 
.............................................................................. 
log-sharegd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
log-share-~~ 1 .2382404 .0233906 10.19 0.000 .I90802 .2856788 
logqrice--o 1 -.072536 .0097789 -7.42 0.000 -.0923686 -.0527034 
time 1 ,0050288 ,0008359 6.02 0.000 .0033336 .006724 
l ~ g g h y ~ - l - p  1 -.Of35224 .079752 - 1.07 0.292 -.2469686 ,0765207 
log income-a 1 .I495986 .0669595 2.23 0.032 .0137985 .2853986 
locrel-de-1 1 -.0025678 .0017 154 - 1.50 0.143 -.0060469 .0009112 
uk 1 .0602926 .0641877 0.94 0.354 -.0698861 ,1904713 
fiance 1 .0104777 .0260063 0.40 0.689 -.0422656 .063221 
US ( -.0570618 .0605487 -0.94 0.352 -.I798602 ,0657367 
- cons 1 -1.004236 .6810173 -1.47 0.149 -2.385403 .3769315 
STATA Output of Table 7.12 
Log-log regression for antipsychotics in the US, UK, France and Italy. 
Omitted country: Italy 
Dependent Variable: logshare-pd 
Detailing variable lamed 4 awters. 
Source I SS df MS Number of obs = 57 
-------------+------------------I------------ F( 9, 47) = 174.50 
Model 1 .lo5514931 9 .011723881 Prob > F = 0.0000 
Residual 1 .003 157635 47 .000067184 R-squared = 0.9709 
-------------+------------------------------ Adj R-squared = 0.9654 
Total 1 .I08672566 56 .001940582 Root MSE = .0082 
log-shareqd I Coef. Std. Err. t P>ltl [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
log-share--~ 1 .2274 107 .0255494 8.90 0.000 .I7601 19 .2788094 
loggrice--o 1 -.0606487 .0078 193 -7.76 0.000 -.0763792 4449 182 
time 1 .0045731 .0007795 5.87 0.000 .0030048 .0061413 
10g~hys-1-p 1 -.0902488 .07 17227 - 1.26 0.2 14 -.2345362 .0540386 
log-income-a 1 .I489769 .062946 1 2.37 0.022 .0223458 .275608 1 
log-rel-de-4 1 -.0004702 .OO 1 134 -0.4 1 0.680 -.00275 15 .OO 18 1 1 1 
uk 1 .0549435 .056909 0.97 0.339 -.0595426 .I694296 
fiance 1 .0214243 .022487 0.95 0.346 -.0238138 .0666624 
US 1 -.0606324 .054457 -1.1 1 0.271 -.I701858 .0489209 
cons 1 -.9486727 .6436323 -1.47 0.147 -2.243494 .3461485 
- 
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